Korean Journal of Sport Science

Search

Close

ํŒŒํ‚จ์Šจ๋ณ‘ ๋น„์šด๋™ ์ฆ์ƒ์˜ ์ง„๋‹จ๊ณผ ์น˜๋ฃŒ์˜ ์ž„์ƒ์  ์ ‘๊ทผ

Clinical Approach of Diagnosis and Management of Non-Motor Symptoms in Parkinsonโ€™s Disease

Sangjin Lee, MD, Hae-Won Shin, MD, PhD

ํŒŒํ‚จ์Šจ๋ณ‘ ๋น„์šด๋™ ์ฆ์ƒ์˜ ์ง„๋‹จ๊ณผ ์น˜๋ฃŒ์˜ ์ž„์ƒ์  ์ ‘๊ทผ

์ด์ƒ์ง„, ์‹ ํ˜œ์›
Received May 29, 2026; ย  ย  ย  Revised June 17, 2026; ย  ย  ย  Accepted June 18, 2026;
ABSTRACT
Non-motor symptoms are common and clinically important manifestations of Parkinson disease (PD), often occurring from the prodromal stage and throughout the disease course. Although PD has traditionally been defined by motor features, non-motor symptoms substantially affect quality of life, functional independence, caregiver burden, and longterm outcomes. These symptoms are frequently underrecognized because patients may not attribute them to PD and clinicians may focus primarily on motor complications. This review summarizes a practical clinical approach to the diagnosis and management of major nonmotor symptoms in PD, with emphasis on applicability to routine neurological practice in Korea. The main domains covered include neuropsychiatric symptoms such as depression, anxiety, psychosis, and impulse control disorders; cognitive impairment; autonomic dysfunction; sleep disorders; pain; and fatigue. For each domain, appropriate screening tools, clinical assessment strategies, differential diagnostic considerations, and treatment options are reviewed. Pharmacological treatment should be individualized according to symptom pattern, disease stage, motor fluctuation, comorbidities, cognitive status, and potential adverse effects. Non-pharmacological interventions, including exercise, cognitive behavioral therapy, sleep hygiene, behavioral therapy for urinary symptoms, environmental modification for REM sleep behavior disorder, and multidisciplinary care, are also important components of management. Because non-motor symptoms are often interrelated, comprehensive and repeated assessment is essential. Early recognition, structured evaluation, individualized treatment, and patient-caregiver education may improve clinical outcomes and quality of life in patients with PD.
์„œ ๋ก 
์„œ ๋ก 
ํŒŒํ‚จ์Šจ๋ณ‘(Parkinson's disease)์€ ์ „ ์„ธ๊ณ„์ ์œผ๋กœ ๋‘ ๋ฒˆ์งธ๋กœ ํ”ํ•œ ์‹ ๊ฒฝํ‡ดํ–‰์งˆํ™˜์œผ๋กœ ๊ตญ๋‚ด์—์„œ๋„ ์ธ๊ตฌ ๊ณ ๋ นํ™”์— ๋”ฐ๋ผ ์œ ๋ณ‘๋ฅ ์ด ๋น ๋ฅด๊ฒŒ ์ฆ๊ฐ€ํ•˜๊ณ  ์žˆ๋‹ค. ํŒŒํ‚จ์Šจ๋ณ‘์€ ์ „ํ†ต์ ์œผ๋กœ ๋–จ๋ฆผ, ๊ฒฝ์ถ•, ์šด๋™์™„๋งŒ, ์ž์„ธ๋ถˆ์•ˆ์ • ๋“ฑ์˜ ์šด๋™ ์ฆ์ƒ์„ ํŠน์ง•์œผ๋กœ ํ•˜๋Š” ์งˆํ™˜์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ๋น„์šด๋™ ์ฆ์ƒ(non-motor symptoms) ์ด ํ™˜์ž์˜ ์‚ถ์˜ ์งˆ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ์ด ์šด๋™ ์ฆ์ƒ ๋ชป์ง€์•Š๊ฒŒ ํฌ๋‹ค๋Š” ์‚ฌ์‹ค์ด ์ ์ฐจ ๋ช…ํ™•ํ•ด์ง€๊ณ  ์žˆ๋‹ค[1]. ๋น„์šด๋™ ์ฆ์ƒ์€ ํŒŒํ‚จ์Šจ๋ณ‘์˜ ์ „๊ตฌ๊ธฐ๋ถ€ํ„ฐ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์ž„์ƒ๊ธฐ ์ „๋ฐ˜์— ๊ฑธ์ณ ์šด๋™ ์ฆ์ƒ์˜ ์ง„ํ–‰๊ณผ ํ•จ๊ป˜ ๋‹ค์–‘์„ฑ๊ณผ ์ค‘์ฆ๋„๊ฐ€ ์ฆ๊ฐ€ํ•œ๋‹ค[2].
ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ๋น„์šด๋™ ์ฆ์ƒ์˜ ์œ ๋ณ‘๋ฅ ์€ ๋งค์šฐ ๋†’์•„ ๊ฑฐ์˜ ๋ชจ๋“  ํ™˜์ž์—์„œ ํ•˜๋‚˜ ์ด์ƒ์˜ ๋น„์šด๋™ ์ฆ์ƒ์ด ๋™๋ฐ˜๋˜๋Š” ๊ฒƒ์œผ๋กœ ๋ณด๊ณ ๋œ๋‹ค[3]. ๋Œ€ํ‘œ์ ์ธ ๋น„์šด๋™ ์ฆ์ƒ์œผ๋กœ๋Š” ์ธ์ง€์žฅ์• , ์ •์‹ ์‹ ๊ฒฝ ์ฆ์ƒ(์šฐ์šธ, ๋ถˆ์•ˆ, ์ •์‹ ํ–‰๋™ ์ฆ์ƒ), ์ž์œจ์‹ ๊ฒฝ์žฅ์• , ์ˆ˜๋ฉด์žฅ์• , ํ†ต์ฆ, ํ”ผ๋กœ, ํ›„๊ฐ ์ €ํ•˜ ๋“ฑ์ด ์žˆ๋‹ค. ์ด๋Ÿฌํ•œ ์ฆ์ƒ๋“ค์€ ํ™˜์ž ๋ณธ์ธ์ด ํŒŒํ‚จ์Šจ๋ณ‘์˜ ์ฆ์ƒ์œผ๋กœ ์ธ์‹ํ•˜์ง€ ๋ชปํ•˜๊ฑฐ๋‚˜ ์˜๋ฃŒ์ง„์ด ์šด๋™ ์ฆ์ƒ ๊ด€๋ฆฌ์— ์ง‘์ค‘ํ•˜๋‹ค๋ณด๋‹ˆ ๊ฐ„๊ณผ๋˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ๋น„์šด๋™ ์ฆ์ƒ์€ ํ™˜์ž์˜ ์‚ถ์˜ ์งˆ ์ €ํ•˜, ๊ธฐ๋Šฅ์žฅ์• , ์š”์–‘์‹œ์„ค ์ž…์†Œ์˜ ์ฃผ์š” ์›์ธ์ด ๋˜๋ฉฐ ์ ์ ˆํ•œ ๊ด€๋ฆฌ๊ฐ€ ์ด๋ฃจ์–ด์ง€์ง€ ์•Š์„ ๊ฒฝ์šฐ ํ™˜์ž์™€ ๊ฐ€์กฑ ๋ชจ๋‘์—๊ฒŒ ํฐ ๋ถ€๋‹ด์„ ์ฃผ๊ธฐ ๋•Œ๋ฌธ์— ํŒŒํ‚จ์Šจ๋ณ‘์˜ ์ดˆ๊ธฐ ๋‹จ๊ณ„๋ถ€ํ„ฐ ์ข…ํ•ฉ์ ์ธ ํ‰๊ฐ€์™€ ๊ด€๋ฆฌ๊ฐ€ ํ•„์š”ํ•˜๋‹ค[4].
๋น„์šด๋™ ์ฆ์ƒ์€ ํŒŒํ‚จ์Šจ๋ณ‘์˜ ์ „๊ตฌ๊ธฐ์™€ ์งˆ๋ณ‘์˜ ๋‹ค์–‘ํ•œ ์•„ํ˜•์„ ์ดํ•ดํ•˜๋Š” ๋ฐ์—๋„ ์ค‘์š”ํ•œ ์˜๋ฏธ๋ฅผ ๊ฐ€์ง„๋‹ค. ๊ตญ์ œ ํŒŒํ‚จ์Šจ๋ณ‘ ๋ฐ ์ด์ƒ์šด๋™์งˆํ™˜ํ•™ํšŒ(International Parkinsonism and Movement Disorders Society, MDS)๋Š” ์ „๊ตฌ๊ธฐ ํŒŒํ‚จ์Šจ๋ณ‘(prodromal Parkinsonโ€™s disease)์˜ ์—ฐ๊ตฌ ๊ธฐ์ค€์„ ์ œ์‹œํ•˜์˜€๋‹ค. ์ด ๊ธฐ์ค€์—์„œ ์ „๊ตฌ๊ธฐ ํŒŒํ‚จ์Šจ๋ณ‘์€ ํŒŒํ‚จ์Šจ๋ณ‘ ์‹ ๊ฒฝํ‡ดํ–‰์„ ์‹œ์‚ฌํ•˜๋Š” ์ดˆ๊ธฐ ์ฆ์ƒ์ด๋‚˜ ์ง•ํ›„๊ฐ€ ์กด์žฌํ•˜์ง€๋งŒ ํŒŒํ‚จ์Šจ๋ณ‘์˜ ์ž„์ƒ ์ง„๋‹จ์ด ๊ฐ€๋Šฅํ•œ ์ „ํ˜•์ ์ธ ์šด๋™ ์ฆ์ƒ์€ ์•„์ง ๋ฐœํ˜„ํ•˜์ง€ ์•Š์€ ์ƒํƒœ๋กœ ์ •์˜ํ•œ๋‹ค[5,6]. ์ด ๊ธฐ์ค€์€ ํ›„๊ฐ ์ €ํ•˜, ๋ณ€๋น„, ์šฐ์šธ์ฆ, ๋ ˜์ˆ˜๋ฉดํ–‰๋™์žฅ์• (rapid eye movement sleep behavior disorder), ์ž์œจ์‹ ๊ฒฝ์žฅ์•  ๋“ฑ ์—ฌ๋Ÿฌ ๋น„์šด๋™ ์ฆ์ƒ๊ณผ ์œ„ํ—˜์ธ์ž ๋ฐ ๋ณด์กฐ ๊ฒ€์‚ฌ ์†Œ๊ฒฌ์„ ๊ฒฐํ•ฉํ•˜์—ฌ ์ „๊ตฌ๊ธฐ ๊ฐ€๋Šฅ์„ฑ์„ ์ถ”์ •ํ•˜๋„๋ก ์„ค๊ณ„๋˜์—ˆ์œผ๋‚˜ ํ˜„์žฌ๋กœ์„œ๋Š” ์—ฐ๊ตฌ ๋ชฉ์ ์œผ๋กœ ๊ฐœ๋ฐœ๋œ ๊ธฐ์ค€์ด๋ฉฐ, ์ผ๋ฐ˜ ์ž„์ƒ ์ง„๋ฃŒ์—์„œ ์ง„๋‹จ ๋„๊ตฌ๋กœ ์ ์šฉํ•˜๊ธฐ์—๋Š” ์ œํ•œ์ด ์žˆ๋‹ค. ์ตœ๊ทผ์—๋Š” ์•ŒํŒŒ-์‹œ๋ˆ„ํด๋ ˆ์ธ(ฮฑ-synuclein) ๋ณ‘๋ฆฌ๊ฐ€ ์žฅ๊ด€์‹ ๊ฒฝ๊ณ„(enteric nervous system) ๋˜๋Š” ํ›„๊ฐ๊ณ„/์ค‘์ถ”์‹ ๊ฒฝ๊ณ„์—์„œ ์‹œ์ž‘๋˜์–ด ์„œ๋กœ ๋‹ค๋ฅธ ๊ฒฝ๋กœ๋กœ ์ง„ํ–‰ํ•  ์ˆ˜ ์žˆ๋‹ค๋Š” ์žฅ-๋‡Œ์ถ•(gut-brain axis) ์ด๋ก ์ด ๋‚˜์™”๋‹ค. ์ด ์ด๋ก ์— ๊ทผ๊ฑฐํ•œ ๋ง์ดˆ ๊ธฐ์›ํ˜•/์ค‘์ถ” ๊ธฐ์›ํ˜•(body-first/brain-first) ๋ชจ๋ธ์€ ๋ ˜์ˆ˜๋ฉดํ–‰๋™์žฅ์• , ๋ณ€๋น„, ๊ธฐ๋ฆฝ์ €ํ˜ˆ์••๊ณผ ๊ฐ™์€ ๋น„์šด๋™ ์ฆ์ƒ์˜ ๋ฐœ์ƒ ์‹œ์ ๊ณผ ๋ถ„ํฌ๊ฐ€ ํŒŒํ‚จ์Šจ๋ณ‘ ์•„ํ˜• ๋ฐ ์ง„ํ–‰ ์–‘์ƒ์„ ์ดํ•ดํ•˜๋Š” ๋‹จ์„œ๊ฐ€ ๋  ์ˆ˜ ์žˆ์Œ์„ ์ œ์‹œํ•œ๋‹ค[7]. ๋‹ค๋งŒ ์ด๋Ÿฌํ•œ ๊ฐœ๋…์€ ์•„์ง ์—ฐ๊ตฌ์ , ๋ณ‘ํƒœ์ƒ๋ฆฌ์  ๋ชจ๋ธ์˜ ์„ฑ๊ฒฉ์ด ๊ฐ•ํ•˜๋ฏ€๋กœ ์‹ค์ œ ์ง„๋ฃŒ์—์„œ๋Š” ๋น„์šด๋™ ์ฆ์ƒ์˜ ์กฐ๊ธฐ ์ธ์‹๊ณผ ๊ตฌ์กฐํ™”๋œ ํ‰๊ฐ€๋กœ ์—ฐ๊ฒฐํ•˜๋Š” ์ž„์ƒ์  ์˜๋ฏธ๋ฅผ ์ค‘์‹ฌ์œผ๋กœ ํ•ด์„ํ•˜๋Š” ๊ฒƒ์ด ๋ฐ”๋žŒ์งํ•˜๋‹ค.
ํŒŒํ‚จ์Šจ๋ณ‘์˜ ๋น„์šด๋™ ์ฆ์ƒ ๊ด€๋ฆฌ์— ๊ด€ํ•œ ๊ตญ์ œ ๊ฐ€์ด๋“œ๋ผ์ธ๊ณผ ๊ทผ๊ฑฐ ๊ธฐ๋ฐ˜ ๋ฌธํ—Œ์ด ์žˆ์œผ๋‚˜ ํ•œ๊ตญ์˜ ์˜๋ฃŒ ํ™˜๊ฒฝ๊ณผ ๊ตญ๋‚ด ์‚ฌ์šฉ ๊ฐ€๋Šฅํ•œ ํ‰๊ฐ€ ๋„๊ตฌ๋ฅผ ๋ฐ˜์˜ํ•œ ์‹ค์šฉ์  ์ง€์นจ์€ ๋ถ€์กฑํ•œ ์‹ค์ •์ด๋‹ค. ๋”ฐ๋ผ์„œ ๋ณธ ์ข…์„ค์€ ๋น„์šด๋™ ์ฆ์ƒ๊ณผ ๊ด€๋ จ๋œ ํŒŒํ‚จ์Šจ๋ณ‘์˜ ๋ณ‘ํƒœ์ƒ๋ฆฌ ๋ชจ๋ธ์„ ๊ณ ์ฐฐํ•˜๋Š”๋ฐ ๋ชฉ์ ์„ ๋‘์ง€ ์•Š์•˜๋‹ค. ๋Œ€์‹  ๊ตญ๋‚ด ์ž„์ƒ ํ˜„์žฅ์—์„œ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž๋ฅผ ์ง„๋ฃŒํ•˜๋Š” ์ž„์ƒ๊ฐ€๊ฐ€ ๋น„์šด๋™ ์ฆ์ƒ์„ ์กฐ๊ธฐ์— ์ธ์‹ํ•˜๊ณ  ์ง„๋‹จ ๋ฐ ์น˜๋ฃŒ์— ์ ์šฉํ•  ์ˆ˜ ์žˆ๋„๋ก ์‹ค์šฉ์  ์ ‘๊ทผ์„ ์ œ์‹œํ•˜๋Š” ๋ฐ์— ์ดˆ์ ์„ ๋งž์ถ”์—ˆ๋‹ค. ์ด ์ข…์„ค์—์„œ ๋‹ค๋ฃจ๋Š” ๋น„์šด๋™ ์ฆ์ƒ์˜ ๋ฒ”์ฃผ๋Š” ์ •์‹ ์‹ ๊ฒฝ ์ฆ์ƒ(์šฐ์šธ, ๋ถˆ์•ˆ ๋ฐ ์ •์‹ ํ–‰๋™ ์ฆ์ƒ), ์ธ์ง€์žฅ์• , ์ž์œจ์‹ ๊ฒฝ์žฅ์• , ์ˆ˜๋ฉด์žฅ์• , ํ†ต์ฆ, ํ”ผ๋กœ๋กœ ๊ตฌ์„ฑํ•˜์˜€๋‹ค. ๊ฐ ๋น„์šด๋™ ์ฆ์ƒ์˜ ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€์— ์‚ฌ์šฉ๋˜๋Š” ์ฃผ์š” ๋„๊ตฌ๋Š” Table 1์—, ์•ฝ๋ฌผ ์น˜๋ฃŒ์™€ ๋น„์•ฝ๋ฌผ ์น˜๋ฃŒ์˜ ํ•ต์‹ฌ ์‚ฌํ•ญ์€ ๊ฐ๊ฐ Table 2์™€ Table 3์— ์š”์•ฝํ•˜์˜€๋‹ค.
๋ณธ ๋ฌธ
๋ณธ ๋ฌธ
ํŒŒํ‚จ์Šจ๋ณ‘ ๋น„์šด๋™ ์ฆ์ƒ์˜ ์ž๊ฐ€ ๋ณด๊ณ ํ˜• ์„ค๋ฌธ ๋„๊ตฌ๋Š” ํฌ๊ด„์  ๋น„์šด๋™ ์ฆ์ƒ ํ‰๊ฐ€์™€ ๊ฐœ๋ณ„ ์˜์—ญ ํ‰๊ฐ€ ๋„๊ตฌ๋กœ ๋‚˜๋ˆŒ ์ˆ˜ ์žˆ๋‹ค. ํฌ๊ด„์  ๋น„์šด๋™ ์ฆ์ƒ ๋„๊ตฌ๋ฅผ ํ™œ์šฉํ•˜์—ฌ ๋น„์šด๋™ ์ฆ์ƒ์— ๋Œ€ํ•œ ์Šคํฌ๋ฆฌ๋‹ ํ›„ ์ด์ƒ ์ฆ์ƒ์ด ์˜์‹ฌ๋˜๋Š” ํ•ญ๋ชฉ์— ๋Œ€ํ•ด ์ถ”๊ฐ€ ๊ฒ€์‚ฌ๋ฅผ ์ง„ํ–‰ํ•˜๋Š” ๋ฐฉ์‹์œผ๋กœ ์กฐ์‚ฌํ•  ์ˆ˜ ์žˆ๋‹ค. ๋น„์šด๋™์ฆ์ƒ์ฒ™๋„(non-motor symptoms scale, NMSS)๋Š” 9๊ฐœ ๋„๋ฉ”์ธ(์‹ฌํ˜ˆ๊ด€, ์ˆ˜๋ฉด/ํ”ผ๋กœ, ๊ธฐ๋ถ„/๋ฌด๊ฐ๋™, ์ง€๊ฐ/ํ™˜์‹œ, ์ฃผ์˜/๊ธฐ์–ต, ์œ„์žฅ๊ด€, ๋น„๋‡จ๊ธฐ/์„ฑ๊ธฐ๋Šฅ, ๊ธฐํƒ€), 30๋ฌธํ•ญ์„ ํฌํ•จํ•˜๊ณ , ๋ฉด๋‹ด์ž๊ฐ€ ๊ฐ ์ฆ์ƒ์˜ ๋นˆ๋„์™€ ์ค‘๋“ฑ๋„๋ฅผ ์ ์ˆ˜ํ™”ํ•˜๋Š” ๊ตฌ์กฐ์ด๋‹ค[8-10]. NMSS๋Š” ๊ตญ๋‚ด ๋‹ค๊ธฐ๊ด€ ์—ฐ๊ตฌ๋กœ ํ‘œ์ค€ํ™”๋˜์–ด ์žˆ๋‹ค[9]. MDS-NMS๋Š” MDS๊ฐ€ ์ฃผ๋„ํ•œ ๊ฐœ์ •ํŒ์œผ๋กœ NMSS๋ฅผ ๋ณด์™„ํ•œ ์„ค๋ฌธ์ง€์ด๋‹ค[11]. ๋น„์šด๋™์ฆ์ƒ์„ค๋ฌธ์ง€(non-motor symptoms questionnaire, NMSQ)๋Š” ์ž๊ฐ€ ๋ณด๊ณ ํ˜• ์„ค๋ฌธ์ด๋ฏ€๋กœ ์„ ๋ณ„ ๊ฒ€์‚ฌ ๋„๊ตฌ๋กœ ์งง์€ ์‹œ๊ฐ„์— ์ž‘์„ฑ์ด ๊ฐ€๋Šฅํ•˜๊ณ  ํŒŒํ‚จ์Šจ๋ณ‘์˜ ๋น„์šด๋™ ์ฆ์ƒ ์กด์žฌ ์—ฌ๋ถ€๋ฅผ ํŒŒ์•…ํ•˜๋Š” ๋ฐ์— ์ดˆ์ ์„ ๋‘๊ณ  ์žˆ์œผ๋ฏ€๋กœ ์ง„๋ฃŒ ์ „ ๋Œ€๊ธฐ์‹ค์—์„œ ์œ ์šฉํ•˜๊ฒŒ ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ๋‹ค[12]. ๊ทธ๋Ÿฌ๋‚˜ MDS-NMS์™€ NMSQ๋Š” ํ•œ๊ตญ์–ด ๋ฒ„์ „์ด ๊ณต์‹์ ์œผ๋กœ ๋ฐฐํฌ๋˜์ง€ ์•Š์•„ ๊ฐœ๋ณ„ ์—ฐ๊ตฌ์—์„œ ๋น„๊ณต์‹ ๋ฒˆ์—ญ๋ณธ์ด ์‚ฌ์šฉ๋œ๋‹ค.
์ •์‹ ์‹ ๊ฒฝ ์ฆ์ƒ
์ •์‹ ์‹ ๊ฒฝ ์ฆ์ƒ
1. ์šฐ์šธ์ฆ
1. ์šฐ์šธ์ฆ
์šฐ์šธ์ฆ์€ ํŒŒํ‚จ์Šจ๋ณ‘์—์„œ ๊ฐ€์žฅ ํ”ํ•˜๊ณ  ์ž„์ƒ์ ์œผ๋กœ ์ค‘์š”ํ•œ ๋น„์šด๋™ ์ฆ์ƒ ์ค‘ ํ•˜๋‚˜๋กœ, ์œ ๋ณ‘๋ฅ ์€ ์—ฐ๊ตฌ์— ๋”ฐ๋ผ ์ฐจ์ด๊ฐ€ ์žˆ์œผ๋‚˜ ์•ฝ 35-50%์˜ ํ™˜์ž์—์„œ ๋ฐœ์ƒํ•˜๋Š” ๊ฒƒ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ๋‹ค[13]. ์šฐ์šธ์ฆ์€ ํŒŒํ‚จ์Šจ๋ณ‘์˜ ์šด๋™ ์ฆ์ƒ ๋ฐœํ˜„ ์ด์ „์—๋„ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋Š” ์ „๊ตฌ ์ฆ์ƒ์ด๋ฉฐ, ํŒŒํ‚จ์Šจ๋ณ‘์˜ ์‹ ๊ฒฝํ‡ดํ–‰ ๊ณผ์ • ์ž์ฒด์™€ ๋ฐ€์ ‘ํ•œ ๊ด€๋ จ์ด ์žˆ๋‹ค[14]. ํŒŒํ‚จ์Šจ๋ณ‘ ์šฐ์šธ์ฆ์˜ ์ฃผ์š” ๊ธฐ์ „์€ ๋„ํŒŒ๋ฏผ์„ฑ(dopaminergic), ์„ธ๋กœํ† ๋‹Œ์„ฑ(serotonergic), ๋…ธ๋ฅด์—ํ”ผ๋„คํ”„๋ฆฐ์„ฑ(norepinephrinergic) ์‹ ๊ฒฝ์ „๋‹ฌ ์‹œ์Šคํ…œ์˜ ์ด์ƒ์œผ๋กœ ์„ค๋ช…ํ•œ๋‹ค[15]. ํŒŒํ‚จ์Šจ๋ณ‘ ์šฐ์šธ์ฆ์€ ์ผ๋ฐ˜ ์šฐ์šธ์ฆ๊ณผ ๋‹ฌ๋ฆฌ ์ฃ„์ฑ…๊ฐ์ด๋‚˜ ์ž๊ธฐ ๋น„๋‚œ๋ณด๋‹ค๋Š” ๋ถˆ์พŒ๊ฐ, ๋ฌด๊ฐ๋™, ๋ถˆ์•ˆ, ๋น„๊ด€์ฃผ์˜๊ฐ€ ๋‘๋“œ๋Ÿฌ์ง€๋Š” ํŠน์ง•์„ ๋ณด์ธ๋‹ค.

1) ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€

1) ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€

ํŒŒํ‚จ์Šจ๋ณ‘์—์„œ ์šฐ์šธ์ฆ์˜ ์ง„๋‹จ์€ ์ •์‹ ์žฅ์• ์ง„๋‹จํ†ต๊ณ„ํŽธ๋žŒ ์ œ5ํŒ(Diagnostic and Statistical Manual of Mental Disorders, 5th edition, DSM-5) ๊ธฐ์ค€์„ ์‚ฌ์šฉํ•˜๋‚˜ ํŒŒํ‚จ์Šจ๋ณ‘ ์ž์ฒด์˜ ์ฆ์ƒ(์ˆ˜๋ฉด์žฅ์• , ํ”ผ๋กœ, ์ •์‹ ์šด๋™์ง€์ฒด, ์‹์š• ์ €ํ•˜ ๋“ฑ)์ด ์šฐ์šธ์ฆ ์ฆ์ƒ๊ณผ ์ค‘๋ณต๋  ์ˆ˜ ์žˆ์–ด ์ฃผ์˜๊ฐ€ ํ•„์š”ํ•˜๋‹ค. ๋˜ํ•œ ๋ฌด๊ฐ๋™์€ ์šฐ์šธ์ฆ๊ณผ ์ž„์ƒ์ ์œผ๋กœ ์œ ์‚ฌํ•˜์ง€๋งŒ ์Šฌํ””์ด๋‚˜ ์ •์„œ์  ๊ณ ํ†ต์ด ๋™๋ฐ˜๋˜์ง€ ์•Š๋Š” ์ ์—์„œ ๊ตฌ๋ณ„๋˜๋ฉฐ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ๋…๋ฆฝ์ ์œผ๋กœ ํ‰๊ฐ€๋˜์–ด์•ผ ํ•œ๋‹ค. ์ฒด๊ณ„์  ๋ฌธํ—Œ ๊ณ ์ฐฐ์„ ํ†ตํ•ด์„œ ํ•ด๋ฐ€ํ„ด์šฐ์šธ ํ‰๊ฐ€์ฒ™๋„(Hamilton Depression Rating Scale, HAMD), ๋ฒก์šฐ์šธ์ฒ™๋„(Beck Depression Inventory, BDI), ๋ณ‘์› ๋ถˆ์•ˆ-์šฐ์šธ์ฒ™๋„(Hospital Anxiety and Depression Rating Scale, HADS), ๋ชฝ๊ณ ๋ฉ”๋ฆฌ-์•„์Šค๋ฒ„๊ทธ์šฐ์šธํ‰๊ฐ€์ฒ™๋„(Montgomery-Asberg Depression Rating Scale, MADRS), ๋…ธ์ธ์šฐ์šธ์ฒ™๋„(Geriatric Depression Scale, GDS)๊ฐ€ ํŒŒํ‚จ์Šจ๋ณ‘ ๊ด€๋ จ ์šฐ์šธ์˜ ์„ ๋ณ„์—๋Š” ์œ ํšจํ•˜๋ฉฐ HAMD, MADRS, BDI, GDS๋Š” ์šฐ์šธ ์ค‘์ฆ๋„ ์ธก์ •์—๋„ ์ ํ•ฉํ•˜๋‹ค๊ณ  ๊ถŒ๊ณ ํ•˜์˜€๋‹ค[16]. ์ดํ›„ ๋ฌธํ—Œ์„ ์—…๋ฐ์ดํŠธํ•œ ๋น„ํŒ์  ๊ณ ์ฐฐ์—์„œ๋Š” ์ž„์ƒ์˜ ํ‰์ • ์ฒ™๋„๋กœ๋Š” HAMD-17, ์ž๊ธฐ ๊ธฐ์ž… ์ฒ™๋„๋กœ๋Š” GDS (ํŠนํžˆ 15๋ฌธํ•ญํŒ)๋ฅผ 1์ฐจ ์„ ํƒ์ง€๋กœ ์ œ์•ˆํ•˜๋ฉด์„œ HADS-D, BDI, MADRS ์—ญ์‹œ ์‹ ๋ขฐ๋„์™€ ํƒ€๋‹น๋„๊ฐ€ ์ž…์ฆ๋œ ๋„๊ตฌ๋กœ ์ œ์‹œํ•˜์˜€๋‹ค[17]. ํŠนํžˆ GDS-30 ๋ฐ GDS-15๋Š” ์ฒด์„ฑ ํ•ญ๋ชฉ ๋น„์ค‘์ด ์ ๊ณ  ์˜ˆ/์•„๋‹ˆ์˜ค ํ˜•์‹์˜ ๋‹จ์ˆœํ•œ ๊ตฌ์กฐ๋ฅผ ๊ฐ€์ง€๋ฉฐ ๋…ธ์ธ ์ธ๊ตฌ๋ฅผ ๋Œ€์ƒ์œผ๋กœ ๊ฐœ๋ฐœ๋˜์—ˆ๊ณ  ์ €์ž‘๊ถŒ ์ œํ•œ์ด ์—†์–ด ๊ฐ€์žฅ ํšจ์œจ์ ์ธ ํŒŒํ‚จ์Šจ๋ณ‘ ์šฐ์šธ ์„ ๋ณ„ ์ฒ™๋„๋กœ ์ œ์‹œํ•˜์˜€๋‹ค. ์ž„์ƒ ํ˜„์žฅ์—์„œ๋Š” ์ž๊ฐ€ ๋ณด๊ณ ํ˜• ์„ค๋ฌธ์ง€๋ฅผ ํ†ตํ•ด ์šฐ์šธ์ฆ์„ ์„ ๋ณ„ํ•˜๊ณ  ์šฐ์šธ์˜ ์ค‘์ฆ๋„ ์ธก์ •์„ ์œ„ํ•ด HAMD-17, BDI, MADRS, HADS-D ์ฒ™๋„ ๊ฒ€์‚ฌ๋ฅผ ํ•˜๋Š” ๊ฒƒ์ด ๊ฐ€์žฅ ์ ํ•ฉํ•˜๋‹ค๊ณ  ํŒ๋‹จํ•œ๋‹ค. ์ดํ•˜์—์„œ๋Š” ํ•œ๊ตญ์–ดํŒ์ด ๊ฐœ๋ฐœ๋˜์—ˆ๊ฑฐ๋‚˜ ๊ตญ๋‚ด์—์„œ ์‚ฌ์šฉ๋˜๋Š” ํ‰๊ฐ€ ๋„๊ตฌ๋ฅผ ํ•„์š”ํ•œ ๊ฒฝ์šฐ ์› ์•ฝ์–ด ์•ž์— K-๋ฅผ ๋ถ™์—ฌ ํ‘œ๊ธฐํ•˜์˜€์œผ๋ฉฐ ๊ณต์‹ ํƒ€๋‹น๋„ ๊ฒ€์ฆ ์—ฌ๋ถ€๋Š” Table 1์— ๋ณ„๋„๋กœ ์ œ์‹œํ•˜์˜€๋‹ค. ๊ตญ์ œ์  ๊ถŒ๊ณ ์•ˆ ๋ฐ ๊ตญ๋‚ด ๊ฒ€์ฆ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ๋ฅผ ์ข…ํ•ฉํ•˜๋ฉด ์‹ค๋ฌด์ ์œผ๋กœ๋Š” GDS-15 ์„ ๋ณ„ ๊ฒ€์‚ฌ๋ฅผ ํ†ตํ•˜์—ฌ ์šฐ์šธ์ฆ์ด ์˜์‹ฌ๋˜๋ฉด DSM-5 ์ง„๋‹จ ๊ธฐ์ค€์— ์˜๊ฑฐํ•˜์—ฌ ์šฐ์šธ์ฆ์„ ์ง„๋‹จํ•˜๊ณ , ์šฐ์šธ์ฆ ์ค‘์ฆ๋„ ์ •๋„๋ฅผ ํ‰๊ฐ€ํ•˜์—ฌ ์น˜๋ฃŒ ๋ฐ˜์‘ ๋˜๋Š” ์ฆ์ƒ์˜ ๊ฒฝ๊ณผ๋ฅผ ํ™•์ธํ•˜๊ธฐ ์œ„ํ•˜์—ฌ Korean version of the Hamilton Depression Rating Scale (K-HDRS), K-HADS, K-BDI-II๋ฅผ ํ™œ์šฉํ•  ์ˆ˜ ์žˆ๋‹ค. MADRS์˜ ๊ณต์‹ ํ•œ๊ตญ์–ดํŒ์€ ๋ณด๊ธ‰๋˜์ง€ ์•Š์•˜๋‹ค.

2) ์•ฝ๋ฌผ ์น˜๋ฃŒ

2) ์•ฝ๋ฌผ ์น˜๋ฃŒ

(1) ํŒŒํ‚จ์Šจ ์•ฝ๋ฌผ
(1) ํŒŒํ‚จ์Šจ ์•ฝ๋ฌผ
ํŒŒํ‚จ์Šจ๋ณ‘ ์šฐ์šธ ์ฆ์ƒ์ด ์•ฝํšจ ์†Œ์ง„ ์‹œ๊ธฐ(wearing-off)์— ๋ฐœ์ƒํ•˜๋Š” ์˜คํ”„ ์ƒํƒœ(off-state)์˜ ์šฐ์šธ์ฆ์ธ ๊ฒฝ์šฐ ์ด๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ ์•ฝ๋ฌผ ์กฐ์ •๋งŒ์œผ๋กœ๋„ ์ƒ๋‹น ๋ถ€๋ถ„ ๊ฐœ์„ ๋  ์ˆ˜ ์žˆ๋‹ค. ์ž„์ƒ์‹œํ—˜์—์„œ ์ž…์ฆ๋œ ์•ฝ์ œ๋Š” ํ”„๋ผ๋ฏธํŽ™์†”(pramipexole)๋กœ ๋ฌด์ž‘์œ„ ๋Œ€์กฐ์‹œํ—˜(randomized controlled trial, RCT)์—์„œ ์•ฝํšจ ์†Œ์ง„ ์ฆ์ƒ์˜ ๊ฐ์†Œ์™€ ํ•จ๊ป˜ ์œ ์˜๋ฏธํ•œ ์šฐ์šธ์ฆ ๊ฐœ์„ ์„ ๋ณด์—ฌ์ฃผ์—ˆ๋‹ค[18]. ๋”ฐ๋ผ์„œ ํ•ญ ์šฐ์šธ์ œ ์ถ”๊ฐ€ ์ „์— ๊ธฐ์กด ํŒŒํ‚จ์Šจ๋ณ‘ ์•ฝ๋ฌผ์˜ ์šฉ๋Ÿ‰, ํˆฌ์—ฌ ๊ฐ„๊ฒฉ ๋ฐ ์šด๋™๋™์š”์™€ ๊ด€๋ จ๋œ ์šฐ์šธ ์ฆ์ƒ์˜ ์‹œ๊ฐ„๊ด€๊ณ„๋ฅผ ์ž˜ ํŒŒ์•…ํ•˜์—ฌ ๊ธฐ์กด ํŒŒํ‚จ์Šจ๋ณ‘ ์•ฝ๋ฌผ์˜ ์šฉ๋Ÿ‰, ํˆฌ์—ฌ ๊ฐ„๊ฒฉ, ์•ฝํšจ ์ง€์† ์‹œ๊ฐ„์„ ์žฌํ‰๊ฐ€ํ•˜๊ณ  ์กฐ์ •ํ•˜๋Š” ๊ฒƒ์ด ๊ถŒ์žฅ๋œ๋‹ค. ์‚ฌํ”ผ๋‚˜๋งˆ์ด๋“œ(safinamide)๋Š” ๋ชจ๋…ธ์•„๋ฏผ์‚ฐํ™”ํšจ์†ŒB (monoamine oxidase B, MAO-B)์–ต์ œ์ œ ๊ณ„์—ด ์ค‘ ํ•˜๋‚˜๋กœ ๋‹ค๋ฅธ MAO-B์–ต์ œ์ œ๋“ค๊ณผ๋Š” ์ฐจ๋ณ„์ ์œผ๋กœ ๊ธ€๋ฃจํƒ€๋ฉ”์ดํŠธ(glutamate) ๊ธธํ•ญ์ž‘์šฉ์„ ๊ฐ€์ง€๊ณ  ์žˆ๋‹ค. ์‚ฌํ”ผ๋‚˜๋งˆ์ด๋“œ๋Š” ํ›„ํ–ฅ ์—ฐ๊ตฌ์—์„œ ์˜๋ฏธ ์žˆ๋Š” ํ•ญ์šฐ์šธํšจ๊ณผ๋ฅผ ์ž…์ฆํ•˜์˜€๋Š”๋ฐ, ์ด๋Š” ์‚ฌํ”ผ๋‚˜๋งˆ์ด๋“œ์˜ ์•ฝํšจ ์†Œ์ง„ ํ˜„์ƒ์˜ ๊ฐ์†Œ๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ๊ธ€๋ฃจํƒ€๋ฉ”์ดํŠธ ๊ธธํ•ญ์ž‘์šฉ์„ ํ†ตํ•œ ๊ฒƒ์œผ๋กœ ํŒ๋‹จํ•œ๋‹ค[19].
(2) ํ•ญ์šฐ์šธ์ œ
(2) ํ•ญ์šฐ์šธ์ œ
ํŒŒํ‚จ์Šจ๋ณ‘ ์šฐ์šธ์ฆ์˜ ์•ฝ๋ฌผ ์น˜๋ฃŒ์—์„œ๋Š” ์„ ํƒ์ ์„ธ๋กœํ† ๋‹Œ์žฌ ํก์ˆ˜์–ต์ œ์ œ(selective serotonin reuptake inhibitor, SSRI), ์„ธ๋กœํ† ๋‹Œ-๋…ธ๋ฅด์—ํ”ผ๋„คํ”„๋ฆฐ์žฌํก์ˆ˜์–ต์ œ์ œ(serotoninnorepinephrine reuptake inhibitor, SNRI), ์‚ผํ™˜๊ณ„ํ•ญ์šฐ์šธ์ œ(tricyclic antidepressant, TCA) ๋“ฑ์„ ๊ณ ๋ คํ•  ์ˆ˜ ์žˆ๋‹ค. SSRI๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ ์šฐ์šธ์ฆ์—์„œ ๋น„๊ต์  ํ”ํžˆ ์‚ฌ์šฉ๋˜์ง€๋งŒ ์•ฝ์ œ๋ณ„ ์ž„์ƒ์‹œํ—˜ ๊ฒฐ๊ณผ๋Š” ์ผ๊ด€์ ์ด์ง€ ์•Š๋‹ค[20-24]. ํŒŒ๋ก์„ธํ‹ด(paroxetine)์€ ๋‹ค๊ธฐ๊ด€ RCT ์—ฐ๊ตฌ์—์„œ ์šฐ์šธ ์ฆ์ƒ ๊ฐœ์„  ํšจ๊ณผ๊ฐ€ ๋ณด๊ณ ๋˜์—ˆ์œผ๋‚˜ ๋‹ค๋ฅธ RCT ์—์„œ๋Š” ์œ„์•ฝ ๋Œ€๋น„ ์œ ์˜ํ•œ ํšจ๊ณผ๋ฅผ ๋ณด์ด์ง€ ์•Š์•˜๋‹ค. ์‹œํƒˆ๋กœํ”„๋žŒ(citalopram) ์—ญ์‹œ ์ผ๋ถ€ ์—ฐ๊ตฌ์—์„œ๋Š” ์œ„์•ฝ ๋Œ€๋น„ ์œ ์˜ํ•œ ํšจ๊ณผ๊ฐ€ ๋ณด๊ณ ๋˜์—ˆ์œผ๋‚˜ ๋‹ค๋ฅธ ์—ฐ๊ตฌ์—์„œ๋Š” ๊ตฐ ๊ฐ„ ์ฐจ์ด๊ฐ€ ๋ช…ํ™•ํ•˜์ง€ ์•Š์•˜๋‹ค. ์„คํŠธ๋ž„๋ฆฐ(sertraline)์€ ์ €์šฉ๋Ÿ‰ ์•„๋ฏธํŠธ๋ฆฝํ‹ธ๋ฆฐ(amitriptyline)๊ณผ ๋น„๊ตํ•œ ์†Œ๊ทœ๋ชจ ๋ฌด์ž‘์œ„ ์—ฐ๊ตฌ์—์„œ ์šฐ์šธ ์ฆ์ƒ๊ณผ ์‚ถ์˜ ์งˆ ๊ฐœ์„  ํšจ๊ณผ๊ฐ€ ๋ณด๊ณ ๋˜์—ˆ์œผ๋‚˜ ์œ„์•ฝ ๋Œ€์กฐ ๊ทผ๊ฑฐ๋Š” ์ œํ•œ์ ์ด๋‹ค. ์ด๋Ÿฌํ•œ ๊ฒฐ๊ณผ๋ฅผ ๋ฐ”ํƒ•์œผ๋กœ MDS ๊ทผ๊ฑฐ ๊ธฐ๋ฐ˜ ๋ฌธํ—Œ ๊ณ ์ฐฐ์—์„œ๋Š” ํŒŒ๋ก์„ธํ‹ด, ์‹œํƒˆ๋กœํ”„๋žŒ, ์„คํŠธ๋ž„๋ฆฐ ๋“ฑ SSRI๋ฅผ ํŒŒํ‚จ์Šจ๋ณ‘ ์šฐ์šธ์ฆ ์น˜๋ฃŒ์—์„œ ์ž„์ƒ์ ์œผ๋กœ ์œ ์šฉํ•  ๊ฐ€๋Šฅ์„ฑ์ด ์žˆ์Œ(possibly useful)์œผ๋กœ ๋ถ„๋ฅ˜ํ•˜์˜€๋‹ค[4]. ์ž„์ƒ์ ์œผ๋กœ๋Š” ํ™˜์ž์˜ ์šฐ์šธ์ฆ ์ค‘์ฆ๋„, ๋ถˆ์•ˆ ๋™๋ฐ˜ ์—ฌ๋ถ€, ์ˆ˜๋ฉด์žฅ์• , ํ†ต์ฆ, ์ธ์ง€๊ธฐ๋Šฅ, ์ž์œจ์‹ ๊ฒฝ๊ณ„ ์ฆ์ƒ, ๋ณ‘์šฉ ์•ฝ๋ฌผ์„ ์ข…ํ•ฉํ•˜์—ฌ ํ•ญ์šฐ์šธ์ œ๋ฅผ ์„ ํƒํ•œ๋‹ค. SSRI๋Š” ํ•ญ์ฝœ๋ฆฐ ๋ถ€์ž‘์šฉ์ด ์ƒ๋Œ€์ ์œผ๋กœ ์ ์–ด ํ”ํžˆ ์‚ฌ์šฉ๋˜์ง€๋งŒ MAO-B์–ต์ œ์ œ์™€ ๋ณ‘์šฉ ์‹œ ์„ธ๋กœํ† ๋‹Œ์ฆํ›„๊ตฐ ๊ฐ€๋Šฅ์„ฑ์„ ๊ณ ๋ คํ•ด์•ผ ํ•˜๋ฉฐ, ์ €๋‚˜ํŠธ๋ฅจํ˜ˆ์ฆ(hyponatremia)์ด๋‚˜ ๋–จ๋ฆผ ์•…ํ™”๊ฐ€ ๋ฐœ์ƒํ•  ์ˆ˜ ์žˆ๋‹ค. ํŠนํžˆ ์‹œํƒˆ๋กœํ”„๋žŒ์€ 60์„ธ ์ด์ƒ์—์„œ 20 mg/day๋ฅผ ์ดˆ๊ณผํ•  ๊ฒฝ์šฐ ์‹ฌ์ „๋„์—์„œ QT๊ฐ„๊ฒฉ ์—ฐ์žฅ ์œ„ํ—˜์ด ์ฆ๊ฐ€ํ•˜๋ฏ€๋กœ ์‹ฌ์ „๋„ ๊ฐ์‹œ๋ฅผ ๊ณ ๋ คํ•ด์•ผ ํ•œ๋‹ค. SNRI์ธ ๋ฒค๋ผํŒ์‹ (venlafaxine)์€ ํŒŒ๋ก์„ธํ‹ด๊ณผ ํ•จ๊ป˜ ์‹œํ–‰๋œ ๋‹ค๊ธฐ๊ด€ RCT์—์„œ ์œ„์•ฝ ๋Œ€๋น„ ์œ ์˜ํ•œ ์šฐ์šธ ์ฆ์ƒ ๊ฐœ์„  ํšจ๊ณผ๋ฅผ ๋ณด์˜€์œผ๋ฉฐ[24,25] MDS ๊ทผ๊ฑฐ ๊ธฐ๋ฐ˜ ๋ฌธํ—Œ ๊ณ ์ฐฐ์—์„œ๋„ ํšจ๋Šฅ ์ž…์ฆ(efficacious) ๋ฐ ์ž„์ƒ์ ์œผ๋กœ ์œ ์šฉํ•จ(clinically useful)์œผ๋กœ ํ‰๊ฐ€๋˜์—ˆ๋‹ค[4]. ๋”ฐ๋ผ์„œ ๋ฒค๋ผํŒ์‹ ์€ ํŒŒํ‚จ์Šจ๋ณ‘ ์šฐ์šธ์ฆ์—์„œ ๊ทผ๊ฑฐ ์ˆ˜์ค€์ด ์ƒ๋Œ€์ ์œผ๋กœ ๋†’์€ ํ•ญ์šฐ์šธ์ œ๋กœ ๊ณ ๋ คํ•  ์ˆ˜ ์žˆ์œผ๋‚˜ ํ˜ˆ์•• ์ƒ์Šน, ์˜ค์‹ฌ, ๋ถˆ๋ฉด ๋“ฑ์˜ ๋ถ€์ž‘์šฉ์„ ํ™•์ธํ•ด์•ผ ํ•œ๋‹ค. ๊ณผ๊ฑฐ์—๋Š” ์ •์‹ ๊ฑด๊ฐ•์˜ํ•™๊ณผ ์ด์™ธ์˜ ์ง„๋ฃŒ๊ณผ์—์„œ SSRI ๋“ฑ ํ•ญ์šฐ์šธ์ œ๋ฅผ ์žฅ๊ธฐ๊ฐ„ ๋ฐ˜๋ณต ์ฒ˜๋ฐฉํ•˜๋Š” ๋ฐ ์ œํ•œ์ด ์žˆ์—ˆ์œผ๋‚˜ 2022๋…„ 12์›” 1์ผ ์‹œํ–‰๋œ ๊ธ‰์—ฌ ๊ธฐ์ค€ ๊ด€๋ จ ์งˆ์˜์‘๋‹ต ์ดํ›„์—๋Š” ์šฐ์šธ ์ฆ์ƒ์ด 2์ฃผ ์ด์ƒ ์ง€์†๋˜๊ณ  ์ •์‹ ๊ฑด๊ฐ•์˜ํ•™๊ณผ ์ž๋ฌธ ์˜๋ขฐ๊ฐ€ ํ•„์š”ํ•œ ๊ฒฝ์šฐ์— ํ•ด๋‹นํ•˜์ง€ ์•Š์œผ๋ฉด ์‹ ๊ฒฝ๊ณผ๋ฅผ ํฌํ•จํ•œ ํƒ€ ์ง„๋ฃŒ๊ณผ์—์„œ๋„ ์ƒ์šฉ๋Ÿ‰์œผ๋กœ 1ํšŒ 60์ผ ๋ฒ”์œ„ ๋‚ด ๋ฐ˜๋ณต ์ฒ˜๋ฐฉ์ด ๊ฐ€๋Šฅํ•ด์กŒ๋‹ค[26]. ๋‹ค๋งŒ ์ž์‚ด ์‚ฌ๊ณ ๋‚˜ ๊ตฌ์ฒด์ ์ธ ์ž์‚ด ๊ณ„ํš์ด ์žˆ๊ฑฐ๋‚˜ ์ •์‹ ๋ณ‘์  ์ฆ์ƒ์ด ๋™๋ฐ˜๋œ ๊ฒฝ์šฐ ๋˜๋Š” ์ค‘์ฆ ์šฐ์šธ์ฆ์ด ๋ฐ˜๋ณต๋˜๋Š” ๊ฒฝ์šฐ์—๋Š” ์ •์‹ ๊ฑด๊ฐ•์˜ํ•™๊ณผ ์ „๋ฌธ์˜์™€์˜ ํ˜‘์ง„์ด ํ•„์š”ํ•˜๋‹ค.

3) ๋น„์•ฝ๋ฌผ ์น˜๋ฃŒ

3) ๋น„์•ฝ๋ฌผ ์น˜๋ฃŒ

๋น„์•ฝ๋ฌผ์  ์น˜๋ฃŒ๋กœ๋Š” ์ธ์ง€ํ–‰๋™ ์น˜๋ฃŒ(cognitive behavior therapy)์™€ ๊ทœ์น™์ ์ธ ์œ ์‚ฐ์†Œ ์šด๋™์ด ์šฐ์šธ ์ฆ์ƒ ๊ฐœ์„ ์— ๋„์›€์ด ๋˜๋Š” ๊ฒƒ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ๋‹ค[27]. ๋ฐ˜๋ณต๊ฒฝ๋‘๊ฐœ๋‡Œ์ž๊ธฐ์ž๊ทน์ˆ (repetitive transcranial magnetic stimulation)์„ ํŒŒํ‚จ์Šจ๋ณ‘ ์šฐ์šธ์ฆ์— ์ ์šฉํ•  ์ˆ˜ ์žˆ๋‹ค. ์ขŒ์ธก ๋ฐฐ์™ธ์ธก์ „์ „๋‘์—ฝํ”ผ์งˆ(dorsolateral prefrontal cortex)์„ ๊ณ ์ฃผํŒŒ๋กœ ์ž๊ทนํ•˜๋Š” ํ”„๋กœํ† ์ฝœ์ด ๊ฐ€์žฅ ๋งŽ์ด ์—ฐ๊ตฌ๋˜์—ˆ๋‹ค. ๋ฐ˜๋ณต๊ฒฝ๋‘๊ฐœ๋‡Œ์ž๊ธฐ์ž๊ทน์ˆ ์€ ํ•ญ์šฐ์šธ์ œ์— ๋ฐ˜์‘์ด ๋ถˆ์ถฉ๋ถ„ํ•˜๊ฑฐ๋‚˜ ์•ฝ๋ฌผ ๋ถ€์ž‘์šฉ์œผ๋กœ ์•ฝ๋ฌผ ์น˜๋ฃŒ๊ฐ€ ์–ด๋ ค์šด ํ™˜์ž์—๊ฒŒ ๋Œ€์•ˆ์ ์œผ๋กœ ๊ณ ๋ คํ•  ์ˆ˜ ์žˆ๋‹ค[4].
2. ๋ถˆ์•ˆ์žฅ์• 
2. ๋ถˆ์•ˆ์žฅ์• 
๋ถˆ์•ˆ์žฅ์• ๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์˜ ์•ฝ 30-40%์—์„œ ๋ฐœ์ƒํ•˜๋ฉฐ ๋ฒ”๋ถˆ์•ˆ์žฅ์• , ๊ณตํ™ฉ์žฅ์• , ์‚ฌํšŒ๋ถˆ์•ˆ์žฅ์• , ํŠน์ • ๊ณตํฌ์ฆ ๋“ฑ ๋‹ค์–‘ํ•œ ํ˜•ํƒœ๋กœ ๋‚˜ํƒ€๋‚œ๋‹ค[28]. ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ๋ถˆ์•ˆ์€ ๋„ํŒŒ๋ฏผ์„ฑ ์‹ ๊ฒฝํšŒ๋กœ์˜ ๊ธฐ๋Šฅ ์ด์ƒ, ๋ ˆ๋ณด๋„ํŒŒ ํ˜ˆ์ค‘ ๋†๋„ ๋ณ€๋™์— ๋”ฐ๋ฅธ ์˜คํ”„ ์ƒํƒœ(off state) ๋ฐ ์ด์™€ ์—ฐ๊ด€๋œ ์šด๋™ ์ฆ์ƒ ์•…ํ™”์— ๋Œ€ํ•œ ๋‘๋ ค์›€, ์ง„ํ–‰์„ฑ ์‹ ๊ฒฝํ‡ดํ–‰์— ๋Œ€ํ•œ ์‹ฌ๋ฆฌ์  ๋ฐ˜์‘ ๋“ฑ ๋ณตํ•ฉ์ ์ธ ๊ธฐ์ „์— ์˜ํ•ด ๋ฐœ์ƒํ•œ๋‹ค. ํŠนํžˆ ์˜คํ”„ ์ƒํƒœ ์‹œ๊ฐ„๊ณผ ์—ฐ๋™๋œ ๋ถˆ์•ˆ์€ ํŒŒํ‚จ์Šจ๋ณ‘ ํŠน์ด์ ์ธ ํ˜„์ƒ์œผ๋กœ ๋ ˆ๋ณด๋„ํŒŒ(levodopa) ํ˜ˆ์ค‘ ๋†๋„๊ฐ€ ๋‚ฎ์•„์ง€๋Š” ์‹œ๊ฐ„๋Œ€์— ๋ฐ˜๋ณต์ ์œผ๋กœ ๋ฐœ์ƒํ•˜๋Š” ๊ณตํ™ฉ ๋ฐœ์ž‘์ด๋‚˜ ๋ถˆ์•ˆ ์‚ฝํ™”๋กœ ๋‚˜ํƒ€๋‚œ๋‹ค. ๋ถˆ์•ˆ์€ ์•ฝ 50% ์ •๋„์—์„œ ์šฐ์šธ์ฆ๊ณผ ํ•จ๊ป˜ ๋™๋ฐ˜๋˜๋Š” ๊ฒƒ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ๋‹ค. ๋ถˆ์•ˆ์žฅ์• ๋Š” ํŠนํžˆ ๋ณดํ–‰๋™๊ฒฐ ์ฆ์ƒ์„ ์œ ๋ฐœํ•˜์—ฌ ๋‚™์ƒ์œผ๋กœ ์ด์–ด์ง€๋Š” ๊ฒฝ์šฐ๊ฐ€ ์žˆ์–ด ๋…๋ฆฝ์ ์œผ๋กœ ์‚ถ์˜ ์งˆ๊ณผ ์ผ์ƒ์ƒํ™œ๊ธฐ๋Šฅ์„ ์•…ํ™”์‹œํ‚ค๋Š” ์ค‘์š”ํ•œ ๋น„์šด๋™ ์ฆ์ƒ์ด๋‹ค.

1) ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€

1) ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€

๋ถˆ์•ˆ ์ฆ์ƒ์˜ ํ‰๊ฐ€๋ฅผ ์œ„ํ•ด ๋‹ค์Œ ์ฒ™๋„๋“ค์ด ์‚ฌ์šฉ๋œ๋‹ค. ํŒŒํ‚จ์Šจ๋ณ‘๋ถˆ์•ˆ์ฒ™๋„(Parkinson Anxiety Scale, PAS)๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ ํŠน์ด์ ์œผ๋กœ ๊ฐœ๋ฐœ๋œ ์ฒ™๋„๋กœ ์ง€์†์„ฑ ๋ถˆ์•ˆ, ์‚ฝํ™”์„ฑ ๋ถˆ์•ˆ(์˜คํ”„ ์ƒํƒœ ๋ถˆ์•ˆ ํฌํ•จ), ํšŒํ”ผ ํ–‰๋™์˜ ์„ธ ํ•˜์œ„ ์ฒ™๋„๋กœ ๊ตฌ์„ฑ๋˜์–ด ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ๋ถˆ์•ˆ ์–‘์ƒ์„ ๋” ์ •ํ™•ํ•˜๊ฒŒ ๋ฐ˜์˜ํ•œ๋‹ค[29]. ํ•ด๋ฐ€ํ„ด๋ถˆ์•ˆํ‰๊ฐ€ ์ฒ™๋„(Hamilton Anxiety Rating Scale, HAMA), ๋ฒก๋ถˆ์•ˆ์ฒ™๋„(Beck Anxiety Inventory, BAI), ๋…ธ์ธ๋ถˆ์•ˆ์ฒ™๋„(Geriatric Anxiety Inventory, GAI) ๋“ฑ ์—ญ์‹œ ์‚ฌ์šฉ๋œ๋‹ค. ์ž„์ƒ ํ˜„์žฅ์—์„œ ์˜คํ”„ ์ƒํƒœ ์‹œ๊ฐ„๋Œ€์™€ ๋ถˆ์•ˆ ๋ฐœ์ƒ์˜ ์—ฐ๊ด€์„ฑ์„ ํ™•์ธํ•˜๋Š” ๊ฒƒ์ด ์น˜๋ฃŒ ๋ฐฉํ–ฅ ๊ฒฐ์ •์— ๋งค์šฐ ์ค‘์š”ํ•˜๋‹ค.

2) ์น˜๋ฃŒ

2) ์น˜๋ฃŒ

์˜คํ”„ ์ƒํƒœ์™€ ์—ฐ๋™๋œ ๋ถˆ์•ˆ์ด ํ™•์ธ๋œ ๊ฒฝ์šฐ ๋ ˆ๋ณด๋„ํŒŒ ์šฉ๋Ÿ‰ ๋ฐ ํˆฌ์•ฝ ๊ฐ„๊ฒฉ ์ตœ์ ํ™”, ๋„ํŒŒ๋ฏผ์ž‘์šฉ์ œ(dopamine agonist) ๋˜๋Š” ์นดํ…Œ์ฝœ-O-๋ฉ”ํ‹ธ์ „์ดํšจ์†Œ(catechol-O-methyltransferase)์–ต์ œ์ œ ์ถ”๊ฐ€ ๋“ฑ ํŒŒํ‚จ์Šจ ์•ฝ์ œ๋ฅผ ์กฐ์ ˆํ•˜๋Š” ๊ฒƒ์ด ์šฐ์„ ์ด๋‹ค[4]. SSRI ๊ณ„์—ด ํ•ญ์šฐ์šธ์ œ๋Š” ์šฐ์šธ์ฆ์ด ๋™๋ฐ˜๋œ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์˜ ๋ถˆ์•ˆ ์ฆ์ƒ์—์„œ ์ž„์ƒ์ ์œผ๋กœ ๊ณ ๋ คํ•  ์ˆ˜ ์žˆ์œผ๋‚˜ ํŒŒํ‚จ์Šจ๋ณ‘ ๋ถˆ์•ˆ์„ ์ผ์ฐจ ํ‰๊ฐ€๋ณ€์ˆ˜๋กœ ํ•œ ๋ฌด์ž‘์œ„ ๋Œ€์กฐ ์—ฐ๊ตฌ ๊ทผ๊ฑฐ๋Š” ์ œํ•œ์ ์ด๋‹ค. ์ผ๋ถ€ ๋น„๋Œ€์กฐ ์—ฐ๊ตฌ ๋ฐ ์šฐ์šธ์ฆ ์น˜๋ฃŒ ์—ฐ๊ตฌ์˜ ์ด์ฐจ ํ‰๊ฐ€๋ณ€์ˆ˜์—์„œ ์‹œํƒˆ๋กœํ”„๋žŒ, ํŒŒ๋ก์„ธํ‹ด, ์„คํŠธ๋ž„๋ฆฐ์˜ ๋ถˆ์•ˆ ์ฆ์ƒ ๊ฐœ์„  ๊ฐ€๋Šฅ์„ฑ์ด ๋ณด๊ณ ๋˜์—ˆ๋‹ค[24]. ๋ถ€์Šคํ”ผ๋ก (buspirone)์€ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์˜ ๋ถˆ์•ˆ์„ ๋Œ€์ƒ์œผ๋กœ ํ•œ ์†Œ๊ทœ๋ชจ RCT์—์„œ ์ฆ์ƒ ๊ฐœ์„  ๊ฐ€๋Šฅ์„ฑ์ด ๊ด€์ฐฐ๋˜์—ˆ์œผ๋‚˜ ๋‚ด์•ฝ์„ฑ ๋ฌธ์ œ์™€ ์šด๋™ ์ฆ์ƒ ์•…ํ™” ๊ฐ€๋Šฅ์„ฑ์ด ๋ณด๊ณ ๋˜์–ด ์‹ ์ค‘ํ•œ ์‚ฌ์šฉ์ด ํ•„์š”ํ•˜๋‹ค[30]. ๋ฒค์กฐ๋””์•„์ œํ•€(benzodiazepine) ๊ณ„์—ด ์•ฝ๋ฌผ์€ ๋‹จ๊ธฐ๊ฐ„ ์‚ฌ์šฉ์€ ๊ฐ€๋Šฅํ•˜๋‚˜ ๋‚™์ƒ ์œ„ํ—˜ ์ฆ๊ฐ€, ์ธ์ง€๊ธฐ๋Šฅ ์ €ํ•˜, ๋‚ด์„ฑ ๋ฐ ์˜์กด์„ฑ ์œ„ํ—˜์œผ๋กœ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ์žฅ๊ธฐ ์‚ฌ์šฉ์€ ๊ถŒ๊ณ ํ•˜์ง€ ์•Š๋Š”๋‹ค[31].
3. ์ •์‹ ํ–‰๋™ ์ฆ์ƒ
3. ์ •์‹ ํ–‰๋™ ์ฆ์ƒ
ํŒŒํ‚จ์Šจ๋ณ‘์—์„œ ์ •์‹ ํ–‰๋™ ์ฆ์ƒ์€ ํ™˜์‹œ, ์ฐฉ๊ฐ, ๋ง์ƒ, ์ƒ์ƒํ•œ ๊ฟˆ(vivid dreaming)์„ ํฌํ•จํ•˜๋ฉฐ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์˜ ์•ฝ 20-40%์—์„œ ๋‚˜ํƒ€๋‚œ๋‹ค[32]. ํ™˜์‹œ(visual hallucination)๊ฐ€ ๊ฐ€์žฅ ํ”ํ•˜๋ฉฐ, ์ดˆ๊ธฐ์—๋Š” ๋ˆ„๊ตฐ๊ฐ€ ๊ณ์— ์žˆ๋Š” ๋А๋‚Œ์œผ๋กœ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๊ณ  ์ ์ฐจ ์ƒ์ƒํ•˜๊ณ  ๋ณต์žกํ•œ ํ˜•ํƒœ์˜ ์‚ฌ๋žŒ์ด๋‚˜ ๋™๋ฌผ์ด ๋ณด์ด๋Š” ํŠน์ง•์ ์ธ ์–‘์ƒ์„ ๋ณด์ธ๋‹ค. ํ™˜์ฒญ์€ ๋“œ๋ฌผ๊ฒŒ ๋‚˜ํƒ€๋‚œ๋‹ค. ๋ง์ƒ์€ ์ฃผ๋กœ ํ”ผํ•ด, ์งˆํˆฌ ๋ง์ƒ์œผ๋กœ ๋‚˜ํƒ€๋‚˜๋ฉฐ ๋ณ‘์‹์ด ์†Œ์‹ค๋˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค. ์ •์‹ ํ–‰๋™ ์ฆ์ƒ์€ ๋„ํŒŒ๋ฏผ์„ฑ ์•ฝ๋ฌผ์— ์˜ํ•ด ์œ ๋ฐœ ๋˜๋Š” ์•…ํ™”๋  ์ˆ˜ ์žˆ์œผ๋ฉฐ ์งˆ๋ณ‘ ์ž์ฒด์˜ ๋ณ‘๋ฆฌ์™€๋„ ๊ด€๋ จ์ด ์žˆ๋‹ค. ํŒŒํ‚จ์Šจ๋ณ‘ ์ •์‹ ๋ณ‘(Parkinsonโ€™s disease psychosis, PDP)์˜ ๋ฐœ์ƒ์€ ์ธ์ง€์žฅ์•  ๋ฐ ์น˜๋งค ์ง„ํ–‰์˜ ์œ„ํ—˜์ธ์ž์ด๊ธฐ๋„ ํ•˜๋‹ค. ํ™˜์ž๊ฐ€ ์ด๋Ÿฌํ•œ ์ฆ์ƒ์„ ์น˜๋ฃŒ์ง„์—๊ฒŒ ์ˆจ๊ธฐ๊ฑฐ๋‚˜ ๋ณ‘์œผ๋กœ ์ธ์‹ํ•˜์ง€ ๋ชปํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ์žˆ์–ด ์ ์ ˆํ•œ ์กฐ๊ธฐ ์ง„๋‹จ์„ ์œ„ํ•ด ์ž„์ƒ๊ฐ€์˜ ์ ๊ทน์ ์ธ ๋ณ‘๋ ฅ ์ฒญ์ทจ๊ฐ€ ํ•„์š”ํ•˜๋‹ค.

1) ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€

1) ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€

PDP๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ ํ™•์ง„ ์ดํ›„์— ๋ฐœ์ƒํ•œ ํ™˜๊ฐ, ๋ง์ƒ ๋“ฑ ์ •์‹ ๋ณ‘ ์ฆ์ƒ์ด ์žˆ๊ณ  ์ผ์ • ๊ธฐ๊ฐ„ ์ง€์†๋˜๊ฑฐ๋‚˜ ๋ฐ˜๋ณต๋˜๋ฉฐ ์„ฌ๋ง, ๋‹ค๋ฅธ ์ •์‹ ์งˆํ™˜, ์•ฝ๋ฌผ, ๋…์„ฑ ๋ฐ ๋Œ€์‚ฌ ์ด์ƒ์œผ๋กœ ๋” ์ž˜ ์„ค๋ช…๋˜์ง€ ์•Š์„ ๋•Œ ์ง„๋‹จํ•œ๋‹ค[33]. ์ •์‹ ํ–‰๋™ ์ฆ ์ƒ์˜ ํ‰๊ฐ€๋ฅผ ์œ„ํ•ด ์‹ ๊ฒฝ์ •์‹ ํ–‰๋™๊ฒ€์‚ฌ(Neuropsychiatric Inventory, NPI), ์–‘์„ฑ์ฆ์ƒํ‰๊ฐ€์ฒ™๋„(Scale for the Assessment of Positive Symptoms, SAPS), ์ œ1๋ถ€ MDS-ํ†ตํ•ฉ ํŒŒํ‚จ์Šจ๋ณ‘์ฒ™๋„(MDS-unified Parkinson Disease Rating Scale, MDS-UPDRS Part I) ํ•ญ๋ชฉ๋“ค์„ ํ™œ์šฉํ•  ์ˆ˜ ์žˆ๋Š” ๋ฐ, ํŒŒํ‚จ์Šจ๋ณ‘ ์ ์‘ ๋‹จ์ถ•ํ˜• SAPS-PD (9๋ฌธํ•ญ, ํ™˜๊ฐ-๋ง์ƒ ๋‘ ์„น์…˜)๊ฐ€ ๊ฐœ๋ฐœ๋œ ์ดํ›„ ํŒŒํ‚จ์Šจ๋ณ‘์— ํŠนํ™”๋œ SAPS-PD๋ฅผ ํ™œ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋‚˜ ๊ณต์‹ ํ•œ๊ตญ์–ดํŒ์„ ์œ„ํ•œ ๋ฒˆ์•ˆ๊ณผ ํ‘œ์ค€ํ™”๊ฐ€ ํ•„์š”ํ•˜๋‹ค[34,35].

2) ์น˜๋ฃŒ

2) ์น˜๋ฃŒ

์ •์‹ ํ–‰๋™ ์ฆ์ƒ์˜ ์น˜๋ฃŒ๋Š” ๋จผ์ € ์›์ธ์ด ๋˜๋Š” ์•ฝ๋ฌผ์„ ์ˆœ์ฐจ์ ์œผ๋กœ ๊ฐ๋Ÿ‰ํ•˜๊ฑฐ๋‚˜ ์ค‘๋‹จํ•˜๋Š” ๊ฒƒ์ด ์›์น™์ด๋‹ค. ํ•ญ์ฝœ๋ฆฐ์ œ โ†’ ์•„๋งŒํƒ€๋”˜ โ†’ MAO-B์–ต์ œ์ œ โ†’ ๋„ํŒŒ๋ฏผ์ž‘์šฉ์ œ โ†’ ๋ ˆ๋ณด๋„ํŒŒ ์ˆœ์œผ๋กœ ๊ฐ๋Ÿ‰์„ ๊ณ ๋ คํ•˜๋ฉฐ ๋ ˆ๋ณด๋„ํŒŒ๋Š” ๊ฐ€์žฅ ๋งˆ์ง€๋ง‰์œผ๋กœ ๊ฐ๋Ÿ‰์„ ๊ฒ€ํ† ํ•œ๋‹ค[36]. ์•ฝ๋ฌผ ์กฐ์ • ํ›„์—๋„ ์ฆ์ƒ์ด ์ง€์†๋˜๋ฉด ํ•ญ์ •์‹ ๋ณ‘ ์•ฝ๋ฌผ์„ ๊ณ ๋ คํ•œ๋‹ค. ํด๋กœ์žํ•€(clozapine)์€ PDP์—์„œ ๊ฐ€์žฅ ๊ทผ๊ฑฐ ์ˆ˜์ค€์ด ๋†’์€ ์•ฝ๋ฌผ์ด๋‚˜ ๋ฌด๊ณผ๋ฆฝ๊ตฌ์ฆ ์œ„ํ—˜์œผ๋กœ ์ธํ•ด ์ •๊ธฐ์ ์ธ ํ˜ˆ์•ก ๊ฒ€์‚ฌ ๊ฐ์‹œ๊ฐ€ ํ•„์ˆ˜์ด๋‹ค[37]. ์ฟ ์—ํ‹ฐ์•„ํ•€์€ ์šด๋™๊ธฐ๋Šฅ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ์ด ์ ์–ด ์ž„์ƒ์—์„œ ์ž์ฃผ ์‚ฌ์šฉ๋˜๋‚˜ PDP์—์„œ์˜ RCT ๊ทผ๊ฑฐ๋Š” ์ œํ•œ์ ์ด๋‹ค[38]. ํ”ผ๋งˆ๋ฐ˜์„ธ๋ฆฐ(pimavanserin)์€ ์„ธ๋กœํ† ๋‹Œ2A์ˆ˜์šฉ์ฒด(5-hydroxytryptamine 2A receptor)์—ญ์ž‘์šฉ์ œ(inverse agonist)๋กœ ๋ฏธ๊ตญ์—์„œ PDP ์น˜๋ฃŒ์ œ๋กœ ์Šน์ธ๋˜์—ˆ์œผ๋ฉฐ ๋„ํŒŒ๋ฏผ์ˆ˜์šฉ์ฒด์— ์˜ํ–ฅ ์—†์ด ํ™˜๊ฐ๊ณผ ๋ง์ƒ์„ ๊ฐœ์„ ์‹œํ‚ค๋Š” ๊ฒƒ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ์œผ๋‚˜ ๊ตญ๋‚ด์—๋Š” ๋„์ž…๋˜์ง€ ์•Š์•˜๋‹ค[39]. ์ฝœ๋ฆฐ์—์Šคํ„ฐ๋ถ„ํ•ดํšจ์†Œ(choline esterase)์–ต์ œ์ œ์ธ ๋ฆฌ๋ฐ”์Šคํ‹ฐ๊ทธ๋ฏผ(rivastigmine)์€ ์ธ์ง€์žฅ์• ๊ฐ€ ๋™๋ฐ˜๋œ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ํ™˜๊ฐ ๊ฐ์†Œ์— ํšจ๊ณผ๊ฐ€ ์žˆ๋‹ค๋Š” ๋ณด๊ณ ๊ฐ€ ์žˆ์–ด ํŒŒํ‚จ์Šจ๋ณ‘ ์น˜๋งค(Parkinson's disease dementia, PDD)์™€ PDP๊ฐ€ ๋™๋ฐ˜๋œ ๊ฒฝ์šฐ ๊ณ ๋ คํ•  ์ˆ˜ ์žˆ๋‹ค[40].
์ธ์ง€์žฅ์• 
์ธ์ง€์žฅ์• 
์ธ์ง€์žฅ์• ๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ๋‚˜ํƒ€๋‚˜๋Š” ๊ฐ€์žฅ ํ”ํ•˜๋ฉด์„œ๋„ ์ค‘์š”ํ•œ ๋น„์šด๋™ ์ฆ์ƒ ์ค‘ ํ•˜๋‚˜๋กœ ์งˆ๋ณ‘์ด ์ง„ํ–‰ํ•จ์— ๋”ฐ๋ผ ๋Œ€๋‹ค์ˆ˜์˜ ํ™˜์ž์—์„œ ์น˜๋งค๊ฐ€ ๋ฐœ์ƒํ•˜๋Š” ๊ฒƒ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ๋‹ค[41]. ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ์ธ์ง€ ์žฅ์• ๋Š” ๊ธฐ์–ต๋ ฅ(memory), ์ฃผ์˜๋ ฅ(attention), ์‹คํ–‰๊ธฐ๋Šฅ(executive function), ์–ธ์–ด(language), ์‹œ๊ฐ ์ธ์ง€(visuocognition) ๋“ฑ ๋‹ค์–‘ํ•œ ์˜์—ญ์— ์˜ํ–ฅ์„ ๋ฏธ์นœ๋‹ค[42]. ํŒŒํ‚จ์Šจ๋ณ‘ ์ธ์ง€ ์žฅ์• ๋Š” ์ •์ƒ ์ธ์ง€๊ธฐ๋Šฅ๋ถ€ํ„ฐ ๊ฒฝ๋„์ธ์ง€์žฅ์• (Parkinson's disease mild cognitive impairment, PD-MCI), PDD์— ์ด๋ฅด๋Š” ์—ฐ์†์ ์ธ ์ŠคํŽ™ํŠธ๋Ÿผ์œผ๋กœ ๋‚˜ํƒ€๋‚œ๋‹ค. ์น˜๋งค๊ฐ€ ์—†๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž ์ค‘ ์•ฝ 20-30%๊ฐ€ PD-MCI๋ฅผ ๋ณด์ด๋ฉฐ ์ „์ฒด ํ™˜์ž์˜ 10-20% ์ •๋„๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ ์ง„๋‹จ ์‹œ ์ด๋ฏธ ์ธ์ง€ ์ €ํ•˜๊ฐ€ ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒƒ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ๋‹ค. PD-MCI ํ™˜์ž์˜ ์•ฝ 30%๊ฐ€ 7๋…„ ์ด๋‚ด์— ์น˜๋งค๋กœ ์ง„ํ–‰ํ•œ๋‹ค[43,44].
1. ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€
1. ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€
ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ PD-MCI์™€ ์น˜๋งค์˜ ์ง„๋‹จ์€ MDS ํƒœ์Šคํฌํฌ์Šค(Task Force) ๊ถŒ๊ณ ์— ๋”ฐ๋ผ ๋‘ ๋‹จ๊ณ„์˜ ํ‰๊ฐ€๋ฅผ ์ง„ํ–‰ํ•œ๋‹ค. ์ฒซ ๋ฒˆ์งธ ๋‹จ๊ณ„(Level I)๋Š” ์ „๋ฐ˜์ ์ธ ์ธ์ง€๊ธฐ๋Šฅ ์ƒํƒœ ๋ฐ ํŠน์ • ์ธ์ง€ ๊ณผ์ œ ์ˆ˜ํ–‰ ๋Šฅ๋ ฅ์„ ํ‰๊ฐ€ํ•˜๋Š” ๊ฐ„์ด ์„ ๋ณ„ ๊ฒ€์‚ฌ์ด๋ฉฐ ๋‘ ๋ฒˆ์งธ ๋‹จ๊ณ„(Level II)๋Š” ์‹คํ–‰๊ธฐ๋Šฅ, ์ฃผ์˜๋ ฅ, ์ž‘์—…๊ธฐ์–ต, ๊ธฐ์–ต๋ ฅ, ์‹œ๊ฐ ์ธ์ง€, ์–ธ์–ด ๋“ฑ ์ตœ์†Œ 2๊ฐ€์ง€ ์ด์ƒ์˜ ์ธ์ง€ ์˜์—ญ์„ ์‹ฌ์ธต์ ์œผ๋กœ ํ‰๊ฐ€ํ•˜๋Š” ์ƒ์„ธํ•œ ์‹ ๊ฒฝ์‹ฌ๋ฆฌ ๊ฒ€์‚ฌ์ด๋‹ค[42,45].
PD-MCI์˜ ์ฒซ ๋ฒˆ์งธ ๋‹จ๊ณ„ ์„ ๋ณ„ ๊ฒ€์‚ฌ๋กœ๋Š” ๋ชฌํŠธ๋ฆฌ์˜ฌ์ธ์ง€ํ‰๊ฐ€(Montreal Cognitive Assessment, MoCA)๊ฐ€ ๊ถŒ๊ณ ๋œ๋‹ค[42]. MoCA๋Š” ์‹œ๊ณต๊ฐ„/์‹คํ–‰๊ธฐ๋Šฅ, ์ด๋ฆ„ ๋Œ€๊ธฐ, ๊ธฐ์–ต๋ ฅ, ์ฃผ์˜๋ ฅ, ์–ธ์–ด, ์ถ”์ƒ์  ์‚ฌ๊ณ , ์ง€๋‚จ๋ ฅ ๋“ฑ ๋‹ค์–‘ํ•œ ์ธ์ง€ ์˜์—ญ์„ 30์  ๋งŒ์ ์œผ๋กœ ํ‰๊ฐ€ํ•˜๋ฉฐ ์ด์  26์  ๋ฏธ๋งŒ์„ ์ด์ƒ์œผ๋กœ ๊ฐ„์ฃผํ•œ๋‹ค. ์ด ์™ธ์—๋„ ํŒŒํ‚จ์Šจ๋ณ‘์ธ์ง€ํ‰๊ฐ€์ฒ™๋„(Parkinsonโ€™s disease-cognitive rating scale, PD-CRS), ํŒŒํ‚จ์Šจ๋ณ‘๊ฒฐ๊ณผ์ฒ™๋„-์ธ์ง€(scales for outcomes of Parkinsonโ€™s disease-cognition, SCOPACOG), ๋งคํ‹ฐ์Šค์น˜๋งคํ‰๊ฐ€์ฒ™๋„(Mattis Dementia Rating Scale, MDRS)๋ฅผ PD-MCI์˜ ์„ ๋ณ„ ๊ฒ€์‚ฌ๋กœ ์ด์šฉํ•  ์ˆ˜ ์žˆ๋‹ค. ๊ฐ„์ด์ •์‹ ์ƒํƒœ๊ฒ€์‚ฌ(Mini-Mental State Examination, MMSE)๋Š” ์ดˆ๊ธฐ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ์ฒœ์žฅ ํšจ๊ณผ(ceiling effect)์™€ ๋‚ฎ์€ ๋ฏผ๊ฐ๋„๋กœ ์ธํ•ด PD-MCI ์„ ๋ณ„์—๋Š” ์œ ์šฉํ•˜์ง€ ์•Š์œผ๋‚˜ PDD์˜ ์ฒซ ๋ฒˆ์งธ ๋‹จ๊ณ„ ํ‰๊ฐ€์—๋Š” ์‚ฌ์šฉ ๊ฐ€๋Šฅํ•˜๋‹ค[45]. ์ฒซ ๋ฒˆ์งธ ๋‹จ๊ณ„ ํ‰๊ฐ€์—์„œ MMSE 25์  ์ดํ•˜๋ฅผ ์ธ์ง€์žฅ์• ์˜ ์ฐธ๊ณ  ๊ธฐ์ค€์œผ๋กœ ์‚ฌ์šฉํ•˜๋Š”๋ฐ, PDD๋ฅผ ์ง„๋‹จํ•˜๊ธฐ ์œ„ํ•ด์„œ๋Š” MMSE์™€ ํ•จ๊ป˜ ์‹œ๊ณ„๊ทธ๋ฆฌ๊ธฐ๋ฅผ ๋ณ‘ํ–‰ํ•œ๋‹ค. ์ด ๋‘ ๊ฐ€์ง€ ํ‰๊ฐ€์—์„œ ๋‘ ๊ฐœ ์ด์ƒ์˜ ์˜์—ญ์—์„œ ์žฅ์• ๊ฐ€ ์žˆ๊ณ  ์ผ์ƒ์ƒํ™œํ‰๊ฐ€์—์„œ ์ธ์ง€๋กœ ์ธํ•œ ๊ธฐ๋Šฅ ์ €ํ•˜๊ฐ€ ์žˆ๋Š” ๊ฒฝ์šฐ์— PDD ์ด์™ธ์˜ ๋‹ค๋ฅธ ์›์ธ์˜ ์น˜๋งค๋ฅผ ๋ฐฐ์ œํ•˜๊ฒŒ ๋˜๋ฉด PDD๋กœ ์ง„๋‹จํ•  ์ˆ˜ ์žˆ๋‹ค. ์ฒซ ๋ฒˆ์งธ ๋‹จ๊ณ„ ํ‰๊ฐ€์—์„œ ์ง„๋‹จ์ด ๋ถˆํ™•์‹คํ•˜๊ฑฐ๋‚˜ ์ž„์ƒ ๋ชจ๋‹ˆํ„ฐ๋ง, ์—ฐ๊ตฌ ๋ฐ ์ž„์ƒ์‹œํ—˜ ๋ชฉ์ ์œผ๋กœ ์ธ์ง€ ์˜์—ญ๋ณ„ ์†์ƒ์„ ์ •๋ฐ€ํ•˜๊ฒŒ ๊ทœ๋ช…ํ•  ๊ฒฝ์šฐ ๋‘ ๋ฒˆ์งธ ๋‹จ๊ณ„ ํ‰๊ฐ€์—์„œ ์ƒ์„ธ ์‹ ๊ฒฝ์‹ฌ๋ฆฌ ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•œ๋‹ค. ๋‘ ๋ฒˆ์งธ ๋‹จ๊ณ„ ํ‰๊ฐ€์—์„œ ์ƒ์„ธ ์‹ ๊ฒฝ์‹ฌ๋ฆฌ ๊ฒ€์‚ฌ๋Š” ๊ฐ ์ธ์ง€ ์˜์—ญ๋ณ„๋กœ ์ตœ์†Œ ๋‘ ๊ฐ€์ง€ ์ด์ƒ์˜ ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•˜๋ฉฐ ๊ตญ๋‚ด์—์„œ ํ‘œ์ค€ํ™”๋œ ๊ฒ€์‚ฌ๋“ค์„ ํ™œ์šฉํ•  ์ˆ˜ ์žˆ๋‹ค. ์ฃผ์˜๋ ฅ ๋ฐ ์ฒ˜๋ฆฌ์†๋„ ํ‰๊ฐ€์—๋Š” ์„ ๋กœ์ž‡๊ธฐ๊ฒ€์‚ฌ(trail making test, TMT) Aํ˜•, ๊ธฐํ˜ธ์ˆซ์ž์–‘์‹๊ฒ€์‚ฌ(symbol digit modalities test, SDMT)๊ฐ€ ์‚ฌ์šฉ๋œ๋‹ค. ์‹คํ–‰๊ธฐ๋Šฅ ํ‰๊ฐ€์—๋Š” TMT Bํ˜•, ์ „๋‘์—ฝํ‰๊ฐ€๊ฒ€์‚ฌ(frontal assessment battery, FAB), ์œ„์Šค์ฝ˜์‹ ์นด๋“œ๋ถ„๋ฅ˜๊ฒ€์‚ฌ(Wisconsin Card Sorting Test, WCST) ์ถ•์•ฝํŒ์ด ํ™œ์šฉ๋œ๋‹ค. ๊ธฐ์–ต๋ ฅ ํ‰๊ฐ€์—๋Š” ์„œ์šธ์–ธ์–ดํ•™์Šต๊ฒ€์‚ฌ(Seoul Verbal Learning Test, SVLT), ๋ ˆ์ด๋ณตํ•ฉ๋„ํ˜•๊ฒ€์‚ฌ(Rey Complex Figure Test, RCFT), ์ง€์—ฐ ํšŒ์ƒ์ด ์‚ฌ์šฉ๋œ๋‹ค. ์–ธ์–ด ํ‰๊ฐ€์—๋Š” ํ•œ๊ตญํŒ ๋ณด์Šคํ„ด์ด๋ฆ„๋Œ€๊ธฐ๊ฒ€์‚ฌ(Korean Boston Naming Test, K-BNT)์™€ ์˜๋ฏธ ์œ ์ฐฝ์„ฑ(๋ฒ”์ฃผ ์œ ์ฐฝ์„ฑ) ๊ฒ€์‚ฌ๊ฐ€ ํ™œ์šฉ๋œ๋‹ค. ์‹œ๊ฐ์ธ์ง€ ํ‰๊ฐ€์—๋Š” RCFT ๋ชจ์‚ฌ, ์„ ๋ถ„๋ฐฉํ–ฅํŒ๋‹จ๊ฒ€์‚ฌ(judgment of line orientation, JLO)๊ฐ€ ์‚ฌ์šฉ๋œ๋‹ค. ์ด๋Ÿฌํ•œ ์ข…ํ•ฉ์ ์ธ ์‹ ๊ฒฝ์‹ฌ๋ฆฌ ๊ฒ€์‚ฌ๋Š” ์ž„์ƒ์‹ ๊ฒฝ์‹ฌ๋ฆฌ์‚ฌ๊ฐ€ ์‹œํ–‰ํ•˜๋Š” ๊ฒƒ์ด ์ด์ƒ์ ์ด๋ฉฐ, ๊ฒฐ๊ณผ ํ•ด์„์— ๊ต์œก ์ˆ˜์ค€๊ณผ ์—ฐ๋ น์— ๋”ฐ๋ฅธ ๊ทœ์ค€์„ ์ ์šฉํ•˜๋Š” ๊ฒƒ์ด ์ค‘์š”ํ•˜๋‹ค.
PD-MCI ์ง„๋‹จ์—์„œ ์ธ์ง€ ์ €ํ•˜์˜ ์ •๋„๋Š” ์—ฐ๋ น ๋ฐ ๊ต์œก ์ˆ˜์ค€์— ๋”ฐ๋ฅธ ๊ทœ์ค€ ์ ์ˆ˜ ๋Œ€๋น„ 1-2 ํ‘œ์ค€ํŽธ์ฐจ(standard deviation) ์ด ํ•˜๋กœ ์ •์˜๋œ๋‹ค. PD-MCI๋Š” ๋‹จ์ผ ์˜์—ญ ๊ธฐ์–ต์„ฑ(single-domain amnestic type), ๋‹จ์ผ ์˜์—ญ ๋น„๊ธฐ์–ต์„ฑ(single-domain nonamnestic type), ๋‹ค์ค‘ ์˜์—ญ(multi-domain amnestic/nonamnestic type) ๋“ฑ ์—ฌ๋Ÿฌ ์•„ํ˜•์œผ๋กœ ๋ถ„๋ฅ˜๋˜๋ฉฐ, ํŠนํžˆ ๋‹ค์ค‘ ์˜์—ญ PD-MCI๋Š” PDD๋กœ์˜ ์ง„ํ–‰ ์œ„ํ—˜์ด ๋” ๋†’์€ ๊ฒƒ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ๋‹ค[44]. ํŒŒํ‚จ์Šจ๋ณ‘ ์ธ์ง€์žฅ์• ์—์„œ๋Š” ์‹คํ–‰๊ธฐ๋Šฅ, ์ฃผ์˜๋ ฅ ๋ฐ ์‹œ๊ณต๊ฐ„๊ธฐ๋Šฅ ์ €ํ•˜๊ฐ€ ๋น„๊ต์  ํ”ํ•˜๋ฉฐ, ์ด๋Š” ์ดˆ๊ธฐ๋ถ€ํ„ฐ ๊ธฐ์–ต๋ ฅ ์ €ํ•˜๊ฐ€ ๋‘๋“œ๋Ÿฌ์ง€๋Š” ์•Œ์ธ ํ•˜์ด๋จธ๋ณ‘(Alzheimer disease)์˜ ์ „ํ˜•์ ์ธ ์ธ์ง€์žฅ์•  ์–‘์ƒ๊ณผ๋Š” ๊ตฌ๋ณ„๋˜๋Š” ํŠน์ง•์ด๋‹ค[46].
๊ตญ๋‚ด์—์„œ ํฌ๊ด„์  ๋‘ ๋ฒˆ์งธ ๋‹จ๊ณ„ ์‹ ๊ฒฝ์‹ฌ๋ฆฌ ๊ฒ€์‚ฌ ๋ฐฐํ„ฐ๋ฆฌ๋กœ๋Š” ์„œ์šธ์‹ ๊ฒฝ์‹ฌ๋ฆฌ๊ฒ€์‚ฌ(Seoul Neuropsychological Screening Battery, SNSB)๊ฐ€ ๊ฐ€์žฅ ๋„๋ฆฌ ์‚ฌ์šฉ๋œ๋‹ค[47]. ๋‹จ SNSB-dementia version (SNSB-D)์˜ ๊ณต์‹ ํ‘œ์ค€ํ™” ๋ฐ ํƒ€๋‹น๋„ ๊ฒ€์ฆ์€ ์•Œ์ธ ํ•˜์ด๋จธ๋ณ‘๊ณผ ๊ฒฝ๋„์ธ์ง€์žฅ์•  ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ์ด๋ฃจ์–ด์กŒ์œผ๋ฉฐ, PDD๋ฅผ ๋Œ€์ƒ์œผ๋กœ ํ•œ ๋ณ„๋„์˜ ํ•œ๊ตญ์–ดํŒ ํƒ€๋‹น๋„ ๊ฒ€์ฆ ์—ฐ๊ตฌ๋Š” ํ˜„์žฌ๊นŒ์ง€ ๋ณด๊ณ ๋˜์ง€ ์•Š์•˜๋‹ค. ๋”ฐ๋ผ์„œ PDD ํ™˜์ž์— ๋Œ€ํ•œ ๋‘ ๋ฒˆ์งธ ๋‹จ๊ณ„ ํ‰๊ฐ€ ์‹œ SNSB์˜ ๊ฐœ๋ณ„ ์†Œ๊ฒ€์‚ฌ๋“ค(SVLT, RCFT, K-BNT, TMT, K-FAB ๋“ฑ)์€ ํ•œ๊ตญ ๊ทœ์ค€์— ๋”ฐ๋ผ ์ ์šฉ ๊ฐ€๋Šฅํ•˜๋‚˜ ์ „์ฒด ๋ฐฐํ„ฐ๋ฆฌ ์ ์ˆ˜์— ๋Œ€ํ•œ PDD ํŠน์ด์  ํ•ด์„ ๊ธฐ์ค€์ด ์—†๊ธฐ ๋•Œ๋ฌธ์— ์ž„์ƒ์˜์˜ ๊ฒฝํ—˜์  ํŒ๋‹จ์ด ํ•„์š”ํ•˜๋‹ค.
2. ์น˜๋ฃŒ
2. ์น˜๋ฃŒ
PDD์˜ ์•ฝ๋ฌผ ์น˜๋ฃŒ์—์„œ ๋ฆฌ๋ฐ”์Šคํ‹ฐ๊ทธ๋ฏผ(rivastigmine)์€ ์ „๋ฐ˜์  ์ธ์ง€๊ธฐ๋Šฅ, ๊ธฐ์–ต๋ ฅ, ์–ธ์–ด ๋Šฅ๋ ฅ ๋ฐ ์ฃผ์˜๋ ฅ ๋“ฑ์˜ ๊ฐœ์„ ์„ ๋ณด์—ฌ ํ˜„์žฌ PDD ์น˜๋ฃŒ๋ฅผ ์œ„ํ•ด ์ผ์ฐจ์ ์œผ๋กœ ๊ถŒ๊ณ ๋˜๋Š” ์•ฝ๋ฌผ์ด๋‹ค[4,48]. ๋ฆฌ๋ฐ”์Šคํ‹ฐ๊ทธ๋ฏผ์€ ๊ฒฝ๊ตฌ ์ œ์ œ์™€ ๊ฒฝํ”ผ ํŒจ์น˜ ์ œํ˜•์ด ์žˆ๋‹ค. ๋„๋„คํŽ˜์งˆ(donepezil)์€ ๋Œ€๊ทœ๋ชจ RCT์—์„œ ํ†ต๊ณ„์  ์œ ์˜์„ฑ์€ ์ œํ•œ์ ์ด์—ˆ์œผ๋‚˜[49] ๋ฉ”ํƒ€๋ถ„์„์—์„œ ์ฝœ๋ฆฐ์—์Šคํ„ฐ๋ถ„ํ•ดํšจ์†Œ์–ต์ œ์ œ ์ „๋ฐ˜์˜ ์œ ์˜๋ฏธํ•œ ์ธ์ง€๊ธฐ๋Šฅ ๊ฐœ์„  ํšจ๊ณผ๊ฐ€ ๋ณด๊ณ ๋˜์—ˆ๋‹ค[50]. ์ฝœ๋ฆฐ์—์Šคํ„ฐ๋ถ„ํ•ดํšจ์†Œ์–ต์ œ์ œ ์‚ฌ์šฉ ์‹œ ์„œ๋งฅ, ์‹ค์‹ , ์œ„์žฅ๊ด€ ์ฆ์ƒ ๋“ฑ์˜ ๋ถ€์ž‘์šฉ์„ ๊ฐ์‹œํ•ด์•ผ ํ•˜๋ฉฐ ํˆฌ์—ฌ ์ „ ์‹ฌ์ „๋„ ํ™•์ธ์ด ๊ถŒ์žฅ๋œ๋‹ค. ๋ฉ”๋งŒํ‹ด(memantine)์€ ์ผ๋ถ€ RCT์—์„œ ํšจ๊ณผ๋ฅผ ๋ณด์˜€์œผ๋‚˜ ์ผ๊ด€์„ฑ์ด ๋ถ€์กฑํ•˜์—ฌ PDD์—์„œ ๊ถŒ๊ณ ๋˜์ง€ ์•Š๋Š”๋‹ค[51,52]. ์ตœ๊ทผ ๋ฒ ํƒ€-๊ธ€๋ฃจ์ฝ”์„ธ๋ ˆ๋ธŒ๋กœ์‹œ๋‹ค์ œ ์ƒคํŽ˜๋ก ์ธ ์•”๋ธŒ๋ก์†”(ambroxol)์˜ 2์ƒ RCT์—์„œ๋Š” PDD ํ™˜์ž์˜ ์œ ์˜๋ฏธํ•œ ์ธ์ง€๊ธฐ๋Šฅ ๊ฐœ์„  ํšจ๊ณผ๊ฐ€ ํ™•์ธ๋˜์ง€ ์•Š์•˜๋‹ค[53]. ์ธ์ง€์žฅ์• ๊ฐ€ ๋™๋ฐ˜๋œ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ๋Š” ํ•ญ์ฝœ๋ฆฐ์•ฝ๋ฌผ(ํŠธ๋ฆฌํ—ฅ์‹œํŽ˜๋‹ˆ๋”œ, ๋ฒค์ฆˆํŠธ๋กœํ•€, ๋ฐฉ๊ด‘ ๊ณผ๋ฏผ์ฆ ์น˜๋ฃŒ์ œ ์ค‘ ํ•ญ๋ฌด์Šค์นด๋ฆฐ์ œ ๋“ฑ)์˜ ์‚ฌ์šฉ์„ ๊ฐ€๋Šฅํ•œ ํ•œํ”ผํ•˜๊ฑฐ๋‚˜ ์ตœ์†Œํ™”ํ•ด์•ผ ํ•œ๋‹ค.
ํ˜„์žฌ๊นŒ์ง€ PD-MCI์— ๋Œ€ํ•ด ์Šน์ธ๋œ ์•ฝ๋ฌผ ์น˜๋ฃŒ๋Š” ์—†์œผ๋ฉฐ ๋Œ€๋ถ€๋ถ„์˜ RCT์—์„œ ์œ ์˜๋ฏธํ•œ ํšจ๊ณผ๋ฅผ ํ™•์ธํ•˜์ง€ ๋ชปํ•˜์˜€๋‹ค[4,41]. ๋ฆฌ๋ฐ”์Šคํ‹ฐ๊ทธ๋ฏผ์„ ์ด์šฉํ•œ ์ด์ค‘ ๋งน๊ฒ€ ์—ฐ๊ตฌ์—์„œ ์ผ์ฐจ ๋ชฉํ‘œ์ธ ์ „๋ฐ˜์  ์ธ์ง€ ๊ธฐ๋Šฅ ๊ฐœ์„ ์—๋Š” ๋„๋‹ฌํ•˜์ง€ ๋ชปํ•˜์˜€์œผ๋‚˜ ์ˆ˜ํ–‰ ๊ธฐ๋ฐ˜ ์ธ์ง€ ๊ธฐ๋Šฅ ์ธก์ •์น˜์—์„œ ์ด์ฐจ์  ์ด๋“์ด ๊ด€์ฐฐ๋˜์—ˆ๋‹ค[54]. ๋„๋„คํŽ˜์งˆ๊ณผ ๋ฉ”๋งŒํ‹ด์„ ์ด์šฉํ•œ ์—ฐ๊ตฌ์—์„œ๋„ ์œ ์˜๋ฏธํ•œ PD-MCI ๊ฐœ์„ ์€ ํ™•์ธ๋˜์ง€ ์•Š์•˜๋‹ค[55,56]. ๋น„์•ฝ๋ฌผ ์น˜๋ฃŒ๋กœ๋Š” ์ธ์ง€ ํ›ˆ๋ จ(cognitive training)์ด ์ผ๋ถ€ ์ธ์ง€ ๊ธฐ๋Šฅ ๊ฐœ์„ ์— ๋„์›€์ด ๋œ๋‹ค๋Š” ๋ฉ”ํƒ€๋ถ„์„ ๊ฒฐ๊ณผ๊ฐ€ ์žˆ์œผ๋‚˜ ๊ทผ๊ฑฐ ์ˆ˜์ค€์€ ๋‚ฎ๋‹ค[57]. ์œ ์‚ฐ์†Œ ์šด๋™์„ ์ด์šฉํ•œ RCT์—์„œ ๋Œ€์กฐ๊ตฐ ๋Œ€๋น„ ์ „๋ฐ˜์ ์ธ ์ธ์ง€๊ธฐ๋Šฅ ๊ฐœ์„  ํšจ๊ณผ๊ฐ€ ๋ณด๊ณ ๋˜์—ˆ์œผ๋ฉฐ ์šด๋™ ์ค‘๋‹จ 6๊ฐœ์›” ํ›„์—๋„ ํšจ๊ณผ๊ฐ€ ์œ ์ง€๋˜์—ˆ๋‹ค[58]. ์ด์— ๋”ฐ๋ผ ๊ทœ์น™์ ์ธ ์šด๋™์„ ๋น„์•ฝ๋ฌผ์  ์ธ์ง€์žฅ์•  ๊ด€๋ฆฌ์— ์ ๊ทน ๊ถŒ์žฅํ•˜๋Š” ๊ฒƒ์ด ํ•ฉ๋ฆฌ์ ์ด๋‹ค.
์ž์œจ์‹ ๊ฒฝ์žฅ์• 
์ž์œจ์‹ ๊ฒฝ์žฅ์• 
ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ์ž์œจ์‹ ๊ฒฝ๊ณ„ ์ฆ์ƒ์€ ๋งค์šฐ ํ”ํ•˜๋ฉฐ ๊ธฐ๋ฆฝ์ €ํ˜ˆ์••์„ ๋น„๋กฏํ•œ ์‹ฌํ˜ˆ๊ด€๊ณ„์žฅ์• , ์œ„์žฅ์žฅ์• , ๋ฐฐ๋‡จ ๋ฐ ์„ฑ๊ธฐ๋Šฅ์žฅ์• , ๋ฐœํ•œ ๋ฐ ์ฒด์˜จ์กฐ์ ˆ์žฅ์•  ๋“ฑ ๊ด‘๋ฒ”์œ„ํ•œ ์˜์—ญ์— ๊ฑธ์ณ ๋‚˜ํƒ€๋‚œ๋‹ค. ๊ณ ์ „์ ์œผ๋กœ ํŒŒํ‚จ์Šจ๋ณ‘์˜ ์ž์œจ์‹ ๊ฒฝ๊ณ„ ์ด์ƒ์€ ์ง„ํ–‰์„ฑ ํŒŒํ‚จ์Šจ๋ณ‘์—์„œ ๋‘๋“œ๋Ÿฌ์ง€๋Š” ๊ฒƒ์œผ๋กœ ์•Œ๋ ค์กŒ์œผ๋‚˜ ๊ทผ๋ž˜ ์—ฐ๊ตฌ๋“ค์€ ์ดˆ๊ธฐ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž ์ค‘ ์ ˆ๋ฐ˜ ์ด์ƒ์ด ๊ธฐ๋ฆฝ ์‹œ ์–ด์ง€๋Ÿฌ์›€์„ ๊ฒฝํ—˜ํ•˜๋ฉฐ, ์ผ๋ถ€์—์„œ๋Š” ์šด๋™ ์ฆ์ƒ ๋ฐœํ˜„ ์ „์ด๋‚˜ ๋ฐœํ˜„ 1๋…„ ์ด๋‚ด์— ์ด๋ฏธ ๊ธฐ๋ฆฝ์ €ํ˜ˆ์••์ด ๋™๋ฐ˜๋จ์„ ๋ณด๊ณ ํ•˜์˜€๋‹ค[59]. ์ด๋Ÿฌํ•œ ์ž์œจ์‹ ๊ฒฝ๊ณ„ ๋น„์šด๋™ ์ฆ์ƒ๋“ค์€ ํ™˜์ž์˜ ๋‚™์ƒ ์œ„ํ—˜์„ ๋†’์ด๊ณ  ์š”๋กœ๊ฐ์—ผ ๋“ฑ ํ•ฉ๋ณ‘์ฆ๊ณผ ์ง๊ฒฐ๋˜๋ฉฐ ํ›„๊ธฐ ํŒŒํ‚จ์Šจ๋ณ‘์—์„œ ์ธ์ง€์žฅ์• ์™€ ํ•จ๊ป˜ ํ™˜์ž์˜ ์ผ์ƒ์ƒํ™œ ์ฃผ์š” ์žฅ์•  ๋ฐ ์š”์–‘์‹œ์„ค ์ž…์†Œ์˜ ์š”์ธ์œผ๋กœ ์ž‘์šฉํ•œ๋‹ค. ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž๋“ค์ด ์ž์œจ์‹ ๊ฒฝ๊ณ„ ์ฆ์ƒ์„ ํŒŒํ‚จ์Šจ๋ณ‘์— ์˜ํ•œ ๊ฒƒ์œผ๋กœ ์ธ์‹ํ•˜์ง€ ๋ชปํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์œผ๋ฏ€๋กœ ์˜๋ฃŒ์ง„์ด ๊ตฌ์กฐํ™”๋œ ๋ฌธ์ง„๊ณผ ์„ค๋ฌธ์กฐ์‚ฌ๋ฅผ ํ†ตํ•ด ํ™•์ธํ•˜๋Š” ๋…ธ๋ ฅ์ด ํ•„์š”ํ•˜๋‹ค.
1. ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€
1. ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€
์ž์œจ์‹ ๊ฒฝ๊ณ„ ์ฆ์ƒ ํ‰๊ฐ€๋ฅผ ์œ„ํ•ด ์ž๊ฐ€ ๋ณด๊ณ ํ˜• ํŒŒํ‚จ์Šจ๋ณ‘๊ฒฐ๊ณผ์ฒ™๋„-์ž์œจ์‹ ๊ฒฝ(scales for outcomes in Parkinsonโ€™s diseaseautonomic, SCOPA-AUT)์ด ๊ฐ€์žฅ ๋„๋ฆฌ ์‚ฌ์šฉ๋œ๋‹ค. SCOPAAUT๋Š” ์œ„์žฅ๊ด€, ๋น„๋‡จ๊ธฐ, ์‹ฌํ˜ˆ๊ด€, ์ฒด์˜จ ์กฐ์ ˆ/๋ฐœํ•œ, ๋™๊ณต, ์„ฑ๊ธฐ๋Šฅ ์˜์—ญ์„ ๋‹ค๋ฃจ๋Š” 25๋ฌธํ•ญ ์ž๊ฐ€ ๋ณด๊ณ  ์„ค๋ฌธ์ด๋ฉฐ ํŒŒํ‚จ์Šจ๋ณ‘ ์ž์œจ ์‹ ๊ฒฝ์žฅ์•  ํ‰๊ฐ€์— ํŠนํ™”๋˜์–ด ์žˆ๋‹ค[60]. M DS ํƒœ์Šคํฌ ํฌ ์Šค์—์„œ๋Š” SCOPA-AUT, ๋ณตํ•ฉ์ž์œจ์‹ ๊ฒฝ์ฆ์ƒ์ฒ™๋„(Composite Autonomic Symptoms Scale, COMPASS)๋ฅผ ์ œํ•œ์ ์ด ์žˆ์œผ๋‚˜ ๊ถŒ๊ณ  ๊ฐ€๋Šฅํ•œ(recommended with limitation) ๋„๊ตฌ๋กœ ์ œ์‹œํ•˜์˜€๋‹ค[61]. ๊ตญ๋‚ด์—์„œ๋Š” K-SCOPA-AUT ๋ฐ K-COMPASS-31์ด ๊ฐœ๋ฐœ๋˜์–ด ์žˆ์œผ๋ฏ€๋กœ ์‚ฌ์šฉ์ด ๊ฐ€๋Šฅํ•˜๋‹ค[62,63].
์‹ ๊ฒฝ๊ณผ ํด๋ฆฌ๋‹‰์—์„œ ์‹œํ–‰ํ•˜๋Š” ์ž์œจ์‹ ๊ฒฝ ๊ฒ€์‚ฌ๋Š” ์ฃผ๋กœ ์‹ฌํ˜ˆ๊ด€๊ณ„ ์ž์œจ์‹ ๊ฒฝ ๊ฒ€์‚ฌ์— ํ•œ์ •๋œ๋‹ค. ์‹ฌํ˜ˆ๊ด€ ์ž์œจ์‹ ๊ฒฝ ๊ฒ€์‚ฌ๋กœ๋Š” ๊ธฐ๋ฆฝ๊ฒฝ์‚ฌ๊ฒ€์‚ฌ(head-up tilt test, HUTT)๋ฅผ ์‹œํ–‰ํ•˜์—ฌ ๊ธฐ๋ฆฝ ํ›„ 3๋ถ„ ์ด๋‚ด ์ˆ˜์ถ•๊ธฐํ˜ˆ์•• >20 mmHg ๋˜๋Š” ์ด์™„๊ธฐํ˜ˆ์•• >10 mmHg ๊ฐ์†Œ ์‹œ ๊ธฐ๋ฆฝ์ €ํ˜ˆ์••์œผ๋กœ ์ง„๋‹จํ•˜๋ฉฐ, 3๋ถ„ ์ดํ›„์— ๊ธฐ์ค€์— ๋„๋‹ฌํ•˜๋ฉด ์ง€์—ฐ ๊ธฐ๋ฆฝ์ €ํ˜ˆ์••์œผ๋กœ ์ง„๋‹จํ•œ๋‹ค[64]. ์‹ฌํ˜ธํก์— ๋”ฐ๋ฅธ ์‹ฌ๋ฐ•์ˆ˜ ๋ณ€๋™(E:I ratio), ๋ฐœ์‚ด๋ฐ”์ˆ˜๊ธฐ(Valsalva maneuver), ๊ธฐ๋ฆฝ ํ›„ 30:15 ์‹ฌ๋ฐ•๋น„(30:15 ratio) ๋“ฑ์„ ํฌํ•จํ•œ ์‹ฌํ˜ˆ๊ด€ ์ž์œจ๋ฐ˜์‚ฌ ๊ฒ€์‚ฌ๋ฅผ ํ†ตํ•ด ๋ถ€๊ต๊ฐ์‹ ๊ฒฝ ๋ฐ ๊ต๊ฐ์‹ ๊ฒฝ ๊ธฐ๋Šฅ์„ ํ‰๊ฐ€ํ•  ์ˆ˜ ์žˆ๋‹ค[65]. ๋ฐœํ•œ๊ธฐ๋Šฅ ํ‰๊ฐ€๋ฅผ ์œ„ํ•ด ์ •๋Ÿ‰๋ฐœํ•œ์ถ•์‚ญ๋ฐ˜์‚ฌ๊ฒ€์‚ฌ(quantitative sudomotor axon reflex test, QSART)์™€ ์ฒด์˜จ์กฐ์ ˆ๋ฐœํ•œ๊ฒ€์‚ฌ(thermoregulatory sweat test, TST) ๋“ฑ์„ ์‹œํ–‰ํ•  ์ˆ˜ ์žˆ๋‹ค[64].
์œ„์žฅ๊ด€๊ณ„ ํ‰๊ฐ€๋Š” ์ฆ์ƒ๋ณ„๋กœ ๋‚˜๋ˆ„์–ด ์ ‘๊ทผํ•˜๋Š” ๊ฒƒ์ด ์ข‹๋‹ค. ๋ณ€๋น„์˜ ๊ฒฝ์šฐ ๋ฐฐ๋ณ€ ๋นˆ๋„, Bristol stool form, ๋ฐฐ๋ณ€ ์‹œ ๊ณผ๋„ํ•œ ํž˜์ฃผ๊ธฐ, ๋ถˆ์™„์ „ ๋ฐฐ๋ณ€๊ฐ, ์ˆ˜์ง€๋ณด์กฐ ์—ฌ๋ถ€, ๋ณ€์‹ค๊ธˆ ์—ฌ๋ถ€๋ฅผ ํ™•์ธํ•˜๊ณ  ํ•„์š”์‹œ ๋ฐฐ๋ณ€์ผ์ง€๋ฅผ ํ™œ์šฉํ•œ๋‹ค. ์ฒด์ค‘ ๊ฐ์†Œ, ํ† ํ˜ˆ, ํ‘์ƒ‰๋ณ€, ์ง„ํ–‰์„ฑ ์‚ผํ‚ด๊ณค๋ž€, ๋นˆํ˜ˆ ๋“ฑ์˜ ์ฆ์ƒ์ด ์žˆ์œผ๋ฉด ๊ธฐ์งˆ์  ์งˆํ™˜ ๊ฐ๋ณ„์ด ์šฐ์„ ์ด๋‹ค. ์ƒ๋ถ€์œ„์žฅ๊ด€ ์ฆ์ƒ์ด๋‚˜ ๋ ˆ๋ณด๋„ํŒŒ ๋ฐ˜์‘์˜ ์ง€์—ฐ, ์‹ํ›„ ๋ณต๋ถ€ํŒฝ๋งŒ, ์กฐ๊ธฐ ํฌ๋งŒ๊ฐ, ์˜ค์‹ฌ์ด ๋‘๋“œ๋Ÿฌ์ง€๋ฉด ์œ„๋ฐฐ์ถœ ์ง€์—ฐ์„ ์˜์‹ฌํ•  ์ˆ˜ ์žˆ๋‹ค. ์œ„์žฅ๊ด€์žฅ์• ์˜ ๊ฒฝ์šฐ ์‹๋„๋‚ด์•• ๊ฒ€์‚ฌ ๋ฐ ์œ„๋ฐฐ์ถœ ์‹ ํ‹ฐ๊ทธ๋ž˜ํ”ผ ๋“ฑ์„ ํ•  ์ˆ˜ ์žˆ๋‹ค. 2024๋…„ ์ œ์‹œํ•œ ํ•ฉ์˜์•ˆ์—์„œ๋Š” ๋ชจ๋“  ๋ณ‘๊ธฐ์—์„œ ์œ„์žฅ๊ด€ ์ฆ์ƒ์„ ์ •๊ธฐ์ ์œผ๋กœ ์„ ๋ณ„ ๊ฒ€์‚ฌํ•˜๊ณ  ํ•„์š”์‹œ ์†Œํ™”๊ธฐ๋‚ด๊ณผ ํ˜‘์ง„์„ ํ•˜๋„๋ก ๊ถŒ๊ณ ํ•œ๋‹ค[66].
๋ฐฐ๋‡จ์žฅ์• ์— ํ‰๊ฐ€๋Š” ๋นˆ๋‡จ, ์ ˆ๋ฐ•๋‡จ, ์•ผ๊ฐ„๋‡จ, ์ ˆ๋ฐ•์š”์‹ค๊ธˆ ๋“ฑ์˜ ์ €์žฅ์žฅ์• (storage symptoms)์™€ ๋ฐฐ๋‡จ ์ง€์—ฐ, ์ž”๋‡จ๊ฐ, ์š”์ €๋ฅ˜ ๋“ฑ์˜ ๋ฐฐ์ถœ์žฅ์• (voiding symptoms)๋ฅผ ๊ตฌ๋ถ„ํ•˜๋Š” ๊ฒƒ์ด ์น˜๋ฃŒ์˜ ๋ฐฉํ–ฅ ์„ค๋ฆฝ์— ์ค‘์š”ํ•˜๋‹ค. ๊ตญ์ œ์ „๋ฆฝ์„ ์ฆ์ƒ์ ์ˆ˜(International Prostate Symptom Score, IPSS), ๋ฐฐ๋‡จ์ผ์ง€(voiding diary), ๋ฐฐ๋‡จ ํ›„ ์ž”๋‡จ๋Ÿ‰(post-void residual urine volume) ์ธก์ •์ด ์œ ์šฉํ•˜๋‹ค. ์š”๋กœ๊ฐ์—ผ, ์ „๋ฆฝ์„ ๋น„๋Œ€, ๊ณจ๋ฐ˜์žฅ๊ธฐํƒˆ์ถœ, ์ด๋‡จ์ œ ์‚ฌ์šฉ, ์‹ฌ๋ถ€์ „ ๋“ฑ ์ด์ฐจ ์›์ธ์„ ํ•จ๊ป˜ ํ™•์ธํ•ด์•ผ ํ•œ๋‹ค. ์ฆ์ƒ์ด ๋ณตํ•ฉ์ ์ธ ๊ฒฝ์šฐ ์š”์—ญ๋™ํ•™ ๊ฒ€์‚ฌ(urodynamic study)๋ฅผ ๊ณ ๋ คํ•ด์•ผ ํ•˜๊ณ , ๋น„๋‡จ์˜ํ•™๊ณผ ํ˜‘์ง„์ด ํ•„์š”ํ•˜๋‹ค.
2. ์น˜๋ฃŒ
2. ์น˜๋ฃŒ

1) ๊ธฐ๋ฆฝ์ €ํ˜ˆ์••

1) ๊ธฐ๋ฆฝ์ €ํ˜ˆ์••

์น˜๋ฃŒ๋ฅผ ์œ„ํ•ด ๊ฐ€์žฅ ๋จผ์ € ํ•ด์•ผ ํ•  ์ผ์€ ์•…ํ™” ์ธ์ž๋ฅผ ๊ต์ •ํ•˜๋Š” ๊ฒƒ์ด๋‹ค. ํƒˆ์ˆ˜, ๋นˆํ˜ˆ ๋“ฑ์˜ ์ „์‹  ์ƒํƒœ ์ ๊ฒ€๊ณผ ๋”๋ถˆ์–ด ํ•ญ๊ณ ํ˜ˆ์••์ œ, ์ด๋‡จ์ œ, ์•ŒํŒŒ์ฐจ๋‹จ์ œ ๋“ฑ ๋‹ค๋ฅธ ์งˆํ™˜์˜ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•ด ์‚ฌ์šฉํ•˜๋Š” ์•ฝ๋ฌผ์˜ ์šฉ๋Ÿ‰์„ ์ ๊ฒ€ํ•˜๊ฑฐ๋‚˜ ๋งŒ์•ฝ ๊ฐ€๋Šฅํ•˜๋‹ค๋ฉด ์•ฝ์ œ๋ฅผ ๋ณ€๊ฒฝํ•˜๋Š” ๊ฒƒ์ด ๋„์›€์ด ๋œ๋‹ค.
ํ•˜๋ฃจ 2-3 L์˜ ์ถฉ๋ถ„ํ•œ ์ˆ˜๋ถ„ ์„ญ์ทจ์™€ ๊ณ ์—ผ์‹(ํ•˜๋ฃจ ์†Œ๊ธˆ 2-10 g)์„ ๊ถŒ์žฅํ•œ๋‹ค. ๊ฐ‘์ž‘์Šค๋Ÿฌ์šด ๊ธฐ๋ฆฝ ์ž์„ธ ํšŒํ”ผ, ๊ธฐ๋ฆฝ ์‹œ ๋ฐœ ๊ตฌ๋ฅด๊ธฐ ๋“ฑ ๋ฌผ๋ฆฌ์  ๋Œ€์‘ ๋™์ž‘์„ ๊ต์œกํ•˜๋ฉฐ ์žฅ์‹œ๊ฐ„ ์„œ ์žˆ๊ธฐ, ๊ณ ์˜จ ํ™˜๊ฒฝ, ๊ณผ์‹ ๋“ฑ ์ฆ์ƒ ์œ ๋ฐœ ์ƒํ™ฉ์„ ํ”ผํ•˜๋„๋ก ์ง€๋„ํ•œ๋‹ค. ์••๋ฐ•์Šคํƒ€ํ‚น(๋ฌด๋ฆŽ ์ด์ƒ ๊ธธ์ด)์ด๋‚˜ ๋ณต๋ถ€ ์••๋ฐ•๋Œ€๊ฐ€ ๋„์›€์ด ๋  ์ˆ˜ ์žˆ์œผ๋‚˜ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์˜ ์šด๋™๊ธฐ๋Šฅ ์ €ํ•˜๋กœ ์ฐฉ์šฉ์ด ์–ด๋ ค์šด ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค.
์•ฝ๋ฌผ ์น˜๋ฃŒ๋กœ๋Š” ๋Œ€ํ‘œ์ ์œผ๋กœ ํ”Œ๋ฃจ๋“œ๋กœ์ฝ”๋ฅดํ‹ฐ์†(fludrocortisone) ์„ ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ ๋ฏธ๋„ค๋ž„์ฝ”๋ฅดํ‹ฐ์ฝ”์ด๋“œ ์ž‘์šฉ์„ ํ†ตํ•ด ํ˜ˆ์žฅ ์šฉ๋Ÿ‰์„ ๋Š˜๋ฆฌ๋Š” ํšจ๊ณผ๊ฐ€ ์žˆ๋‹ค. ํˆฌ์•ฝ ์‹œ ํ•˜์ง€๋ถ€์ข…, ๋ˆ„์šด์ž์„ธ๊ณ ํ˜ˆ์••(supine hypertension), ์ €์นผ๋ฅจํ˜ˆ์ฆ(hypokalemia)์— ์ฃผ์˜ํ•ด์•ผ ํ•˜๋ฉฐ ์‹ฌ๊ธฐ๋Šฅ ํ‰๊ฐ€ ํ›„ ์‚ฌ์šฉํ•˜๋Š” ๊ฒƒ์ด ๊ถŒ์žฅ๋œ๋‹ค[67]. ๋ฏธ๋„๋“œ๋ฆฐ(midodrine)์€ ์•ŒํŒŒ1-์ˆ˜์šฉ์ฒด์ž‘์šฉ์ œ๋กœ ๋ง์ดˆ ํ˜ˆ๊ด€ ์ˆ˜์ถ•์„ ์œ ๋„ํ•œ๋‹ค. ๋ฏธ๋„๋“œ๋ฆฐ ๋ณต์šฉ ์‹œ ๋ˆ„์šด์ž์„ธ๊ณ ํ˜ˆ์••์ด ํ”ํ•˜๋ฉฐ ์‹ฌ๊ฐํ•  ์ˆ˜ ์žˆ์–ด ์ฃผ์˜๊ฐ€ ํ•„์š”ํ•˜๋‹ค[67]. ๋“œ๋ก์‹œ๋„ํŒŒ(droxidopa)๋Š” ๋…ธ๋ฅด์—ํ”ผ๋„คํ”„๋ฆฐ ์ „๊ตฌ์ฒด๋กœ ์‹ ๊ฒฝ์„ฑ ๊ธฐ๋ฆฝ์ €ํ˜ˆ์••์— ์‚ฌ์šฉ๋œ๋‹ค[68]. ํ”ผ๋ฆฌ๋„์Šคํ‹ฐ๊ทธ๋ฏผ(pyridostigmine)์€ ์ฝœ๋ฆฐ์—์Šคํ„ฐ๋ถ„ํ•ดํšจ์†Œ์–ต์ œ์ œ๋กœ ๋ง์ดˆ ๊ต๊ฐ์‹ ๊ฒฝ ์‹ ํ˜ธ๋ฅผ ์ฆํญ์‹œํ‚จ๋‹ค[69].

2) ์œ„์žฅ๊ด€ ์ž์œจ์‹ ๊ฒฝ์žฅ์• 

2) ์œ„์žฅ๊ด€ ์ž์œจ์‹ ๊ฒฝ์žฅ์• 

์นจํ˜๋ฆผ(sialorrhea)์€ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์˜ 70% ์ด์ƒ์—์„œ ๋ฐœ์ƒํ•˜๋ฉฐ ์‚ผํ‚ด ๋นˆ๋„ ๊ฐ์†Œ์™€ ๊ตฌ๊ฐ•๊ทผ์œก๊ธฐ๋Šฅ ์ €ํ•˜๊ฐ€ ์›์ธ์ด๋‹ค[70]. ๊ธ€๋ฆฌ์ฝ”ํ”ผ๋กค๋ ˆ์ดํŠธ(glycopyrrolate), ์ดํ”„๋ผํŠธ๋กœํ”ผ์›€(ipratropium) ์Šคํ”„๋ ˆ์ด ๋˜๋Š” ์ดํ•˜์„ /์•…ํ•˜์„ ์— ๋Œ€ํ•œ ๋ณดํ‹€๋ฆฌ๋ˆ„์Šค ๋…์†Œ ์ฃผ์‚ฌ๊ฐ€ ํšจ๊ณผ์ ์ด๋‹ค[66]. ๋ณ€๋น„๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์˜ 60-80%์—์„œ ๋ฐœ์ƒํ•˜๋ฉฐ ์ „๊ตฌ๊ธฐ์—์„œ ๋ฐœ์ƒํ•  ์ˆ˜ ์žˆ๋Š” ๋น„์šด๋™ ์ฆ์ƒ ์ค‘ ํ•˜๋‚˜์ด๋‹ค[71]. ์ถฉ๋ถ„ํ•œ ์ˆ˜๋ถ„ ์„ญ์ทจ, ๊ณ ์„ฌ์œ ์‹, ๊ทœ์น™์  ์šด๋™์„ ๊ธฐ๋ณธ์œผ๋กœ ํ•˜๋ฉฐ ์‚ผํˆฌ์„ฑ ์™„ํ•˜์ œ(macrogol, lactulose) ๋˜๋Š” ์ž๊ทน์„ฑ ์™„ํ•˜์ œ๋ฅผ ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ๋‹ค. ์œ„๋ฐฐ์ถœ ์ง€์—ฐ(gastroparesis)์€ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์˜ ์•ฝ 70-100%์—์„œ ๊ด€์ฐฐ๋˜๋ฉฐ ๊ตฌ์—ญ๊ฐ, ์กฐ๊ธฐ ํฌ๋งŒ๊ฐ, ์‹ํ›„ ํŒฝ๋งŒ๊ฐ, ์ฒด์ค‘ ๊ฐ์†Œ๋กœ ๋‚˜ํƒ€๋‚œ๋‹ค. ์œ„๋ฐฐ์ถœ ์ง€์—ฐ์€ ๋ ˆ๋ณด๋„ํŒŒ์˜ ํก์ˆ˜๋ฅผ ๋ถˆ๊ทœ์น™ํ•˜๊ฒŒ ๋งŒ๋“ค์–ด ์šด๋™ ๋ณ€๋™์„ฑ์„ ์•…ํ™”์‹œํ‚ฌ ์ˆ˜ ์žˆ๋‹ค[72]. ์ง„๋‹จ์„ ์œ„ํ•ด ๋ฐฉ์‚ฌ์„ฑํ•ต์ข… ์œ„ ์Šค์บ”(gastric scintigraphy)์ด ํ‘œ์ค€ ๊ฒ€์‚ฌ๋กœ ์‚ฌ์šฉ๋œ๋‹ค. ์น˜๋ฃŒ์—์„œ๋Š” ์†Œ๋Ÿ‰์”ฉ ์ž์ฃผ ์‹์‚ฌํ•˜๊ธฐ, ์‹์‚ฌ ์‹œ๊ฐ„๊ณผ ๋ ˆ๋ณด๋„ํŒŒ ๋ณต์šฉ ์‹œ๊ฐ„ ์กฐ์ • ๋“ฑ์„ ๋จผ์ € ๊ณ ๋ คํ•ด์•ผ ํ•œ๋‹ค[66]. ์•ฝ๋ฌผ ์น˜๋ฃŒ๋กœ๋Š” ๊ตญ๋‚ด ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ํ•œ ์—ฐ๊ตฌ์—์„œ DA-9701์ด ์œ„๋ฐฐ์ถœ ๊ฐœ์„  ๊ฐ€๋Šฅ์„ฑ์„ ๋ณด์˜€์œผ๋‚˜ ๊ตญ๋‚ด ํ—ˆ๊ฐ€ ์ ์‘์ฆ์€ ๊ธฐ๋Šฅ์„ฑ ์†Œํ™”๋ถˆ๋Ÿ‰์ฆ์ด๋ฉฐ ํŒŒํ‚จ์Šจ๋ณ‘ ์œ„๋ฐฐ์ถœ ์ง€์—ฐ ๋ชฉ์  ์‚ฌ์šฉ์€ ํ—ˆ๊ฐ€ ์ ์‘์ฆ ์™ธ ์‚ฌ์šฉ์— ํ•ด๋‹นํ•œ๋‹ค[73]. ๋”ํŽ˜๋ฆฌ๋ˆ(domperidone)์€ ๋ง์ดˆ ๋„ํŒŒ๋ฏผ D2์ˆ˜์šฉ์ฒด๊ธธํ•ญ์ œ๋กœ ํ˜ˆ์•ก๋‡Œ์žฅ๋ฒฝ ํ†ต๊ณผ๊ฐ€ ์ œํ•œ์ ์ด์–ด์„œ ์ค‘์ถ”์‹ ๊ฒฝ๊ณ„ ๋ถ€์ž‘์šฉ์ด ์ƒ๋Œ€์ ์œผ๋กœ ์ ์ง€๋งŒ ๊ตญ๋‚ด ํ—ˆ๊ฐ€ ์ ์‘์ฆ์€ ์˜ค์‹ฌ๊ณผ ๊ตฌํ†  ์ฆ์ƒ์˜ ์™„ํ™”์ด๋ฉฐ, QT๊ฐ„๊ฒฉ ์—ฐ์žฅ ๋ฐ ๋ถ€์ •๋งฅ ์œ„ํ—˜์„ ๊ณ ๋ คํ•ด์•ผ ํ•œ๋‹ค[74]. ๋ฉ”ํ† ํด๋กœํ”„๋ผ๋ฏธ๋“œ(metoclopramide)์™€ ๋ ˆ๋ณด์„คํ”ผ๋ฆฌ๋“œ(levosulpiride)์ฒ˜๋Ÿผ ํ˜ˆ์•ก๋‡Œ์žฅ๋ฒฝ์„ ํ†ต๊ณผํ•˜๋Š” ๋„ํŒŒ๋ฏผ์ˆ˜์šฉ์ฒด์ฐจ๋‹จ์ œ๋Š” ํŒŒํ‚จ์Šจ ์ฆ์ƒ์„ ์•…ํ™”์‹œํ‚ฌ ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ๋Š” ์‚ฌ์šฉ์„ ํ”ผํ•˜๋Š” ๊ฒƒ์ด ์›์น™์ด๋‹ค[75].

3) ๋ฐฐ๋‡จ์žฅ์• 

3) ๋ฐฐ๋‡จ์žฅ์• 

๋นˆ๋‡จ, ์ ˆ๋ฐ•๋‡จ, ์•ผ๊ฐ„๋‡จ, ์ ˆ๋ฐ•์š”์‹ค๊ธˆ์˜ ํ˜•ํƒœ๋กœ ๋‚˜ํƒ€๋‚˜๋Š” ์ €์žฅ ์žฅ์• ๊ฐ€ ํŒŒํ‚จ์Šจ๋ณ‘์—์„œ๋Š” ๊ฐ€์žฅ ํ”ํ•˜๋‹ค[76,77]. ์น˜๋ฃŒ ์ „ ์š”๋กœ ๊ฐ์—ผ, ์ „๋ฆฝ์„ ๋น„๋Œ€, ์ด๋‡จ์ œ ๋ณต์šฉ ์—ฌ๋ถ€, ์‹ฌํ•œ ๋ณ€๋น„์™€ ๊ฐ™์€ ์ด์ฐจ ์›์ธ์ด ์žˆ๋Š” ๊ฒฝ์šฐ ์ด๋ฅผ ๋จผ์ € ๊ต์ •ํ•œ๋‹ค. ๋ฐฉ๊ด‘ ํ›ˆ๋ จ, ์‹œ๊ฐ„์ œ ๋ฐฐ๋‡จ(timed voiding) ๋“ฑ๊ณผ ๊ฐ™์€ ๋น„์•ฝ๋ฌผ ์น˜๋ฃŒ์ธ ํ–‰๋™ ์น˜๋ฃŒ๊ฐ€ ์•ฝ๋ฌผ ์น˜๋ฃŒ์— ๋น„ํ•ด ์—ด๋“ฑํ•˜์ง€ ์•Š์•„ ์šฐ์„  ์‹œ๋„ํ•ด ๋ณผ ์ˆ˜ ์žˆ๋‹ค[78]. ํ•ญ๋ฌด์Šค์นด๋ฆฐ์ œ์ธ ์†”๋ฆฌํŽ˜๋‚˜์‹ (solifenacin), ์˜ฅ์‹œ๋ถ€ํ‹ฐ๋‹Œ(oxybutynin)์„ ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋‚˜ ํ•ญ์ฝœ๋ฆฐ ๋ถ€์ž‘์šฉ(์ธ์ง€ ์ €ํ•˜, ๋ณ€๋น„, ๊ตฌ๊ฐˆ)์— ์ฃผ์˜ํ•œ๋‹ค[79]. ๋ฒ ํƒ€-3์•„๋“œ๋ ˆ๋‚ ๋ฆฐ์ˆ˜์šฉ์ฒด(ฮฒ3-adrenoreceptor)์ž‘์šฉ์ œ์ธ ๋ฏธ๋ผ๋ฒ ๊ทธ๋ก (mirabegron)์€ ํ•ญ์ฝœ๋ฆฐ ๋ถ€์ž‘์šฉ์ด ์—†์–ด ๊ณ ๋ น ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—๊ฒŒ ์„ ํ˜ธ๋  ์ˆ˜ ์žˆ๋‹ค[80]. ์•ฝํ•œ ์š”์ค„๊ธฐ, ์ž”๋‡จ๊ฐ, ์š”์ €๋ฅ˜์™€ ๊ฐ™์€ ๋ฐฐ์ถœ์žฅ์• ์˜ ๊ฒฝ์šฐ ์šฐ์„  ํ•ญ์ฝœ๋ฆฐ ํšจ๊ณผ๊ฐ€ ์žˆ๋Š” ์•ฝ๋ฌผ์„ ๋ณต์šฉ ์—ฌ๋ถ€๋ฅผ ์ฃผ์˜ ๊นŠ๊ฒŒ ํ™•์ธํ•ด์•ผ ํ•œ๋‹ค. ์ดํ›„ ์ž”๋‡จ๋Ÿ‰ ์ธก์ •๊ณผ ์š”์—ญ๋™ํ•™ ๊ฒ€์‚ฌ๋ฅผ ํ†ตํ•˜์—ฌ ๋ฐฐ๋‡จ๊ทผ ๊ณผํ™œ๋™์„ฑ์˜ ๋™๋ฐ˜ ์—ฌ๋ถ€์™€ ๊ด€๊ณ„์—†์ด ์œ ์˜๋ฏธํ•œ ๋ฐฉ๊ด‘ ์ถœ๊ตฌ ํ์ƒ‰์„ ํ™•์ธํ•œ๋‹ค[81]. ๋ฐฉ๊ด‘ ์ถœ๊ตฌ ํ์ƒ‰์ด ๊ฐ๊ด€์ ์œผ๋กœ ํ™•์ธ ๋œ ๊ฒฝ์šฐ ์ˆ˜์ˆ ์„ ๊ณ ๋ คํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ ํƒ์Šค๋กœ์‹ (tamsulosin)๊ณผ ๊ฐ™์€ ์•ŒํŒŒ-1์•„๋“œ๋ ˆ๋‚ ๋ฆฐ ์ˆ˜์šฉ์ฒด(ฮฑ1-adrenoreceptor)์ฐจ๋‹จ์ œ๋ฅผ ์‹œ๋„ํ•ด ๋ณผ ์ˆ˜ ์žˆ์œผ๋‚˜ ๋น„๋‡จ์˜ํ•™๊ณผ ์ „๋ฌธ ์ง„๋ฃŒ๋ฅผ ๊ถŒ์žฅํ•œ๋‹ค[82].
์ˆ˜๋ฉด์žฅ์• 
์ˆ˜๋ฉด์žฅ์• 
ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ์ˆ˜๋ฉด์žฅ์• ๋Š” ๋Œ€ํ‘œ์ ์ธ ๋น„์šด๋™ ์ฆ์ƒ ์ค‘ ํ•˜๋‚˜๋กœ ์ˆ˜๋ฉด ๊ตฌ์กฐ(sleep architecture)์˜ ์†์ƒ์— ๋”ฐ๋ฅธ ์ˆ˜๋ฉด ๊ฐœ์‹œ ๋ฐ ์ˆ˜๋ฉด์œ ์ง€์žฅ์• , ์ฃผ๊ฐ„๊ณผ๋‹ค์กธ๋ฆผ์ฆ, ๋žจ์ˆ˜๋ฉดํ–‰๋™์žฅ์•  ๋“ฑ ๋งค์šฐ ๋‹ค์–‘ํ•œ ์–‘์ƒ์œผ๋กœ ๋‚˜ํƒ€๋‚œ๋‹ค. ์ด ์ค‘ ๋žจ์ˆ˜๋ฉดํ–‰๋™์žฅ์• ์™€ ์ฃผ๊ฐ„๊ณผ๋‹ค์กธ๋ฆผ์ฆ์€ ๋Œ€ํ‘œ์ ์ธ ํŒŒํ‚จ์Šจ๋ณ‘์˜ ์ „๊ตฌ๊ธฐ ์ฆ์ƒ์ด๋‹ค. ์ˆ˜๋ฉด์žฅ์• ๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ ์ง„๋‹จ ํ›„ ์•ฝ 5๋…„์ด ์ง€๋‚˜๋ฉด 70% ์ด์ƒ์˜ ํ™˜์ž์—์„œ ๊ฒช๊ฒŒ ๋˜๋Š” ๊ฒƒ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ๋‹ค[83,84]. ์ˆ˜๋ฉด์žฅ์• ๋กœ ์•…ํ™”๋œ ์ˆ˜๋ฉด์˜ ์งˆ์€ ์ธ์ง€๊ธฐ๋Šฅ ์ €ํ•˜์™€ ๋”๋ถˆ์–ด ์ผ์ƒ์ƒํ™œ์— ๋ถ€์ •์  ์˜ํ–ฅ์„ ๋ผ์น˜๋ฉฐ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์˜ ์‚ถ์˜ ์งˆ ์ €ํ•˜์™€ ์งˆ๋ณ‘ ๊ฐ€์†ํ™”์— ๊ธฐ์—ฌํ•œ๋‹ค[85]. ๋Œ€๋ถ€๋ถ„์˜ ํ™˜์ž๋“ค์€ ์ˆ˜๋ฉด์žฅ์• ๋ฅผ ํŒŒํ‚จ์Šจ๋ณ‘์— ์˜ํ•œ ๊ฒƒ์œผ๋กœ ์ธ์‹ํ•˜์ง€ ๋ชปํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์•„ ๋œ ๋ณด๊ณ ํ•˜๋Š” ๊ฒฝํ–ฅ์ด ์žˆ์–ด ์ ๊ทน์ ์ธ ๋ณ‘๋ ฅ ์ฒญ์ทจ์™€ ํ‰๊ฐ€๊ฐ€ ํ•„์š”ํ•˜๋‹ค
1. ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€
1. ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€
ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์˜ ์ˆ˜๋ฉด์žฅ์•  ํ‰๊ฐ€๋Š” ํ™˜์ž์™€ ๋ณดํ˜ธ์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ํ•œ ๊ตฌ์กฐํ™”๋œ ๋ณ‘๋ ฅ ์ฒญ์ทจ๊ฐ€ ํ•„์ˆ˜์ ์ด๋‹ค. ์ˆ˜๋ฉด ๊ฐœ์‹œ ๋ฐ ์œ ์ง€์˜ ์–ด๋ ค์›€, ์ฃผ๊ฐ„๊ณผ๋‹ค์กธ๋ฆผ์ฆ, ๋žจ์ˆ˜๋ฉด ์ค‘ ์ด์ƒ ํ–‰๋™, ์•ผ๊ฐ„ ๋นˆ๋‡จ์™€ ํ†ต์ฆ, ์•ผ๊ฐ„ ์šด๋™ ์ฆ์ƒ ์•…ํ™”, ์นดํŽ˜์ธ ๋˜๋Š” ์•Œ์ฝ”์˜ฌ ์„ญ์ทจ ๋“ฑ ์ˆ˜๋ฉด์— ์˜ํ–ฅ์„ ์ค„ ์ˆ˜ ์žˆ๋Š” ์š”์ธ์„ ํฌ๊ด„์ ์œผ๋กœ ํ™•์ธํ•ด์•ผ ํ•œ๋‹ค. ํŒŒํ‚จ์Šจ๋ณ‘์—์„œ ์ถ”์ฒœ๋˜๋Š” ์ˆ˜๋ฉด์žฅ์•  ์„ค๋ฌธ ๋„๊ตฌ๋กœ๋Š” ํŒŒํ‚จ์Šจ๋ณ‘์ˆ˜๋ฉด์ฒ™๋„-2 (Parkinsonโ€™s Disease Sleep Scale-2, PDSS-2), ํŒŒํ‚จ์Šจ๋ณ‘๊ฒฐ๊ณผ์ฒ™๋„-์ˆ˜๋ฉด(SCOPA-Sleep), ์—ก์›Œ์Šค์กธ๋ฆผ์ฒ™๋„(Epworth Sleepiness Scale, ESS), ํ”ผ์ธ ๋ฒ„๊ทธ์ˆ˜๋ฉด์งˆ์ง€์ˆ˜(Pittsburgh Sleep Quality Index, PSQI)์ด๋ฉฐ ํ•œ๊ตญ์–ดํŒ์ด ๋ชจ๋‘ ๊ฐœ๋ฐœ๋˜์–ด ์žˆ๋‹ค[86-90].
๋ ˜์ˆ˜๋ฉดํ–‰๋™์žฅ์• ๋Š” ์ˆ˜๋ฉด๋‹ค์› ๊ฒ€์‚ฌ(polysomnography)๋กœ ํ™•์ง„ํ•ด์•ผ ํ•˜๋‚˜ ์ž„์ƒ ํ˜„์žฅ์—์„œ๋Š” ๋จผ์ € ์„ ๋ณ„ ๊ฒ€์‚ฌ ๋„๊ตฌ๋กœ ์ž„์ƒ ์ง„๋‹จํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค. ๋ ˜์ˆ˜๋ฉดํ–‰๋™์žฅ์• ์„ ๋ณ„์„ค๋ฌธ์ง€(rapid eye movement sleep behavior disorder screening questionnaire, RBDSQ)๋Š” 10๋ฌธํ•ญ์œผ๋กœ ๊ตฌ์„ฑ๋œ ์ž๊ฐ€ ๋ณด๊ณ ํ˜• ๋„๊ตฌ๋กœ ํ•œ๊ตญ์–ดํŒ(RBDSQ-K)์ด ๊ตญ๋‚ด์—์„œ ๊ฒ€์ฆ๋˜์—ˆ๋‹ค[91,92]. ๋ ˜์ˆ˜๋ฉดํ–‰๋™์žฅ์•  ๋‹จ์ผ๋ฌธํ•ญ์„ ๋ณ„๊ฒ€์‚ฌ(rapid eye movement sleep behavior disorder single-question screen, RBD1Q)๊ฐ€ ๊ฐ„๋‹จํ•œ ์˜ˆ/์•„๋‹ˆ์˜ค ๋‹ต๋ณ€์œผ๋กœ ๊ตฌ์„ฑ๋˜์–ด ์™ธ๋ž˜์—์„œ ์ผ์ฐจ์ ์œผ๋กœ ํ™œ์šฉํ•˜๊ธฐ ์ ํ•ฉํ•œ ์‹ ์† ์งˆ๋ฌธ์ง€์ด๋‚˜ ํ•œ๊ตญ์–ดํŒ ๊ฒ€์ฆ์€ ์ด๋ฃจ์–ด์ง€์ง€ ์•Š์•˜๋‹ค[93]. ์ด๋“ค ์„ ๋ณ„ ์„ค๋ฌธ์ง€์—์„œ ์–‘์„ฑ์ด ์˜์‹ฌ๋˜๋Š” ๊ฒฝ์šฐ ์ˆ˜๋ฉด๋‹ค์› ๊ฒ€์‚ฌ๋ฅผ ํ†ตํ•œ ํ™•์ง„์„ ์ง„ํ–‰ํ•˜๋ฉฐ ์ˆ˜๋ฉด๋‹ค์› ๊ฒ€์‚ฌ์—์„œ ๋ ˜์ˆ˜๋ฉด๋ฌด๊ธด์žฅ์ฆ์†Œ์‹ค(rapid eye movement sleep without atonia, RWA)์˜ ํ™•์ธ์ด ์ง„๋‹จ ํ•ต์‹ฌ์ด๋ฏ€๋กœ ์ˆ˜๋ฉด๋‹ค์› ๊ฒ€์‚ฌ๊ฐ€ ๋ฐ˜๋“œ์‹œ ํ•„์š”ํ•˜์ง€๋งŒ ๊ตญ๋‚ด์—์„œ ์•„์ง ๋ ˜์ˆ˜๋ฉดํ–‰๋™์žฅ์• ์—์„œ๋Š” ๊ธ‰์—ฌ ์ ์šฉ์ด ๋˜์ง€ ์•Š์•„ ํ˜„์‹ค์ ์œผ๋กœ ๋ชจ๋“  ๋ ˜์ˆ˜๋ฉดํ–‰๋™์žฅ์• ๊ฐ€ ์˜์‹ฌ๋˜๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—๊ฒŒ ์ฒ˜๋ฐฉํ•˜๊ธฐ์—๋Š” ์ œํ•œ์ด ์žˆ๋‹ค[94].
2. ์น˜๋ฃŒ
2. ์น˜๋ฃŒ

1) ๋ถˆ๋ฉด์ฆ

1) ๋ถˆ๋ฉด์ฆ

๋ถˆ๋ฉด์ฆ์€ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ๊ฐ€์žฅ ํ”ํ•˜๊ฒŒ ๋ฐœ์ƒํ•˜๋Š” ์ˆ˜๋ฉด์žฅ์•  ์ฆ์ƒ์œผ๋กœ ์ž ๋“ค๊ธฐ ์–ด๋ ค์›€, ์ˆ˜๋ฉด ์œ ์ง€์˜ ์–ด๋ ค์›€, ์ด๋ฅธ ์ƒˆ๋ฒฝ์— ์ž ์—์„œ ๊นจ๋Š” ์ฆ์ƒ์„ ํฌํ•จํ•œ๋‹ค. ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ๋ถˆ๋ฉด์ฆ์€ ์•ผ๊ฐ„ ์šด๋™์™„๋งŒ, ๊ทผ๊ธด์žฅ์ด์ƒ์ฆ, ์ˆ˜๋ฉด ์ค‘ ๋–จ๋ฆผ ๋“ฑ์˜ ์šด๋™ ์ฆ์ƒ๊ณผ ํ•จ๊ป˜ ๋ถˆ์•ˆ, ์šฐ์šธ, ํ™˜๊ฐ, ์•ผ๊ฐ„๋‡จ์™€ ๊ฐ™์€ ๋น„์šด๋™ ์ฆ์ƒ์— ์˜ํ•ด์„œ๋„ ์œ ๋ฐœ๋œ๋‹ค[95]. ์น˜๋ฃŒ์—์„œ ๋กœํ”ผ๋‹ˆ๋กค(ropinirole)๊ณผ ๋กœํ‹ฐ๊ณ ํ‹ด(rotigotine)๊ณผ ๊ฐ™์€ ๋„ํŒŒ๋ฏผ์ž‘์šฉ์ œ์˜ ์„œ๋ฐฉํ˜• ์ œ์ œ๊ฐ€ ์•ผ๊ฐ„ ์šด๋™ ์ฆ์ƒ ์–ต์ œ๋ฅผ ํ†ตํ•ด ์ˆ˜๋ฉด์˜ ์งˆ์„ ํ˜ธ์ „์‹œํ‚ค๋Š” ํšจ๊ณผ๊ฐ€ ์žˆ๋‹ค[96,97]. ๋ฉœ ๋ผํ† ๋‹Œ(melatonin)์€ ์ฃผ๊ด€์ ์ธ ์ˆ˜๋ฉด ์งˆ์„ ๊ฐœ์„ ํ•˜๊ณ  ์ˆ˜๋ฉด-๊ฐ์„ฑ ์ฃผ๊ธฐ์˜ ๊ต๋ž€์„ ์™„ํ™”ํ•˜๋Š” ํšจ๊ณผ๋ฅผ ๋ณด์—ฌ PDSS ์ ์ˆ˜ ๊ฐœ์„ ์„ ํ™•์ธ ํ•œ RCT๊ฐ€ ๋ณด๊ณ ๋˜์—ˆ๋‹ค[98,99]. ๋ผ์‚ฌ๊ธธ๋ฆฐ์„ ๋น„๋กฏํ•œ MAO-B์–ต์ œ์ œ ๋Š” ์ˆ˜๋ฉด๋‹ค์› ๊ฒ€์‚ฌ์ƒ ์ˆ˜๋ฉด ๊ตฌ์กฐ ๊ฐœ์„ ์ด ๋ณด๊ณ ๋˜์—ˆ๋‹ค[100]. ๋น„์•ฝ๋ฌผ ์น˜ ๋ฃŒ๋กœ๋Š” ๋น› ์ž๊ทน ์น˜๋ฃŒ(๊ด‘์น˜๋ฃŒ)๊ฐ€ ์ˆ˜๋ฉด ๋ฐ ์ฃผ๊ฐ„์กธ์Œ ๊ฐœ์„ ์— ํšจ๊ณผ ๊ฐ€ ์žˆ์œผ๋ฉฐ[101] ๊ทœ์น™์ ์ธ ์šด๋™์ด ์ˆ˜๋ฉด์˜ ์งˆ์„ ๊ฐœ์„ ์‹œํ‚จ๋‹ค๋Š” RCT ๊ทผ๊ฑฐ๊ฐ€ ์žˆ๋‹ค[102].

2) ์ฃผ๊ฐ„๊ณผ๋‹ค์กธ๋ฆผ์ฆ

2) ์ฃผ๊ฐ„๊ณผ๋‹ค์กธ๋ฆผ์ฆ

์ฃผ๊ฐ„๊ณผ๋‹ค์กธ๋ฆผ์ฆ์€ ์ถฉ๋ถ„ํ•œ ์ˆ˜๋ฉด ์‹œ๊ฐ„์—๋„ ๋ถˆ๊ตฌํ•˜๊ณ  ์ฃผ๊ฐ„์— ์ž ์— ๋น ์ง€๋Š” ๊ฒฝํ–ฅ์ด ์ฆ๊ฐ€ํ•˜๋Š” ์ƒํƒœ๋กœ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์˜ ์ ˆ๋ฐ˜ ์ด์ƒ์—์„œ ๋‚˜ํƒ€๋‚œ๋‹ค[103]. ๋„ํŒŒ๋ฏผ์ž‘์šฉ์ œ๋Š” ์ฃผ๊ฐ„๊ณผ๋‹ค์กธ๋ฆผ์ฆ์˜ ์ฃผ์š” ์›์ธ์ด ๋  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ํŠนํžˆ ๊ฐ‘์ž‘์Šค๋Ÿฝ๊ฒŒ ์ž ์— ๋น ์ง€๋Š” ์ˆ˜๋ฉด๋ฐœ์ž‘(sleep attack)์„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ์–ด ์šด์ „ ๋“ฑ ์œ„ํ—˜ ์ƒํ™ฉ์—์„œ ๊ฐ๋ณ„ํ•œ ์ฃผ์˜๊ฐ€ ํ•„์š”ํ•˜๋‹ค[104].
์น˜๋ฃŒ์—์„œ๋Š” ๋จผ์ € ์ˆ˜๋ฉด ์œ„์ƒ์„ ๊ฐœ์„ ํ•˜๊ณ  ์•ผ๊ฐ„ ์ˆ˜๋ฉด์˜ ์งˆ์„ ํ–ฅ์ƒ์‹œํ‚ค๋Š” ๊ฒƒ์ด ์šฐ์„ ์ด๋‹ค. ๋ชจ๋‹คํ”ผ๋‹(modafinil)์€ ๋ฉ”ํƒ€๋ถ„์„์—์„œ ์ฃผ๊ด€์  ์ฃผ๊ฐ„์กธ์Œ ๊ฐœ์„  ํšจ๊ณผ๊ฐ€ ๋ณด๊ณ ๋˜์—ˆ์œผ๋‚˜ ๊ฐ๊ด€์  ์ง€ํ‘œ ๊ฐœ์„ ์€ ์ œํ•œ์ ์ด์–ด์„œ ์‚ฌ์šฉ ๊ฐ€๋Šฅํ•˜๋‚˜ ๊ทผ๊ฑฐ๋Š” ๋ถˆ๋ถ„๋ช…ํ•˜๋‹ค[105]. ์นดํŽ˜์ธ ๋ณต์šฉ์ด ์ผ๋ถ€ ์—ฐ๊ตฌ์—์„œ ์ฃผ๊ฐ„์กธ์Œ ๊ฐœ์„  ๊ฒฝํ–ฅ์„ ๋ณด์˜€์œผ๋‚˜ ์ž„์ƒ์  ์œ ์˜์„ฑ์€ ๋ฏธํ™•์ธ์ด๋‹ค[105]. ์†”๋ฆฌ์•”ํŽ˜ํ†จ(solriamfetol)์ด ์†Œ๊ทœ๋ชจ ์—ฐ๊ตฌ์—์„œ ํšจ๊ณผ๊ฐ€ ๋ณด๊ณ ๋˜์—ˆ์œผ๋‚˜ ์ถ”๊ฐ€ ์—ฐ๊ตฌ๊ฐ€ ํ•„์š”ํ•˜๋‹ค[106].

3) ๋ ˜์ˆ˜๋ฉดํ–‰๋™์žฅ์• 

3) ๋ ˜์ˆ˜๋ฉดํ–‰๋™์žฅ์• 

๋ ˜์ˆ˜๋ฉดํ–‰๋™์žฅ์• ๋Š” ๋ ˜์ˆ˜๋ฉด ์ค‘ ๊ทผ๊ธด์žฅ๋„ ์†Œ์‹ค์ด ์ด๋ฃจ์–ด์ง€์ง€ ์•Š์•„ ๊ฟˆ ๋‚ด์šฉ์„ ํ–‰๋™์œผ๋กœ ํ‘œ์ถœํ•˜๋Š” ์ˆ˜๋ฉด์žฅ์• ์ด๋‹ค[107]. ํŒŒํ‚จ์Šจ๋ณ‘์˜ ์ค‘์š”ํ•œ ์ „๊ตฌ ์ฆ์ƒ์œผ๋กœ ํŠน๋ฐœ ๋ ˜์ˆ˜๋ฉดํ–‰๋™์žฅ์•  ํ™˜์ž์˜ 80-90%๊ฐ€ ์ˆ˜์‹ญ ๋…„ ๋‚ด์— ์•ŒํŒŒ-์‹œ๋ˆ„ํด๋ ˆ์ธ๋ณ‘์ฆ(ํŒŒํ‚จ์Šจ๋ณ‘, ๋ฃจ์ด์†Œ์ฒด์น˜๋งค, ๋‹ค๊ณ„ํ†ต์œ„์ถ•์ฆ)์œผ๋กœ ์ดํ–‰ํ•œ๋‹ค[108]. ํ™˜์ž๋Š” ๊ฟˆ ๋‚ด์šฉ๊ณผ ์—ฐ๊ด€๋œ ๊ณ ํ•จ ์น˜๊ธฐ, ํŒ”๋‹ค๋ฆฌ ์›€์ง์ž„, ๋‚™์ƒ ๋“ฑ์˜ ํ–‰๋™์„ ๋ณด์ด๋ฉฐ ๋ณดํ˜ธ์ž๋‚˜ ๋™์นจ์ž์—๊ฒŒ ์ƒํ•ด๋ฅผ ์ž…ํžˆ๋Š” ๊ฒฝ์šฐ๋„ ์žˆ๋‹ค.
์น˜๋ฃŒ์—์„œ๋Š” ์นจ์‹ค ํ™˜๊ฒฝ์˜ ์•ˆ์ „ ํ™•๋ณด๊ฐ€ ์šฐ์„ ์ด๋‹ค. ํด๋กœ๋‚˜์ œํŒœ๊ณผ ์†๋ฐฉํ˜• ๋ฉœ๋ผํ† ๋‹Œ์€ ํŒŒํ‚จ์Šจ๋ณ‘์— ๋™๋ฐ˜๋œ ๋ ˜์ˆ˜๋ฉดํ–‰๋™์žฅ์• ์—์„œ ์กฐ๊ฑด๋ถ€๋กœ ๊ถŒ๊ณ ๋œ๋‹ค[109]. ๋‹ค๋งŒ ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ํ•œ ํด๋กœ๋‚˜์ œํŒœ ๋ฐ ์„œ๋ฐฉํ˜• ๋ฉœ๋ผํ† ๋‹Œ์˜ ์†Œ๊ทœ๋ชจ ์œ„์•ฝ๋Œ€์กฐ์‹œํ—˜์—์„œ๋Š” ์œ ์˜ํ•œ ํšจ๊ณผ๊ฐ€ ํ™•์ธ๋˜์ง€ ์•Š์•„ ์น˜๋ฃŒ ๋ฐ˜์‘๊ณผ ๋ถ€์ž‘์šฉ์„ ๊ฐœ๋ณ„์ ์œผ๋กœ ํ‰๊ฐ€ํ•ด์•ผ ํ•œ๋‹ค[110,111].
ํ†ต์ฆ ๋ฐ ํ”ผ๋กœ
ํ†ต์ฆ ๋ฐ ํ”ผ๋กœ
1. ํ†ต์ฆ
1. ํ†ต์ฆ

1) ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€

1) ์ง„๋‹จ ๋ฐ ํ‰๊ฐ€

ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์—์„œ ํ†ต์ฆ์€ ๋งค์šฐ ํ”ํ•˜๋ฉฐ ์•ฝ 30-80%์—์„œ ๋งŒ์„ฑ ํ†ต์ฆ์„ ํ˜ธ์†Œํ•œ๋‹ค[112]. ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž๋“ค์€ ์ €๋ฆผ, ์‘ค์‹ฌ, ์ฐŒ๋ฅด๋Š” ๋“ฏํ•œ ๋А๋‚Œ ํ˜น์€ ๋œจ๊ฑฐ์šด ๋А๋‚Œ๊ณผ ๊ฐ™์€ ๋‹ค์–‘ํ•œ ํ‘œํ˜„์œผ๋กœ ํ†ต์ฆ์„ ํ˜ธ์†Œํ•˜๋ฉฐ, ๋•Œ๋กœ๋Š” ๋งค์šฐ ๋ชจํ˜ธํ•˜๊ฒŒ ์„ค๋ช…ํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ์žˆ๋‹ค. ์ด๋Ÿฌํ•œ ํ†ต์ฆ์ด ํŒŒํ‚จ์Šจ๋ณ‘์— ์˜ํ•œ ๊ฒƒ์œผ๋กœ ์ธ์ง€ํ•˜์ง€ ๋ชปํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์•„ ์‹ ๊ฒฝ๊ณผ ์˜์‚ฌ๊ฐ€ ํ†ต์ฆ์„ ๋†“์น˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋ฐœ์ƒํ•˜๋ฏ€๋กœ ์„ธ์‹ฌํ•œ ์ฃผ์˜๊ฐ€ ํ•„์š”ํ•˜๋‹ค[112]. ํŒŒํ‚จ์Šจ๋ณ‘์—์„œ ํ†ต์ฆ์˜ ํ‰๊ฐ€๋Š” ๋จผ์ € ํ•ด๋‹น ํ†ต์ฆ ์ด ํŒŒํ‚จ์Šจ๋ณ‘๊ณผ ๊ด€๋ จ ์žˆ๋Š”์ง€๋ฅผ ํŒ๋ณ„ํ•˜๋Š” ๊ฒƒ์—์„œ ์‹œ์ž‘ํ•œ๋‹ค. ํ†ต์ฆ์ด ํŒŒํ‚จ์Šจ๋ณ‘ ๋ฐœ๋ณ‘ ์‹œ๊ธฐ์™€ ์ผ์น˜ํ•˜๊ฑฐ๋‚˜ ํŒŒํ‚จ์Šจ๋ณ‘ ๋ฐœ๋ณ‘๊ณผ ํ•จ๊ป˜ ํ†ต์ฆ์ด ์•…ํ™”๋˜๊ฑฐ๋‚˜ ์˜คํ”„ ์ƒํƒœ ๋™์•ˆ ํ†ต์ฆ์ด ์กด์žฌํ•˜๊ฑฐ๋‚˜ ๋„ํŒŒ๋ฏผ ์น˜๋ฃŒ์— ํ†ต์ฆ์ด ๊ฒฝ๊ฐํ•˜๋Š” ๊ฒฝ์šฐ, ๋„ํŒŒ๋ฏผ ๊ณผ๋‹ค ์‹œ ํ†ต์ฆ์ด ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒฝ์šฐ ํŒŒํ‚จ์Šจ๋ณ‘ ๊ด€๋ จ ํ†ต์ฆ์œผ๋กœ ์ •์˜ํ•œ๋‹ค[113]. ๊ฐ€์žฅ ๋งŽ์ด ์‚ฌ์šฉ๋˜๋Š” ํ†ต์ฆ ํ‰๊ฐ€ ๋„๊ตฌ๋Š” ํ‚น์ŠคํŒŒํ‚จ์Šจ๋ณ‘ํ†ต์ฆ์ฒ™๋„(King's Parkinson's Disease Pain Scale, KPPS)๋กœ 7๊ฐœ ์˜์—ญ(๊ทผ๊ณจ๊ฒฉ๊ณ„, ๋งŒ์„ฑ, ์•ผ๊ฐ„, ๋™์š” ๊ด€๋ จ, ๊ตฌ๊ฐ•์•ˆ๋ฉด, ๋ถˆ์พŒ๊ฐ, ์‹ ๊ฒฝ๊ทผ์„ฑ)์˜ ํ†ต์ฆ ๋นˆ๋„์™€ ๊ฐ•๋„๋ฅผ ํ‰๊ฐ€ํ•œ๋‹ค[113]. ํŒŒํ‚จ์Šจ๋ณ‘ ํ†ต์ฆ ๋ถ„๋ฅ˜ ์ฒด๊ณ„(Parkinsonโ€™s Disease Pain Classification System, PD-PCS)๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ ๊ด€๋ จ ํ†ต์ฆ๊ณผ ๋ฌด๊ด€ํ•œ ํ†ต์ฆ์„ ๊ตฌ๋ณ„ํ•˜๊ณ , ์„ธ ๊ฐ€์ง€ ๊ธฐ์ „(์นจํ•ด์ˆ˜์šฉ์„ฑ, ์‹ ๊ฒฝ๋ณ‘์„ฑ, ์‹ ๊ฒฝ๊ฐ€์†Œ์„ฑ)์— ๋”ฐ๋ผ ๋ถ„๋ฅ˜ํ•œ๋‹ค[114].

2) ์น˜๋ฃŒ

2) ์น˜๋ฃŒ

ํŒŒํ‚จ์Šจ๋ณ‘ ๊ด€๋ จ ํ†ต์ฆ์— ๋Œ€ํ•œ ์น˜๋ฃŒ๋Š” ๋„ํŒŒ๋ฏผ ์˜คํ”„ ์ƒํƒœ ๊ด€๋ จ ํ†ต์ฆ์ธ์ง€๋ฅผ ํ™•์ธํ•˜๊ณ  ๋„ํŒŒ๋ฏผ ์น˜๋ฃŒ๋ฅผ ์ตœ์ ํ™”ํ•˜๋Š” ๊ฒƒ์ด ์šฐ์„ ์ด๋‹ค[4]. ๋ ˆ๋ณด๋„ํŒŒ๋Š” ์†Œ๊ทœ๋ชจ ์—ฐ๊ตฌ์—์„œ ์˜จ ์ƒํƒœ(on-state)์—์„œ์˜ ํ†ต์ฆ ๊ฐ์†Œ ํšจ๊ณผ๊ฐ€ ๋ณด๊ณ ๋˜์—ˆ๋‹ค[115]. ๋„ํŒŒ๋ฏผ์ž‘์šฉ์ œ์ธ ๋กœํ‹ฐ๊ณ ํ‹ด์€ ํ†ต์ฆ ๊ฐœ์„  ํšจ๊ณผ๊ฐ€ ์ผ๋ถ€ ๋ณด๊ณ ๋˜์—ˆ๋‹ค[116]. MAO-B์–ต์ œ์ œ์ธ ์‚ฌํ”ผ๋‚˜๋ฏธ๋“œ๋Š” ์šด๋™๋™์š” ํ™˜์ž์—์„œ ํ†ต์ฆ์„ ์ผ๋ถ€ ๊ฐœ์„ ์‹œํ‚ค๋Š” ํšจ๊ณผ๋ฅผ ๋ณด์˜€์œผ๋‚˜ ์ง„ํ†ต ํšจ๊ณผ๋Š” ๋ถˆ๋ถ„๋ช…ํ•˜๋‹ค[117,118]. ์•„ํŽธ์œ ์‚ฌ์ œ(opioid)์ธ ์ง€์†ํ˜• ์˜ฅ์‹œ์ฝ”๋ˆ-๋‚ ๋ก์†(oxycodone-naloxone)์€ ์ผ๋ถ€ ์—ฐ๊ตฌ์—์„œ ๊ทผ๊ณจ๊ฒฉ๊ณ„ ํ†ต์ฆ ๊ฐ์†Œ๋ฅผ ๋ณด์˜€์œผ๋‚˜ ๋‹ค๋ฅธ ์—ฐ๊ตฌ์—์„œ๋Š” ํšจ๊ณผ๊ฐ€ ๋ช…ํ™•ํ•˜์ง€ ์•Š์•˜๋‹ค[119]. SNRI์ธ ๋‘˜๋ก์„ธํ‹ด(duloxetine)์€ ์‹ ๊ฒฝ๊ฐ€์†Œ์„ฑ ํ†ต์ฆ์— ๋Œ€ํ•œ ์—ฐ๊ตฌ์—์„œ ํ˜ผ์žฌ๋œ ๊ฒฐ๊ณผ๋ฅผ ๋ณด์˜€๋‹ค[120,121]. ๋น„์•ฝ๋ฌผ ์น˜๋ฃŒ๋กœ๋Š” ๊ฑท๊ธฐ์™€ ์ŠคํŠธ๋ ˆ์นญ ๋“ฑ ์‹ ์ฒดํ™œ๋™์ด ํ†ต์ฆ ํ˜ธ์ „์— ๋„์›€์ด ๋˜๋ฉฐ ๋ฌผ๋ฆฌ ์น˜๋ฃŒ, ์ž‘์—… ์น˜๋ฃŒ, ๋ฐ˜๋ณต๊ฒฝ๋‘๊ฐœ์ž๊ธฐ์ž๊ทน์ˆ  ๋“ฑ์ด ์—ฐ๊ตฌ๋˜๊ณ  ์žˆ๋‹ค[122].
ํŒŒํ‚จ์Šจ๋ณ‘์—์„œ ์˜คํ”„ ์ƒํƒœ ๊ธฐ๊ฐ„ ๋™์•ˆ์˜ ๊ทผ๊ธด์žฅ์ด์ƒ(dystonia)์€ ํ†ต์ฆ์˜ ์ค‘์š”ํ•œ ์›์ธ์ด๋‹ค. ํŠนํžˆ ์ด๋ฅธ ์•„์นจ์— ๋ฐœ์ƒํ•˜๋Š” ๋ฐœ ๊ทผ๊ธด์žฅ์ด์ƒ(early morning foot dystonia)์ด ํŠน์ง•์ ์ด๋ฉฐ ์ฒซ ๋ ˆ๋ณด๋„ํŒŒ ํˆฌ์—ฌ ์ „ ์˜คํ”„ ์ƒํƒœ์—์„œ ๋ฐœ์ƒํ•˜๋Š” ๊ณ ํ†ต์Šค๋Ÿฌ์šด ๋ฐœ ๋’คํ‹€๋ฆผ์œผ๋กœ ๋‚˜ํƒ€๋‚œ๋‹ค[123]. ์ด๋Š” ๋„ํŒŒ๋ฏผ ๋ถ€์กฑ ์ƒํƒœ์—์„œ ๋ฐ”๋‹ฅํ•ต(basal ganglia) ํšŒ๋กœ์˜ ๊ณผํ™œ์„ฑํ™”๋กœ ์ธํ•œ ๋ถˆ์ˆ˜์˜์  ๊ทผ์ˆ˜์ถ•์ด๋‹ค. ์น˜๋ฃŒ๋กœ๋Š” ์ทจ์นจ ์ „ ์„œ๋ฐฉํ˜• ๋ ˆ๋ณด๋„ํŒŒ ์ถ”๊ฐ€, ์ด๋ฅธ ์•„์นจ ์†ํšจ์„ฑ ๋ ˆ๋ณด๋„ํŒŒ์˜ ์กฐ๊ธฐ ํˆฌ์—ฌ, ๋„ํŒŒ๋ฏผ์ž‘์šฉ์ œ ์•ผ๊ฐ„ ํˆฌ์—ฌ๊ฐ€ ๋„์›€์ด ๋  ์ˆ˜ ์žˆ๋‹ค. ๊ตญ์†Œ์ ์ธ ๊ทผ๊ธด์žฅ์ด์ƒ์— ๋Œ€ํ•ด์„œ๋Š” ๋ณดํ‹€๋ฆฌ๋ˆ„์Šค๋…์†Œ ์ฃผ์‚ฌ๊ฐ€ ํšจ๊ณผ์ ์ด๋‹ค[124]. ์ค‘์ถ” ํŒŒํ‚จ์Šจ๋ณ‘ ํ†ต์ฆ(central Parkinsonian pain)์€ ๋ช…ํ™•ํ•œ ๋ง์ดˆ ์›์ธ ์—†์ด ํŒŒํ‚จ์Šจ๋ณ‘ ์ž์ฒด์˜ ์ค‘์ถ” ๊ฐ๊ฐ ์ฒ˜๋ฆฌ ์ด์ƒ์œผ๋กœ ๋ฐœ์ƒํ•˜๋Š” ํ†ต์ฆ์œผ๋กœ ํ”ํžˆ ์˜คํ”„ ์ƒํƒœ์—์„œ ๋ฐœ์ƒํ•˜๋Š” ์ด์ƒํ•˜๊ฑฐ๋‚˜ ๋ถˆ์พŒํ•œ ๋А๋‚Œ, ํ™”๋ˆ๊ฑฐ๋ฆผ, ์ €๋ฆผ ๋“ฑ์œผ๋กœ ํ‘œํ˜„๋œ๋‹ค. ์ด ๊ฒฝ์šฐ ๋„ํŒŒ๋ฏผ ์น˜๋ฃŒ ์ตœ์ ํ™”๊ฐ€ ์šฐ์„ ์ด๋ฉฐ, ์ฆ์ƒ ์ง€์† ์‹œ ํŠธ๋ผ๋งˆ๋Œ(tramadol)์ด๋‚˜ TCA๊ฐ€ ๋ณด์กฐ ์น˜๋ฃŒ๋กœ ์‚ฌ์šฉ๋  ์ˆ˜ ์žˆ๋‹ค[125].
2. ํ”ผ๋กœ
2. ํ”ผ๋กœ
ํ”ผ๋กœ๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ ํ™˜์ž์˜ ์•ฝ 40-60%์—์„œ ๋‚˜ํƒ€๋‚˜๋Š” ํ”ํ•œ ๋น„์šด๋™ ์ฆ์ƒ์œผ๋กœ ์šด๋™ ํ›„ ๋ฐœ์ƒํ•˜๋Š” ์ผ๋ฐ˜์ ์ธ ํ”ผ๋กœ์™€ ๋‹ฌ๋ฆฌ ํ™œ๋™๊ณผ ๋ฌด๊ด€ํ•˜๊ฒŒ ์ง€์†์ ์œผ๋กœ ๋‚˜ํƒ€๋‚˜๋Š” ์ง€์น˜๊ณ  ๊ธฐ๋ ฅ์ด ์—†๋Š” ๋А๋‚Œ์„ ํŠน์ง•์œผ๋กœ ํ•œ๋‹ค[126]. ํ”ผ๋กœ๋Š” ํŒŒํ‚จ์Šจ๋ณ‘์˜ ์ „๊ตฌ๊ธฐ๋ถ€ํ„ฐ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ์œผ๋ฉฐ ๋…๋ฆฝ์ ์œผ๋กœ ํ™˜์ž์˜ ์‚ถ์˜ ์งˆ์— ์˜ํ–ฅ์„ ๋ฏธ์นœ๋‹ค. ํ”ผ๋กœ๋Š” ์šฐ์šธ์ฆ, ์ˆ˜๋ฉด์žฅ์• , ๋ฌด๊ฐ๋™๊ณผ ์ž„์ƒ์ ์œผ๋กœ ์œ ์‚ฌํ•  ์ˆ˜ ์žˆ์–ด ์ด๋“ค๊ณผ์˜ ๊ฐ๋ณ„์ด ์ค‘์š”ํ•˜๋‹ค. ํ”ผ๋กœ์˜ ๋ณ‘ํƒœ์ƒ๋ฆฌ๋Š” ์•„์ง ๋ช…ํ™•ํ•˜์ง€ ์•Š์œผ๋‚˜ ๋„ํŒŒ๋ฏผ์„ฑ ๋ฐ ์„ธ๋กœํ† ๋‹Œ์„ฑ ์‹ ๊ฒฝํšŒ๋กœ์˜ ์ด์ƒ, ์‹œ์ƒํ•˜๋ถ€-๋‡Œํ•˜์ˆ˜์ฒด-๋ถ€์‹ ์ถ•์˜ ๊ธฐ๋Šฅ ์ด์ƒ ๋“ฑ์ด ๊ด€์—ฌํ•˜๋Š” ๊ฒƒ์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ๋‹ค. ํŒŒํ‚จ์Šจ๋ณ‘์—์„œ ํ”ผ๋กœ ํ‰๊ฐ€๋ฅผ ์œ„ํ•œ ๋„๊ตฌ๋กœ๋Š” ํŒŒํ‚จ์Šจ๋ณ‘ํ”ผ๋กœ์ฒ™๋„(Parkinson Fatigue Scale, PFS-16)๊ฐ€ ํŒŒํ‚จ์Šจ๋ณ‘ ํŠน์ด์ ์œผ๋กœ ๊ฐœ๋ฐœ๋œ 16๋ฌธํ•ญ์˜ ์ž๊ฐ€ ๋ณด๊ณ ํ˜• ์„ค๋ฌธ์ง€์ด๋ฉฐ ํ”ผ๋กœ์ค‘์ฆ๋„์ฒ™๋„(fatigue severity scale, FSS)๋Š” ๋‹ค์–‘ํ•œ ์‹ ๊ฒฝ๊ณ„ ์งˆํ™˜์—์„œ ๊ฒ€์ฆ๋œ 9๋ฌธํ•ญ ์ฒ™๋„์ด๋‹ค[126]. MDS ํƒœ์Šคํฌ ํฌ์Šค๋Š” FSS๋ฅผ ํŒŒํ‚จ์Šจ๋ณ‘ ํ”ผ๋กœ์˜ ๊ถŒ๊ณ  ํ‰๊ฐ€ ๋„๊ตฌ๋กœ ์ œ์‹œํ•˜์˜€๋‹ค[126].
ํŒŒํ‚จ์Šจ๋ณ‘ ํ”ผ๋กœ์˜ ์ž„์ƒ ํ‰๊ฐ€์—์„œ ์ค‘์š”ํ•œ ๊ฒƒ์€ ํ”ผ๋กœ๋ฅผ ์œ ๋ฐœํ•˜๋Š” ๋‹ค๋ฅธ ์›์ธ๋“ค์„ ๋จผ์ € ๋ฐฐ์ œํ•˜๋Š” ๊ฒƒ์ด๋‹ค. ์ˆ˜๋ฉด์žฅ์• (๋ถˆ๋ฉด์ฆ, ์ˆ˜๋ฉด๋ฌดํ˜ธํก์ฆ, ์ฃผ๊ฐ„๊ณผ๋‹ค์กธ๋ฆผ์ฆ)๊ฐ€ ํ”ผ๋กœ์˜ ์›์ธ์ด ๋˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ํ”ํ•˜๋ฉฐ, ์ด ๊ฒฝ์šฐ ์ˆ˜๋ฉด์žฅ์• ๋ฅผ ๋จผ์ € ์น˜๋ฃŒํ•˜๋ฉด ํ”ผ๋กœ๊ฐ€ ๊ฐœ์„ ๋  ์ˆ˜ ์žˆ๋‹ค. ์šฐ์šธ์ฆ๊ณผ ๋ฌด๊ฐ๋™ ์—ญ์‹œ ํ”ผ๋กœ์ฒ˜๋Ÿผ ๋А๊ปด์งˆ ์ˆ˜ ์žˆ์–ด ๊ฐ๋ณ„์ด ํ•„์š”ํ•˜๋‹ค. ์šฐ์šธ์ฆ์—์„œ์˜ ํ”ผ๋กœ๋Š” ๊ธฐ๋ถ„ ์ €ํ•˜, ์ฃ„์ฑ…๊ฐ, ๋ถˆ์พŒ๊ฐ์„ ๋™๋ฐ˜ํ•˜๋Š” ๋ฐ˜๋ฉด ๋ฌด๊ฐ๋™์—์„œ๋Š” ์ •์„œ์  ๊ณ ํ†ต ์—†์ด ๋™๊ธฐ ์ €ํ•˜์™€ ๋ฌด๊ด€์‹ฌ์ด ๋‘๋“œ๋Ÿฌ์ง„๋‹ค. ํŒŒํ‚จ์Šจ๋ณ‘ ์•ฝ๋ฌผ ์ž์ฒด๋„ ํ”ผ๋กœ๋ฅผ ์œ ๋ฐœํ•˜๊ฑฐ๋‚˜ ์•…ํ™”์‹œํ‚ฌ ์ˆ˜ ์žˆ์œผ๋ฉฐ, ํŠนํžˆ ๋„ํŒŒ๋ฏผ์ž‘์šฉ์ œ, ๋ฒ ํƒ€์ฐจ๋‹จ์ œ, ์ผ๋ถ€ ํ•ญ์šฐ์šธ์ œ๊ฐ€ ์ฃผ์˜ ๋Œ€์ƒ์ด๋‹ค. ๊ฐ‘์ƒ์ƒ˜๊ธฐ๋Šฅ์ €ํ•˜์ฆ, ๋นˆํ˜ˆ, ๋น„ํƒ€๋ฏผD ๊ฒฐํ• ๋“ฑ ๋‚ด๊ณผ ์›์ธ๋„ ๋ฐฐ์ œํ•ด์•ผ ํ•œ๋‹ค.
ํŒŒํ‚จ์Šจ๋ณ‘ ํ”ผ๋กœ์— ๋Œ€ํ•œ ๋ช…ํ™•ํ•œ ์•ฝ๋ฌผ ์น˜๋ฃŒ ๊ทผ๊ฑฐ๋Š” ๋ถ€์กฑํ•˜๋‹ค. ๋„ํŒŒ๋ฏผ์„ฑ ์•ฝ๋ฌผ ์ตœ์ ํ™”๊ฐ€ ์šฐ์„ ์ด๋ฉฐ ๋ฉ”ํ‹ธํŽ˜๋‹ˆ๋ฐ์ดํŠธ(methylphenidate) ๊ฐ€ ์ผ๋ถ€ ์—ฐ๊ตฌ์—์„œ ํ”ผ๋กœ ๊ฐœ์„ ์— ํšจ๊ณผ๊ฐ€ ์žˆ๋‹ค๊ณ  ๋ณด๊ณ ๋˜์—ˆ๋‹ค[127]. ๋ผ์‚ฌ๊ธธ๋ฆฐ(rasagiline)๋„ ํ”ผ๋กœ ์ฆ์ƒ ๊ฐœ์„  ํšจ๊ณผ๊ฐ€ ์ผ๋ถ€ ์—ฐ๊ตฌ์—์„œ ๋ณด๊ณ ๋˜์—ˆ๋‹ค[128]. ํŒŒํ‚จ์Šจ๋ณ‘ ํ”ผ๋กœ์— ๋Œ€ํ•œ ๋น„์•ฝ๋ฌผ ์น˜๋ฃŒ๋กœ ๊ทœ์น™์ ์ธ ์œ ์‚ฐ์†Œ ์šด๋™์ด ๊ฐ€์žฅ ๊ทผ๊ฑฐ ์žˆ๋Š” ๋น„์•ฝ๋ฌผ ์น˜๋ฃŒ๋กœ ๊ถŒ๊ณ ๋œ๋‹ค[129]. ์ฃผ 3-5ํšŒ, 30-60๋ถ„์˜ ์ค‘๋“ฑ๋„ ๊ฐ•๋„ ์œ ์‚ฐ์†Œ ์šด๋™(๊ฑท๊ธฐ, ์ž์ „๊ฑฐ ํƒ€๊ธฐ, ์ˆ˜์˜ ๋“ฑ)์ด ๊ถŒ์žฅ๋˜๋ฉฐ ๊ฐœ์ธ์˜ ์‹ ์ฒด ๋Šฅ๋ ฅ๊ณผ ์•ˆ์ „์„ ๊ณ ๋ คํ•œ ๋งž์ถคํ˜• ์šด๋™ ํ”„๋กœ๊ทธ๋žจ์ด ํ•„์š”ํ•˜๋‹ค. ์—๋„ˆ์ง€ ๋ณด์ „ ๊ธฐ๋ฒ•(energy conservation techniques)๊ณผ ํ”ผ๋กœ ๊ด€๋ฆฌ๋„ ๋„์›€์ด ๋œ๋‹ค. ์—๋„ˆ์ง€ ๋ณด์กด ๊ธฐ๋ฒ•์œผ๋กœ๋Š” ํ™œ๋™์˜ ์šฐ์„ ์ˆœ์œ„ ์„ค์ •, ์ ์ ˆํ•œ ํœด์‹ ์‹œ๊ฐ„ ๋ฐฐ์น˜, ๋ณด์กฐ ๋„๊ตฌ ํ™œ์šฉ ๋“ฑ์ด ํฌํ•จ๋œ๋‹ค.
๊ฒฐ ๋ก 
๊ฒฐ ๋ก 
ํŒŒํ‚จ์Šจ๋ณ‘์˜ ๋น„์šด๋™ ์ฆ์ƒ์€ ์šด๋™ ์ฆ์ƒ๊ณผ ๋งˆ์ฐฌ๊ฐ€์ง€๋กœ ํ™˜์ž์˜ ์ผ์ƒ์ƒํ™œ๊ธฐ๋Šฅ๊ณผ ์‚ถ์˜ ์งˆ์— ๋งค์šฐ ํฐ ์˜ํ–ฅ์„ ๋ฏธ์น˜๋ฉฐ ์ฒด๊ณ„์ ์ด๊ณ  ์ ๊ทน์ ์ธ ๊ด€๋ฆฌ๊ฐ€ ํ•„์š”ํ•˜๋‹ค. ์ž„์ƒ ํ˜„์žฅ์—์„œ๋Š” ๊ฐ ๋น„์šด๋™ ์ฆ์ƒ์— ๋Œ€ํ•œ ์ ์ ˆํ•œ ํ‰๊ฐ€ ๋„๊ตฌ๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ์ฆ์ƒ์„ ์กฐ๊ธฐ์— ๋ฐœ๊ฒฌํ•˜๊ณ  ๊ทผ๊ฑฐ ์ค‘์‹ฌ์˜ ์น˜๋ฃŒ๋ฅผ ๊ฐœ๋ณ„ํ™”ํ•˜์—ฌ ์ ์šฉํ•˜๋Š” ๊ฒƒ์ด ์ค‘์š”ํ•˜๋‹ค. ๋น„์šด๋™ ์ฆ์ƒ์€ ๋‹จ์ˆœํžˆ ๊ฐœ๋ณ„ ์ฆ์ƒ์˜ ์ง‘ํ•ฉ์ด ์•„๋‹ˆ๋ผ ์ƒํ˜ธ ์—ฐ๊ด€๋˜์–ด ์žˆ์œผ๋ฉฐ ํ•œ ์ฆ์ƒ์ด ๋‹ค๋ฅธ ์ฆ์ƒ์„ ์•…ํ™”์‹œํ‚ค๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค. ์˜ˆ๋ฅผ ๋“ค์–ด ์ˆ˜๋ฉด์žฅ์• ๋Š” ์ธ์ง€๊ธฐ๋Šฅ๊ณผ ๊ธฐ๋ถ„์— ์˜ํ–ฅ์„ ๋ฏธ์น˜๊ณ  ํ†ต์ฆ๊ณผ ์ž์œจ์‹ ๊ฒฝ์žฅ์• ๋Š” ์ˆ˜๋ฉด์˜ ์งˆ์„ ์ €ํ•˜์‹œํ‚ค๋ฉฐ ์šฐ์šธ์ฆ๊ณผ ๋ถˆ์•ˆ์€ ํ”ผ๋กœ ๋ฐ ํ†ต์ฆ ์ธ์‹์— ์˜ํ–ฅ์„ ์ค€๋‹ค. ๋”ฐ๋ผ์„œ ํŒŒํ‚จ์Šจ๋ณ‘ ๋น„์šด๋™ ์ฆ์ƒ์˜ ๊ด€๋ฆฌ๋Š” ๋‹จํŽธ์  ์ ‘๊ทผ์ด ์•„๋‹Œ, ์ข…ํ•ฉ์ ์ด๊ณ  ํ†ตํ•ฉ์ ์ธ ์‹œ๊ฐ์œผ๋กœ ์ด๋ฃจ์–ด์ ธ์•ผ ํ•œ๋‹ค.
๋น„์šด๋™ ์ฆ์ƒ์˜ ๋‹ค์–‘์„ฑ๊ณผ ๋ณต์žก์„ฑ์„ ๊ณ ๋ คํ•  ๋•Œ ์‹ ๊ฒฝ๊ณผ ์ „๋ฌธ์˜๋ฅผ ์ค‘์‹ฌ์œผ๋กœ ์ •์‹ ๊ฑด๊ฐ•์˜ํ•™๊ณผ, ๋น„๋‡จ์˜ํ•™๊ณผ, ์†Œํ™”๊ธฐ๋‚ด๊ณผ ๋“ฑ์ด ์ฐธ์—ฌํ•˜๋Š” ๋‹คํ•™์ œ ์ ‘๊ทผ์ด ์ตœ์ ์˜ ์น˜๋ฃŒ ๊ฒฐ๊ณผ๋ฅผ ๊ฐ€์ ธ์˜จ๋‹ค. ํ™˜์ž์™€ ๋ณดํ˜ธ์ž ๊ต์œก์„ ํ†ตํ•ด ๋น„์šด๋™ ์ฆ์ƒ์„ ์Šค์Šค๋กœ ์ธ์‹ํ•˜๊ณ  ๋ณด๊ณ ํ•  ์ˆ˜ ์žˆ๋„๋ก ์—ญ๋Ÿ‰์„ ๊ฐ•ํ™”ํ•˜๋Š” ๊ฒƒ๋„ ์ž„์ƒ ๊ด€๋ฆฌ์˜ ์ค‘์š”ํ•œ ๋ถ€๋ถ„์ด๋‹ค. ํ–ฅํ›„ ํŒŒํ‚จ์Šจ๋ณ‘ ๋น„์šด๋™ ์ฆ์ƒ์˜ ๋ณ‘ํƒœ์ƒ๋ฆฌ์— ๋Œ€ํ•œ ์ดํ•ด๊ฐ€ ์‹ฌํ™”๋˜๊ณ  ์ƒˆ๋กœ์šด ์น˜๋ฃŒ๋ฒ•์ด ๊ฐœ๋ฐœ๋จ์— ๋”ฐ๋ผ ๋”์šฑ ํšจ๊ณผ์ ์ธ ๋น„์šด๋™ ์ฆ์ƒ ๊ด€๋ฆฌ๊ฐ€ ๊ฐ€๋Šฅํ•ด์งˆ ๊ฒƒ์œผ๋กœ ๊ธฐ๋Œ€๋œ๋‹ค.

Tableย 1.
Assessment tools for non-motor symptoms in Parkinson's disease
Assessment domain Assessment tool Key features Korean versiona
Comprehensive assessment of non-motor symptoms NMSS 30 items across 9 domains โ—‹ (validated in a Korean multicenter study)
Interviewer-rated
Severity scored as frequencyร—severity
MDS-NMS MDS-developed scale expanding on the NMSS, with more detailed symptom domains ร—
NMSQ 30-item, yes/no self-report screening questionnaire ร—
Suitable for completion in the waiting room
Neuropsychiatric symptoms
โ€ƒDepression GDS-15/GDS-30 Developed for elderly โ—‹
Yes/no responses
Few somatic items
Freely available
Recommended for initial screening
HAMD-17 (K-HDRS) 17-item โ—‹ (K-HDRS)
Interviewer-rated
Suitable for measuring depression severity
Widely used in clinical research
BDI/HADS-D/MADRS BDI, 21-item self-report โ—‹ (K-BDI-II)
HADS-D, depression subscale of a combined anxiety/depression instrument โ—‹ (K-HADS)
MADRS, sensitive to clinical change โ–ณ (MADRS)
โ€ƒAnxiety PAS PD-specific scale with 3 subscales: persistent anxiety, episodic anxiety (including off-related anxiety), and avoidance behavior โ–ณ
HAMA/BAI/GAI HAMA, 14-item interviewer-rated โ—‹ (HAMA)
BAI, self-report โ—‹ (BAI)
GAI, anxiety scale for elderly โ–ณ (GAI)
โ€ƒPsychosis and behavioral symptoms NPI/SAPS-PD NPI, 12 symptom domains, informant-reported โ—‹ (NPI)
SAPS-PD, 9-item scale for psychosis in PD โ–ณ (SAPS-PD)
Cognitive impairment
โ€ƒCognitive screening (Level I) MoCA 30 points across 7 cognitive domains โ—‹
Scores <26 suggest impairment
Recommended for initial PD-MCI screening
Less prone to ceiling effects
โ€ƒCognitive screening (Level I) MMSE 30 points โ—‹
Limited utility for PD-MCI screening because of ceiling effects
May be used for PDD screening (โ‰ค25 points)
โ€ƒComprehensive neuropsychological assessment (Level II) SNSB, TMT-A/B, SVLT, RCFT, K-BNT, FAB, JLO At least 2 tests per cognitive domain โ—‹ (individual tests)
SNSB standardized in Korea
Administration by a clinical neuropsychologist recommended
Autonomic dysfunction
SCOPA-AUT 25-item self-report covering gastrointestinal, urinary, cardiovascular, thermoregulatory, pupillary, and sexual functions โ—‹ (K-SCOPA-AUT)
MDS-recommended measure
COMPASS-31 31 items covering 6 autonomic domains โ—‹ (K-COMPASS-31)
Weighted scoring
Complementary to SCOPA-AUT
Sleep disorders
โ€ƒOverall sleep disturbances PDSS-2/SCOPA-Sleep PDSS-2, 15 items evaluating nocturnal and daytime sleep-related symptoms โ—‹
SCOPA-Sleep, separate assessments of nocturnal sleep disturbances and daytime sleepiness
โ€ƒDaytime sleepiness ESS 8-item self-report โ—‹
Scores โ‰ฅ10 suggest excessive daytime sleepiness
Useful for counseling on driving and sleep attacks
โ€ƒSleep quality PSQI 19-item self-report โ—‹
7 component scores
Scores โ‰ฅ5 indicate poor sleep quality
Assesses the preceding month
โ€ƒRBD screening RBDSQ/RBDQ-KR/RBD1Q (single item) RBDSQ โ—‹ (RBDQ-KR)
10 items โ–ณ (RBD1Q)
Confirmation requires polysomnography showing REM sleep without atonia
RBD1Q
Rapid screening in outpatient clinics
Pain and fatigue
โ€ƒPain KPPS 14 items in 7 domains: musculoskeletal, chronic, fluctuation-related, nocturnal, orofacial, discoloration/edema/swelling, and radicular pain โ—‹
Frequencyร—severity scoring
PD-PCS Three-stage hierarchical classification: PD-relatedness (at least 1 of 4 criteria), pain mechanism (nociceptive, neuropathic, or nociplastic), severity scored by frequencyร—intensityร—interference with daily activities ร—
โ€ƒFatigue FSS/PFS-16 FSS โ–ณ (FSS)
9-item scale validated across multiple conditions โ–ณ (PFS-16)
MDS-recommended measure
PFS-16
PD-specific, 16-item self-report scale

NMSS; Non-Motor Symptoms Scale, MDS; Movement Disorder Society, NMS; Non-Motor Symptoms, NMSQ; Non-Motor Symptoms Questionnaire, GDS; Geriatric Depression Scale, HAMD; Hamilton Depression Rating Scale, KHDRS; Korean Hamilton Depression Rating Scale, BDI; Beck Depression Inventory, HADS; Hospital Anxiety and Depression Scale, MADRS; Montgomery-ร…sberg Depression Rating Scale, PAS; Parkinson Anxiety Scale; PD; Parkinson's disease, HAMA; Hamilton Anxiety Rating Scale, BAI; Beck Anxeity Inventory, GAI; Geriatric Anxiety Inventory, NPI; Neuropsychiatric Inventory, SAPS; Scale for the Assessment of Positive Symptoms, MoCA; Montreal Cognitive Assessment, PD-MCI; Parkinsonโ€™s disease mild cognitive impairment, MMSE; Mini-Mental State Examination, PDD; Parkinsonโ€™s disease dementia, SNSB; Seoul Neuropsychological Screening Battery, TMT; Trail Making Test, SVLT; Seoul Verbal Learning Test, RCFT; Rey Complex Figure Test, K-BNT; Korean Boston Naming Test, FAB; Frontal Assessment Battery, JLO; Judgment of Line Orientation, SCOPA-AUT; Scales for Outcomes in Parkinson's Disease-Autonomic, COMPASS; Composite Autonomic Symptoms Scale, PDSS; Parkinson's Disease Sleep Scale, ESS; Epworth Sleepiness Scale, RBD; rapid eye movement sleep behavior disorder, PSQI; Pittsburgh Sleep Quality Index, RBDSQ; RBD Screening Questionnaire, REM; rapid eye movement, KPPS; King's Parkinson's Disease Pain Scale, PD-PCS; PD Pain Classification System, FSS; Fatigue Severity Scale; PFS; Parkinson Fatigue Scale.

a โ—‹, Korean-language version available or a validation study reported; โ–ณ, unofficial translation or insufficient validation; ร—, no Korean-language version identified.

Tableย 2.
Pharmacological treatments for non-motor symptoms in Parkinson's disease
Symptom Medication Clinical evidencea Key precautions
Neuropsychiatric symptoms
โ€ƒDepression Pramipexole MDS, clinically usefulb Impulse control disorders, somnolence, orthostatic hypotension
Paroxetine (SSRI) MDS, possibly useful Serotonin syndrome (caution with MAO-B inhibitors)
Citalopram (SSRI) MDS, possibly useful QT prolongation at >20 mg/day in patients aged โ‰ฅ60 years
ECG monitoring required
Venlafaxine (SNRI) MDS, clinically useful Increased blood pressure (โ‰ฅ75 mg), nausea
Nortriptyline (TCA) MDS, possibly useful Anticholinergic effects (cognitive impairment, constipation, urinary retention)
Increased fall risk
โ€ƒAnxiety SSRIs (with comorbid depression) No RCTs directly evaluating anxiety in PD Serotonin syndrome with MAO-B inhibitors
Hyponatremia
Buspirone Limited evidence For generalized anxiety disorder
Small studies Onset of effect takes 2-4 weeks
Benzodiazepines No RCTs directly evaluating anxiety in PD Falls, cognitive impairment, and tolerance
Short-term use only
โ€ƒPsychotic and behavioral symptoms Clozapine MDS, clinically useful Risk of agranulocytosis
Regular blood count monitoring (every 2 weeks)
Quetiapine MDS, possibly useful Minimal effect on motor function
Sedation, orthostatic hypotension
Pimavanserinc MDS, clinically useful Not available in Korea (approved by the FDA)
Rivastigmine (comorbid PDD and PDP) PDD, clinically useful Nausea, bradycardia
PDP, limited evidence for reducing hallucinations ECG before initiation
Cognitive impairment
โ€ƒParkinson's disease dementia Rivastigmine MDS, clinically useful Bradycardia, nausea, vomiting, and other gastrointestinal adverse effects
ECG before initiation
Donepezil MDS, possibly useful Bradycardia
โ€ƒMild cognitive impairment in PD No approved medication
Autonomic dysfunction
โ€ƒOrthostatic hypotension Midodrine MDS, possibly useful Supine hypertension, scalp pruritus
Avoid dosing after the evening meal
Droxidopa MDS, possibly useful (short-term) Norepinephrine precursor
Supine hypertension, headache
Fludrocortisone MDS: possibly useful Peripheral edema, supine hypertension, hypokalemia
Cardiac evaluation before use
Pyridostigmine Limited PD-specific evidence Nausea, abdominal cramps, diarrhea, abdominal discomfort
Adjunctive use
โ€ƒConstipation Macrogol (PEG) MDS, possibly useful Generally favorable safety profile
Lactulose Limited PD-specific RCT evidence Osmotic laxative
Evidence from general constipation treatment Abdominal bloating
โ€ƒSialorrhea Botulinum toxin type A (parotid/submandibular gland injection) MDS, clinically useful Rare dysphagia
Effects last approximately 3-6 months
Glycopyrrolate (oral spray/oral administration) MDS, possibly useful Anticholinergic effects (caution regarding cognitive impairment
โ€ƒDelayed gastric emptying/upper gastrointestinal symptoms DA-9701 (Motilitone) Small PD-specific studies Approved in Korea for functional dyspepsia
Potential improvement in gastric emptying and upper gastrointestinal symptoms Use for delayed gastric emptying in PD is off-label
โ€ƒNausea and vomiting Domperidone MDS, possibly useful Approved in Korea for relief of nausea and vomiting
QT prolongation risk
ECG monitoring recommended
โ€ƒUrinary storage symptoms Solifenacin MDS, possibly useful Anticholinergic effects (cognitive impairment, constipation, dry mouth)
Mirabegron (beta-3 agonist) Limited PD-specific evidence No anticholinergic adverse effects
May be preferred in older patients or those with cognitive impairment
Monitor blood pressure
โ€ƒUrinary voiding symptoms Tamsulosin (alpha-1 blocker) Limited PD-specific evidence Orthostatic hypotension, syncope
Use according to underlying etiology Caution regarding IFIS before cataract or glaucoma surgery
Sleep disorders
โ€ƒInsomnia related to motor symptoms Ropinirole ER/rotigotine MDS, possibly useful in Rotigotine May improve sleep by reducing nocturnal motor symptoms
Impulse control disorders, somnolence
โ€ƒInsomnia/poor sleep quality Melatonin MDS, possibly useful Improves subjective sleep quality and may alleviate circadian sleep-wake disruption
Excessive sedation
โ€ƒExcessive daytime sleepiness Modafinil MDS, possibly useful Improvement in subjective sleepiness
Limited objective improvement
Headache, nausea
โ€ƒREM sleep behavior disorder Clonazepam AASM, conditional recommendation Falls, cognitive impairment, dependence
MDS, insufficient evidence Caution in patients with sleep apnea
Melatonin AASM, conditional recommendation Second-line option or alternative to clonazepam
MDS, insufficient evidence Generally fewer adverse effects
Other symptoms
โ€ƒPain associated with the OFF state Optimization of levodopa/dopamine agonist therapy Limited RCT evidence Monitor for worsening motor fluctuations, dyskinesia, somnolence, and impulse control disorders
Mechanistic rationale and clinical experience
Rotigotine MDS, investigational Some reports of pain improvement
May be helpful in patients with motor fluctuations
Oxycodone-naloxone ER MDS, possibly useful Opioid analgesic
Prescribing restrictions and dependence risk
Constipation, nausea
Duloxetine Limited and mixed PD-specific evidence Nociplastic pain
Mixed result
May be beneficial with comorbid depression
โ€ƒPainful OFF-state dystonia Botulinum toxin type A (local injection) Based on principles of dystonia treatment Early-morning foot dystonia
Limited direct evidence for pain in PD Effects last approximately 3-6 months
โ€ƒFatigue Methylphenidate MDS, investigational Some evidence of fatigue improvement
Anxiety, reduced appetite, increased blood pressure
Caution with cognitive impairment
Rasagiline MDS, possibly useful Risk of serotonin syndrome

MDS; Movement Disorder Society, SSRI; selective serotonin reuptake inhibitor, MAO-B; monoamine oxidase B, ECG; electrocardiogram, SNRI; serotonin-norepinephrine reuptake inhibitor, TCA; tricyclic antidepressant, RCT; randomized controlled trial, PD; Parkinson's disease, FDA; United States Food and Drug Administration, PDD; Parkinson's disease dementia, PDP; Parkinson's disease psychosis, PEG; polyethylene glycol, IFIS; intraoperative floppy iris syndrome, ER; extended release, REM; rapid eye movement, AASM; American Academy of Sleep Medicine.

a Where available, the practice implications in the MDS evidence-based medicine review were used to describe the level of clinical evidence. Where an MDS practice implication was not available or PD-specific evidence was limited, the nature and limitations of the evidence are described instead.

b Clinically useful; clinically useful in practice, possibly useful; potentially useful in practice, investigational; insufficient evidence for routine clinical use or still under investigation.

c For clonazepam and melatonin in REM sleep behavior disorder, the conditional recommendations of the AASM clinical practice guideline are also noted. [109]

Tableย 3.
Non-pharmacological treatments for non-motor symptoms in Parkinson's disease
Domain Non-pharmacological intervention Description and practical application Clinical evidencea
Depression CBT Structured CBT targeting negative thought patterns MDS, possibly usefulb
May improve depression and comorbid anxiety
Regular aerobic exercise May improve depressive symptoms and mood, with additional benefits for overall motor function in PD Limited direct evidence for depression in PD
Adjunctive intervention
Repetitive transcranial magnetic stimulation (left DLPFC) High-frequency stimulation MDS, possibly useful (short-term)
Alternative when antidepressant response is inadequate or adverse effects limit medication use
Cognitive impairment Regular aerobic exercise Moderate-intensity exercise for 30-60 minutes, 3-5 times per week Limited direct evidence for cognitive impairment in PD
RCT evidence of improved global cognition, persisting 6 months after discontinuation Adjunctive intervention
Cognitive training Computer-based or group training targeting executive function, processing speed, and memory MDS, investigational
Low-certainty evidence
Orthostatic hypotension Fluid and salt intake Fluid intake of 2-3 L/day and salt intake of 2-10 g/day General principles for neurogenic orthostatic hypotension
Rapid ingestion of 500 mL of water before meals to help prevent postprandial hypotension Limited PD-specific evidence
Physical counterpressure maneuvers Marching in place and leg crossing when standing General principles for neurogenic orthostatic hypotension
Abdominal compression
Lying down for 30 minutes after meals and sleeping with the head of the bed elevated by 30 degrees Limited PD-specific evidence
Compression stockings/abdominal binders Above-knee compression stockings may be used, although motor impairment can make them difficult to put on General principles for neurogenic orthostatic hypotension
Limited PD-specific evidence
Constipation Dietary and lifestyle modification Adequate hydration, a high-fiber diet, regular exercise, and use of a bowel diary General principles of constipation management
Limited direct PD-specific evidence
Urinary dysfunction Bladder training/timed voiding Scheduled voiding to reduce urgency PD-specific RCT evidence
May be combined with pelvic floor muscle training Noninferior to drug therapy
Insomnia Sleep hygiene education Regular sleep schedule General principles of insomnia management
Limit caffeine and alcohol Limited PD-specific evidence
Minimize naps
Stretching before bedtime
CBT-I Sleep restriction, stimulus control, sleep hygiene, and relaxation techniques Evidence-based treatment for insomnia generally
Recommended as first-line therapy for insomnia in older adults Limited PD-specific evidence
Bright light therapy Exposure to bright light for 30-60 minutes in the morning Limited PD-specific RCT evidence
May improve sleep and daytime sleepiness
REM sleep behavior disorder Bedroom safety measures Bed side rails, fall-protection mats, rearrangement of furniture, window lock Safety measure
Protect bed partners Formal evidence grading not applicable
Pain Exercise therapy (walking/stretching) Pain relief and maintenance of muscle strength Limited direct evidence for PD-related pain
Combined with physical and occupational therapy Adjunctive intervention
Individualized exercise prescription
Repetitive transcranial magnetic stimulation Under investigation for PD-related pain Limited direct evidence for PD-related pain
Potential application to central pain Investigational
Fatigue Aerobic exercise Moderate-intensity exercise for 30-60 minutes, 3-5 times per week (walking, cycling, swimming) Limited direct evidence for PD-related fatigue
Described as having the strongest non-pharmacological evidence for PD-related fatigue Adjunctive intervention

CBT; cognitive behavioral therapy, MDS; Movement Disorder Society, PD; Parkinson's disease, DLPFC; dorsolateral prefrontal cortex, RCT; randomized controlled trial, CBT-I; cognitive behavioral therapy for insomnia, REM; rapid eye movement.

a Where available, practice implications from the MDS evidence-based medicine review are reported. For non-pharmacological interventions without an MDS practice implication, descriptions such as โ€œlimited PD-specific evidence,โ€ โ€œgeneral principles of disease management,โ€ โ€œevidence based on studies in the general population,โ€ or โ€œsafety measures for which formal evidence grading is not applicableโ€ are used and should not be interpreted as formal evidence grades.

b Clinically useful, clinically useful in practice; possibly useful, potentially useful in practice; investigational, insufficient evidence for routine clinical use or still under investigation.

REFERENCES
REFERENCES

1. Bloem BR, Okun MS, Klein C. Parkinsonโ€™s disease. Lancet 2021;397:2284-2303.
[Article] [PubMed] [PMC]
2. Schapira AH, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci 2017;18:435-450.
[Article] [PubMed]
3. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinsonโ€™s disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
[Article] [PubMed]
4. Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinsonโ€™s disease - an evidence-based medicine review. Mov Disord 2019;34:180-198.
[Article]
5. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinsonโ€™s disease. Mov Disord 2015;30:1600-1611.

6. Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB. Update of the MDS research criteria for prodromal Parkinsonโ€™s disease. Mov Disord 2019;34:1464-1470.
[Article]
7. Menozzi E, Schapira AH, Borghammer P. The gut-brain axis in Parkinson disease: emerging concepts and therapeutic implications. Mov Disord Clin Pract 2025;12:904-916.
[Article] [PubMed] [PMC]
8. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, et al. The metric properties of a novel non-motor symptoms scale for Parkinsonโ€™s disease: results from an international pilot study. Mov Disord 2007;22:1901-1911.
[Article]
9. Koh SB, Kim JW, Ma HI, Ahn TB, Cho JW, Lee PH, et al. Validation of the Korean-version of the nonmotor symptoms scale for Parkinsonโ€™s disease. J Clin Neurol 2012;8:276-283.
[Article] [PubMed] [PMC]
10. van Wamelen DJ, Martinez-Martin P, Weintraub D, Schrag A, Antonini A, Falup-Pecurariu C, et al. The non-motor symptoms scale in Parkinsonโ€™s disease: validation and use. Acta Neurol Scand 2021;143:3-12.
[Article] [PubMed] [PMC]
11. Chaudhuri KR, Schrag A, Weintraub D, Rizos A, Rodriguez-Blazquez C, Mamikonyan E, et al. The Movement Disorder Society nonmotor rating scale: initial validation study. Mov Disord 2020;35:116-133.
[Article] [PubMed] [PMC]
12. Romenets SR, Wolfson C, Galatas C, Pelletier A, Altman R, Wadup L, et al. Validation of the non-motor symptoms questionnaire (NMSQuest). Parkinsonism Relat Disord 2012;18:54-58.
[Article] [PubMed]
13. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinsonโ€™s disease. Mov Disord 2008;23:183-189.
[Article] [PubMed]
14. Fang F, Xu Q, Park Y, Huang X, Hollenbeck A, Blair A, et al. Depression and the subsequent risk of Parkinsonโ€™s disease in the NIHAARP diet and health study. Mov Disord 2010;25:1157-1162.
[Article] [PubMed] [PMC]
15. Marsh L. Depression and Parkinsonโ€™s disease: current knowledge. Curr Neurol Neurosci Rep 2013;13:409.
[Article] [PubMed] [PMC]
16. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinsonโ€™s disease: critique and recommendations. Mov Disord 2007;22:1077-1092.
[Article] [PubMed] [PMC]
17. Torbey E, Pachana NA, Dissanayaka NN. Depression rating scales in Parkinsonโ€™s disease: a critical review updating recent literature. J Affect Disord 2015;184:216-224.
[Article] [PubMed]
18. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinsonโ€™s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-580.
[Article] [PubMed]
19. Peรฑa E, Borruรฉ C, Mata M, Martรญnez-Castrillo JC, Alonso-Canovas A, Chico JL, et al. Impact of safinamide on depressive symptoms in Parkinsonโ€™s disease patients (SADness-PD study): a multicenter retrospective study. Brain Sci 2021;11:232.
[Article] [PubMed] [PMC]
20. Wermuth L, Sรธrensen P, Timm S, Christensen B, Utzon N, Boas J, et al. Depression in idiopathic Parkinsonโ€™s disease treated with citalopram: a placebo-controlled trial. Nord J Psychiatry 1998;52:163-169.
[Article]
21. Antonini A, Tesei S, Zecchinelli A, Barone P, De Gaspari D, Canesi M, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinsonโ€™s disease and depression: effect on quality of life. Mov Disord 2006;21:1119-1122.
[Article] [PubMed]
22. Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, et al. Comparison of desipramine and citalopram treatments for depression in Parkinsonโ€™s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008;23:850-857.
[Article] [PubMed]
23. Menza M, Dobkin RD, Marin H, Mark M, Gara M, Buyske S, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-892.
[Article] [PubMed] [PMC]
24. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012;78:1229-1236.
[PubMed] [PMC]
25. Broen M, Leentjens A, Kรถhler S, Kuijf M, McDonald W, Richard I. Trajectories of recovery in depressed Parkinsonโ€™s disease patients treated with paroxetine or venlafaxine. Parkinsonism Relat Disord 2016;23:80-85.
[Article] [PubMed]
26. Health Insurance Review & Assessment Service. Questions and answers regarding reimbursement criteria for antidepressants including SSRIs. [online] [cited 2026 May 29]. Available from: https://www.hira.or.kr/rc/drug/insuadtcrtr/bbsView.do?isPopupYn=Y&pgmid=HIRAA030069000400&brdScnBltNo=4&brd-BltNo=52302&isPopupYn=Y.

27. Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, et al. Cognitive-behavioral therapy for depression in Parkinsonโ€™s disease: a randomized, controlled trial. Am J Psychiatry 2011;168:1066-1074.
[Article] [PubMed] [PMC]
28. Dissanayaka NN, Sellbach A, Matheson S, Oโ€™Sullivan JD, Silburn PA, Byrne GJ, et al. Anxiety disorders in Parkinsonโ€™s disease: prevalence and risk factors. Mov Disord 2010;25:838-845.
[Article] [PubMed] [PMC]
29. Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P. The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. Mov Disord 2014;29:1035-1043.
[Article] [PubMed]
30. Schneider RB, Auinger P, Tarolli CG, Iourinets J, Gil-Dรญaz MC, Richard IH. A trial of buspirone for anxiety in Parkinsonโ€™s disease: safety and tolerability. Parkinsonism Relat Disord 2020;81:69-74.
[Article] [PubMed] [PMC]
31. Chen JJ, Marsh L. Anxiety in Parkinsonโ€™s disease: identification and management. Ther Adv Neurol Disord 2014;7:52-59.
[Article] [PubMed] [PMC]
32. Friedman JH. Parkinsonโ€™s disease psychosis 2010: a review article. Parkinsonism Relat Disord 2010;16:553-560.
[Article] [PubMed]
33. Taddei RN, Cankaya S, Dhaliwal S, Chaudhuri KR. Management of psychosis in Parkinsonโ€™s disease: emphasizing clinical subtypes and pathophysiological mechanisms of the condition. Parkinsons Dis 2017;2017:3256542.
[Article] [PubMed] [PMC]
34. Fernandez HH, Aarsland D, Fรฉnelon G, Friedman JH, Marsh L, Trรถster AI, et al. Scales to assess psychosis in Parkinsonโ€™s disease: critique and recommendations. Mov Disord 2008;23:484-500.
[Article] [PubMed]
35. Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H. Performance of a shortened scale for assessment of positive symptoms for Parkinsonโ€™s disease psychosis. Parkinsonism Relat Disord 2013;19:295-299.
[Article] [PubMed]
36. Poewe W. Psychosis in Parkinsonโ€™s disease. Mov Disord 2003;18 Suppl 6:S80-S87.
[Article] [PubMed]
37. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinsonโ€™s disease. N Engl J Med 1999;340:757-763.
[Article] [PubMed]
38. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinsonโ€™s disease versus dementia with Lewy bodies. J Clin Psychiatry 2002;63:513-515.
[Article] [PubMed]
39. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinsonโ€™s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014;383:533-540.
[Article] [PubMed]
40. Weintraub D, Somogyi M, Meng X. Rivastigmine in Alzheimerโ€™s disease and Parkinsonโ€™s disease dementia: an ADAS-cog factor analysis. Am J Alzheimers Dis Other Demen 2011;26:443-449.
[Article] [PubMed] [PMC]
41. Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol 2017;13:217-231.
[Article] [PubMed] [PMC]
42. Litvan I, Goldman JG, Trรถster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinsonโ€™s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349-356.
[Article] [PubMed] [PMC]
43. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010;75:1062-1069.
[Article] [PubMed] [PMC]
44. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al. MDS Task Force on mild cognitive impairment in Parkinsonโ€™s disease: critical review of PD-MCI. Mov Disord 2011;26:1814-1824.
[Article] [PubMed] [PMC]
45. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, et al. Diagnostic procedures for Parkinsonโ€™s disease dementia: recommendations from the Movement Disorder Society Task Force. Mov Disord 2007;22:2314-2324.
[Article] [PubMed]
46. Kalbe E, Rehberg SP, Heber I, Kronenbuerger M, Schulz JB, Storch A, et al. Subtypes of mild cognitive impairment in patients with Parkinsonโ€™s disease: evidence from the LANDSCAPE study. J Neurol Neurosurg Psychiatry 2016;87:1099-1105.
[Article] [PubMed]
47. Ryu HJ, Yang DW. The Seoul neuropsychological screening battery (SNSB) for comprehensive neuropsychological assessment. Dement Neurocogn Disord 2023;22:1-15.
[Article] [PubMed] [PMC]
48. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinsonโ€™s disease. N Engl J Med 2004;351:2509-2518.
[Article] [PubMed] [PMC]
49. Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, et al. Donepezil in Parkinsonโ€™s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012;27:1230-1238.
[Article] [PubMed]
50. Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinsonโ€™s disease, Parkinsonโ€™s disease dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2015;86:135-143.
[PubMed]
51. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinsonโ€™s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8:613-618.
[Article] [PubMed] [PMC]
52. Emre M, Tsolaki M, Bonuccelli U, Destรฉe A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinsonโ€™s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:969-977.
[Article] [PubMed]
53. Silveira CRA, Coleman KKL, Borron K, Tirona RG, Rupar CA, Zou G, et al. Ambroxol as a treatment for Parkinson disease dementia: a randomized clinical trial. JAMA Neurol 2025;82:797-807.
[Article] [PubMed] [PMC]
54. Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord 2015;30:912-918.
[Article] [PubMed]
55. Baik K, Kim SM, Jung JH, Lee YH, Chung SJ, Yoo HS, et al. Donepezil for mild cognitive impairment in Parkinsonโ€™s disease. Sci Rep 2021;11:4734.
[Article] [PubMed] [PMC]
56. Kawashima S; RCIP-Nagoya Study Group, Matsukawa N. Memantine for the patients with mild cognitive impairment in Parkinsonโ€™s disease: a pharmacological fMRI study. BMC Neurol 2022;22:175.
[Article] [PubMed] [PMC]
57. Orgeta V, McDonald KR, Poliakoff E, Hindle JV, Clare L, Leroi I. Cognitive training interventions for dementia and mild cognitive impairment in Parkinsonโ€™s disease. Cochrane Database Syst Rev 2020;2:CD011961.
[Article] [PubMed] [PMC]
58. Avenali M, Picascia M, Tassorelli C, Sinforiani E, Bernini S. Evaluation of the efficacy of physical therapy on cognitive decline at 6-month follow-up in Parkinson disease patients with mild cognitive impairment: a randomized controlled trial. Aging Clin Exp Res 2021;33:3275-3284.
[Article] [PubMed]
59. Malek N, Lawton MA, Grosset KA, Bajaj N, Barker RA, Burn DJ, et al. Autonomic dysfunction in early Parkinsonโ€™s disease: results from the United Kingdom tracking Parkinsonโ€™s study. Mov Disord Clin Pract 2017;4:509-516.
[Article] [PubMed] [PMC]
60. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 2004;19:1306-1312.
[Article] [PubMed]
61. Pavy-Le Traon A, Amarenco G, Duerr S, Kaufmann H, Lahrmann H, Shaftman SR, et al. The Movement Disorders task force review of dysautonomia rating scales in Parkinsonโ€™s disease with regard to symptoms of orthostatic hypotension. Mov Disord 2011;26:1985-1992.
[Article] [PubMed]
62. Kim JY, Song IU, Koh SB, Ahn TB, Kim SJ, Cheon SM, et al. Validation of the Korean version of the scale for outcomes in Parkinsonโ€™s disease-autonomic. J Mov Disord 2017;10:29-34.
[PubMed] [PMC]
63. Ahn JH, Seok JM, Park J, Jeong H, Kim Y, Song J, et al. Validation of the Korean version of the Composite Autonomic Symptom Scale 31 in patients with Parkinsonโ€™s disease. PLoS One 2021;16:e0258897.
[Article] [PubMed] [PMC]
64. Park KH, Sohn EH. Interpretation of autonomic function test. J Korean Neurol Assoc 2021;39:61-67.
[Article]
65. Kang YJ, Lee SW, Park JH, Lee TK. Evaluation of autonomic dysfunction in Parkinson disease by cardiovascular autonomic indexes. J Korean Neurol Assoc 2015;33:282-287.
[Article]
66. Safarpour D, Stover N, Shprecher DR, Hamedani AG, Pfeiffer RF, Parkman HP, et al. Consensus practice recommendations for management of gastrointestinal dysfunction in Parkinson disease. Parkinsonism Relat Disord 2024;124:106982.
[Article] [PubMed]
67. Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006;13:930-936.
[Article] [PubMed]
68. Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinsonโ€™s disease (nOH306B). Mov Disord 2015;30:646-654.
[PubMed]
69. Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63:513-518.
[Article] [PubMed]
70. Srivanitchapoom P, Pandey S, Hallett M. Drooling in Parkinsonโ€™s disease: a review. Parkinsonism Relat Disord 2014;20:1109-1118.
[Article] [PubMed] [PMC]
71. Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinsonโ€™s disease: frequency and pathophysiology. Neurology 1992;42:726-732.
[Article] [PubMed]
72. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinsonโ€™s disease: patients with and without response fluctuations. Neurology 1996;46:1051-1054.
[Article] [PubMed]
73. Choi JH, Lee JY, Cho JW, Koh SB, Yang YS, Yoo D, et al. Double-blind, randomized, placebo-controlled trial of DA-9701 in Parkinsonโ€™s disease: PASS-GI study. Mov Disord 2020;35:1966-1976.
[PubMed] [PMC]
74. Januel E, Corvol JC, Remy P, Meissner WG, Thiriez C, Lanore A, et al. Use and misuse of domperidone in patients living with Parkinson disease in France. Fundam Clin Pharmacol 2025;39:e70002.
[Article] [PubMed] [PMC]
75. Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol 2012;8:15-21.
[Article] [PubMed] [PMC]
76. McDonald C, Winge K, Burn DJ. Lower urinary tract symptoms in Parkinsonโ€™s disease: prevalence, aetiology and management. Parkinsonism Relat Disord 2016;35:8-16.
[Article] [PubMed]
77. Sakakibara R, Tateno F, Yamamoto T, Uchiyama T. Urological dysfunction in synucleinopathies: epidemiology, pathophysiology and management. Clin Auton Res 2018;28:83-101.
[Article] [PubMed]
78. Vaughan CP, Morley JF, Lehosit J, McGwin G, Muirhead L, Khakharia A, et al. Behavioral compared with drug therapy for overactive bladder symptoms in Parkinson disease: a randomized noninferiority trial. JAMA Neurol 2025;82:925-931.
[Article] [PubMed] [PMC]
79. Madan A, Ray S, Burdick D, Agarwal P. Management of lower urinary tract symptoms in Parkinsonโ€™s disease in the neurology clinic. Int J Neurosci 2017;127:1136-1149.
[Article] [PubMed]
80. Saraf U, Batla A, Sakakibara R, Panicker JN. The impact of polypharmacy on management of lower urinary tract symptoms in Parkinsonโ€™s disease. Drugs Aging 2023;40:909-917.
[Article] [PubMed]
81. Yeo L, Singh R, Gundeti M, Barua JM, Masood J. Urinary tract dysfunction in Parkinsonโ€™s disease: a review. Int Urol Nephrol 2012;44:415-424.
[Article] [PubMed]
82. Fowler CJ. Update on the neurology of Parkinsonโ€™s disease. Neurourol Urodyn 2007;26:103-109.
[Article] [PubMed]
83. Xu Z, Anderson KN, Saffari SE, Lawson RA, Chaudhuri KR, Brooks D, et al. Progression of sleep disturbances in Parkinsonโ€™s disease: a 5-year longitudinal study. J Neurol 2021;268:312-320.
[Article] [PubMed] [PMC]
84. Dodet P, Houot M, Leu-Semenescu S, Corvol JC, Lehรฉricy S, Mangone G, et al. Sleep disorders in Parkinsonโ€™s disease, an early and multiple problem. NPJ Parkinsons Dis 2024;10:46.
[Article] [PubMed] [PMC]
85. Iranzo A, De Cock VC, Fantini ML, Pรฉrez-Carbonell L, Trotti LM. Sleep and sleep disorders in people with Parkinsonโ€™s disease. Lancet Neurol 2024;23:925-937.
[Article] [PubMed] [PMC]
86. Hรถgl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, et al. Scales to assess sleep impairment in Parkinsonโ€™s disease: critique and recommendations. Mov Disord 2010;25:2704-2716.
[Article] [PubMed]
87. Cho YW, Lee JH, Son HK, Lee SH, Shin C, Johns MW. The reliability and validity of the Korean version of the Epworth Sleepiness Scale. Sleep Breath 2011;15:377-384.
[Article] [PubMed]
88. Sohn SI, Kim DH, Lee MY, Cho YW. The reliability and validity of the Korean version of the Pittsburgh Sleep Quality Index. Sleep Breath 2012;16:803-812.
[Article] [PubMed]
89. Sung YH, Kim HJ, Koh SB, Kim JS, Kim SJ, Cheon SM, et al. Validation of the Korean version of the Scales for Outcomes in Parkinsonโ€™s Disease-Sleep. J Korean Med Sci 2018;33:e14.
[PubMed] [PMC]
90. Yang HJ, Kim HJ, Koh SB, Kim JS, Ahn TB, Cheon SM, et al. Subtypes of sleep disturbance in Parkinsonโ€™s disease based on the cross-culturally validated Korean version of Parkinsonโ€™s Disease Sleep Scale-2. J Clin Neurol 2020;16:66-74.
[PubMed] [PMC]
91. Lam SP, Li SX, Zhang J, Wing YK. Development of scales for assessment of rapid eye movement sleep behavior disorder (RBD). Sleep Med 2013;14:734-738.
[Article] [PubMed]
92. Lee SA, Paek JH, Han SH, Ryu HU. The utility of a Korean version of the REM sleep behavior disorder screening questionnaire in patients with obstructive sleep apnea. J Neurol Sci 2015;358:328-332.
[Article] [PubMed]
93. Postuma RB, Arnulf I, Hรถgl B, Iranzo A, Miyamoto T, Dauvilliers Y, et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord 2012;27:913-916.
[Article] [PubMed] [PMC]
94. Byun JI, Shin WC. Recent update on treatment and management of rapid eye movement sleep behavior disorder. J Korean Neurol Assoc 2021;39:68-74.
[Article]
95. Diederich NJ, McIntyre DJ. Sleep disorders in Parkinson's disease: many causes, few therapeutic options. J Neurol Sci 2012;314:12-19.
[Article]
96. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-1115.
[Article] [PubMed]
97. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-99.
[Article] [PubMed] [PMC]
98. Ahn JH, Kim M, Park S, Jang W, Park J, Oh E, et al. Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: a randomized trial. Parkinsonism Relat Disord 2020;75:50-54.
[Article] [PubMed]
99. Sugumaran R, Sai Krishna KS, Saibaba J, Narayan SK, Sandhiya S, Rajeswari M. Melatonin on sleep in Parkinson's disease: a randomized double blind placebo controlled trial. Sleep Med 2024;124:502-509.
[Article] [PubMed]
100. Schrempf W, Fauser M, Wienecke M, Brown S, MaaรŸ A, Ossig C, et al. Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial. Eur J Neurol 2018;25:672-679.
[Article] [PubMed]
101. Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: a randomized clinical trial. JAMA Neurol 2017;74:411-418.
[Article]
102. Amara AW, Wood KH, Joop A, Memon RA, Pilkington J, Tuggle SC, et al. Randomized, controlled trial of exercise on objective and subjective sleep in Parkinson's disease. Mov Disord 2020;35:947-958.
[Article]
103. Feng F, Cai Y, Hou Y, Ou R, Jiang Z, Shang H. Excessive daytime sleepiness in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2021;85:133-140.
[Article]
104. Zhu K, van Hilten JJ, Marinus J. Course and risk factors for excessive daytime sleepiness in Parkinson's disease. Parkinsonism Relat Disord 2016;24:34-40.
[Article] [PubMed]
105. Rodrigues TM, Castro Caldas A, Ferreira JJ. Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: systematic review and meta-analysis. Parkinsonism Relat Disord 2016;27:25-34.
[Article] [PubMed]
106. Videnovic A, Amara AW, Comella C, Schweitzer PK, Emsellem H, Liu K, et al. Solriamfetol for excessive daytime sleepiness in parkinson's disease: phase 2 proof-of-concept trial. Mov Disord 2021;36:2408-2412.
[Article] [PubMed] [PMC]
107. St Louis EK, Boeve BF. REM sleep behavior disorder: diagnosis, clinical implications, and future directions. Mayo Clin Proc 2017;92:1723-1736.
[Article] [PubMed] [PMC]
108. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med 2013;14:744-748.
[Article] [PubMed] [PMC]
109. Howell M, Avidan AY, Foldvary-Schaefer N, Malkani RG, During EH, Roland JP, et al. Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 2023;19:759-768.
[Article] [PubMed] [PMC]
110. Shin C, Park H, Lee WW, Kim HJ, Kim HJ, Jeon B. Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: a randomized placebo-controlled trial. J Neurol Sci 2019;401:81-86.
[Article] [PubMed]
111. Gilat M, Coeytaux Jackson A, Marshall NS, Hammond D, Mullins AE, Hall JM, et al. Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: a randomised controlled trial. Mov Disord 2020;35:344-349.
[Article] [PubMed] [PMC]
112. Tinazzi M, Gandolfi M, Artusi CA, Bannister K, Rukavina K, Brefel-Courbon C, et al. Advances in diagnosis, classification, and management of pain in Parkinson's disease. Lancet Neurol 2025;24:331-347.
[Article] [PubMed]
113. Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S, Martino D, et al. King's Parkinson's disease pain scale, the first scale for pain in PD: an international validation. Mov Disord 2015;30:1623-1631.
[Article] [PubMed]
114. Mylius V, Perez Lloret S, Cury RG, Teixeira MJ, Barbosa VR, Barbosa ER, et al. The Parkinson disease pain classification system: results from an international mechanism-based classification approach. Pain 2021;162:1201-1210.
[Article] [PubMed] [PMC]
115. Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson's disease. Mov Disord 2009;24:1233-1237.
[Article] [PubMed]
116. Rascol O, Zesiewicz T, Chaudhuri KR, Asgharnejad M, Surmann E, Dohin E, et al. A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson's disease-associated chronic pain. J Clin Pharmacol 2016;56:852-861.
[Article] [PubMed]
117. Cattaneo C, Barone P, Bonizzoni E, Sardina M. Effects of safinamide on pain in fluctuating parkinson's disease patients: a post-hoc analysis. J Parkinsons Dis 2017;7:95-101.
[Article] [PubMed] [PMC]
118. Cattaneo C, Kulisevsky J, Tubazio V, Castellani P. Long-term efficacy of safinamide on Parkinson's disease chronic pain. Adv Ther 2018;35:515-522.
[Article] [PubMed] [PMC]
119. Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Valiลก M, et al. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 2015;14:1161-1170.
[Article] [PubMed]
120. Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007;30:201-205.
[Article] [PubMed]
121. Iwaki H, Ando R, Tada S, Nishikawa N, Tsujii T, Yamanishi Y, et al. A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease. J Neurol Sci 2020;414:116833.
[Article] [PubMed]
122. Huissoud M, Boussac M, Joineau K, Harroch E, Brefel-Courbon C, Descamps E. The effectiveness and safety of non-pharmacological intervention for pain management in Parkinson's disease: a systematic review. Rev Neurol (Paris) 2024;180:715-735.
[Article] [PubMed]
123. Ford B. Pain in Parkinson's disease. Mov Disord 2010;25 Suppl 1:S98-S103.
[PubMed]
124. Mills R, Bahroo L, Pagan F. An update on the use of botulinum toxin therapy in Parkinson's disease. Curr Neurol Neurosci Rep 2015;15:511.
[Article] [PubMed]
125. Mylius V, Mรถller JC, Bohlhalter S, Ciampi de Andrade D, Perez Lloret S. Diagnosis and management of pain in Parkinson's disease: a new approach. Drugs Aging 2021;38:559-577.
[Article] [PubMed]
126. Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, et al. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord 2010;25:805-822.
[Article] [PubMed]
127. Mendonรงa DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007;22:2070-2076.
[Article] [PubMed]
128. Lim TT, Kluger BM, Rodriguez RL, Malaty IA, Palacio R Jr, Ojo OO, et al. Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease. Mov Disord 2015;30:1825-1830.
[Article] [PubMed]
129. Alageel S, Hibberd J, Deane KHO. Non-pharmacological interventions for managing fatigue in parkinson's disease: a systematic review and meta-analysis. Clin Park Relat Disord 2026;14:100434.
[Article] [PubMed] [PMC]

Go to Top